MXPA00000685A

MXPA00000685A - Novel compounds

Info

Publication number: MXPA00000685A
Application number: MXPA/A/2000/000685A
Authority: MX
Inventors: Simon Guile; Anthony Ingall; Brian Springthorpe; Paul Willis
Original assignee: Astra Pharmaceuticals Ltd
Priority date: 1997-07-22
Filing date: 2000-01-19
Publication date: 2001-05-07

Abstract

The invention provides new triazolo[4,5-i(d)]pyrimidine compounds of formula (I),their use as medicaments, compositions containing them and processes for their preparation.

Description

DERIVATIVES OF TRIAZOLO- [4,5-d] -PIRIMIDINE DESCRIPTION OF THE INVENTION The present invention relates to novel triazolo [4,5-d] -pyrimidine compounds, to their use as medicaments, to compositions that contain them and to processes for their preparation. Platelet adhesion and aggregation are initiating events in arterial thrombosis. Although the process of platelet adhesion to the subendothelial surface may have an important role in the repair of the walls of damaged vessels, the platelet aggregation that is initiated may precipitate an acute thrombotic occlusion of vital vascular beds, causing events with high morbidity such as myocardial infarction and unstable angina. The success of inventions used to prevent or alleviate these disorders, such as thrombolysis and angioplasty, is also compromised by platelet-mediated occlusion or reocclusion. A number of convergent routes cause platelet aggregation. Whatever the initial stimulus, the final common event is a grid of platelets bound by fibrinogen to a membrane binding site, the glycoprotein Ilb / IIIa (GPIIb / IIIa). The high antiplatelet efficacy of the antibodies or antagonists of REF: 32472 GPIIb / IIIa is explained by their interference with this final common event. However, this efficacy can also explain the hemorrhage problems that have been observed with this class of agents. Thrombin can produce platelet aggregation to a large extent independently of other routes, but it is unlikely that substantial amounts of thrombin are present without prior activation of platelets by other mechanisms. Thrombin inhibitors such as hirudin are highly effective as antithrombotic agents, but may again cause excessive bleeding because they function as antiplatelet agents and as anticoagulants (The TIMI 9a Investigator (1994), Circulation 90, pp. 1624- 1630; The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ha Investigators (1994) Circulation 90, pp. 163 ° -1637; Neuhaus KL et al., (1994) Circulation 90, 1638-1642). It has been found that ADP (Adenosine Diphosphate) acts as a key mediator of thrombosis. A primary function for ADP is supported by the fact that other agents, such as adrenaline and 5-hydroxytryptamine (5HT, serotonin) will only aggregate in the presence of ADP. The limited antithrombotic efficacy of aspirin may reflect the fact that it blocks only one source of ADP, which is that released in a thromboxane-dependent manner after platelet adhesion (see for example Antiplatelet Trialists' ColLaboration (1994), BR. J. 308, pp. 81-106; Antiplatelet Trialists' Collaboration (1994), BR. Med. J. 308, pp. 159-168). Aspirin has no effect on aggregation produced by other sources of ADP such as damaged cells or ADP released under turbulent blood flow conditions. The platelet aggregation induced by ADP is regulated by the P2t receptor subtype, which is located in the platelet membrane.

It has recently been shown that antagonists of this receptor offer significant improvements over the other antithrombotic agents. Accordingly, there is a need to find T? Zt antagonists as antithrombotic agents. It has now been found that a series of triazolo- [4,5-d] -pyrimidine derivatives are antagonists of the P2t receptor. Therefore, in a first aspect, the present invention provides a compound of the Formula (I): wherein: - R is an alkyl radical of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or a phenyl group, each group optionally substituted with one or more substituents that are selected or from the group consisting of halogen radicals, OR, NR R, SR11 or alkyl of 1 to 6 carbon atoms (this itself optionally substituted with one or more halogen atoms; R is an alkyl radical of 1 to 8 carbon atoms optionally substituted with one or more substituents selected from the group consisting of halogen radicals, OR 8, NR 9 RX 0, SR 11, cycloalkyl of 3 to 8 carbon atoms, aryl (optionally substituted with one or more alkyl groups and / or halogen atoms) or alkyl of 1 to 6 carbon atoms; or R is a cycloalkyl group of 3 to 8 carbon atoms optionally substituted with one or more substituents which are selected from the group consisting of halogen, OR, alkyl of 1 to 6 carbon atoms or phenyl, these last two groups being optionally substituted with one or more substituents which are selected from the group consisting of halogen radicals, N02, C (0) R8, OR8, SR11, NR12R13, a 5 or 6 membered fused saturated ring containing one or two oxygen atoms, phenyl or alkyl of 1 to 6 carbon atoms, these last two groups being optionally substituted with radicals OR, NR R or one or more halogen atoms; one of R 3 and R 4 is a hydroxy radical and the other is hydrogen, hydroxy or NR 9 R 10; R is a group (CR R) mOR, where m is 0 or 1, R and R are independently a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms or phenyl, these last two groups being optionally substituted with a halogen radical and R is hydrogen, alkyl of 1 to 6 carbon atoms or (CR R) nR, wherein R and R are as defined above, n is 1 to 3 and R14 is COOH, OR15, NR16R17 or CONR16R17; or R is an alkyl radical of 1 to 4 carbon atoms or alkenyl of 2 to 4 carbon atoms, each of which is substituted with one or more groups which are selected from the group consisting of radicals = S, = 0, = NR20 or OR21 and optionally substituted with one or more groups selected from the group consisting of halogen radicals, alkyl of 1 to 4 carbon atoms, phenyl, SR21, N02 or NR22R23 (wherein R21, R22 and R23 are independently hydrogen atom, a radical of alkyl of 1 to 4 carbon atoms or phenyl; R is OR or NR25R26, wherein R24 is hydrogen, alkyl of 1 to 4 carbon atoms or phenyl and R and R are independently hydrogen, alkyl of 1 to 4 carbon atoms, aryl, acyl of 1 to 6 carbon atoms, arylsulfonyl or arylcarbonyl); R8 is a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms optionally substituted with a hydrogen, or R is a phenyl radical optionally substituted with one or more substituents that are selected from the group consisting of halogen, NO2, C radicals (0) R, OR6, SR9, NR ^ R11; R, R and R are independently a hydrogen atom or an alkyl radical of 1 to 6 carbon atoms; R 12 and R 13 are independently a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms, acyl, alkyl, sulfonyl optionally substituted by halogen, or phenylsulfonyl optionally substituted by an alkyl radical of 1 to 4 carbon atoms; Y R, R1 and R are independently a hydrogen atom or an alkyl radical of 1 to 6 carbon atoms; or a pharmaceutically acceptable salt or solvate thereof.

The alkyl groups, either alone or as part of another group, can be straight or branched chain. The compounds of Formula (I) are capable of existing in stereoisomeric forms, including enantiomers, and the present invention extends to each of these stereoisomeric forms and to mixtures thereof, including racemates. The present invention also extends to tautomeric forms and mixtures thereof.

Preferably, the compound of Formula (I) has the following stereogymic: (Ia) Suitably, R is an alkyl radical of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or a phenyl groupeach group being optionally substituted with one or more substituents that are selected from the group consisting of halogen, OR, NR R, SR or alkyl radicals of 1 to 6 carbon atoms (this optionally substituted with one or more halogen atoms) . Preferably, R is an alkyl radical of 1 to 4 carbon atoms or phenyl, each of which may be substituted with a trifluoromethyl group. More preferably, R is a propyl, butyl, trifluoromethylphenyl or 3,3,3-trifluoropropyl radical. 2 _ Suitably, R is an alkyl radical of 1 to 8 carbon atoms optionally substituted with one or more substituents that are selected from the group consisting of radicals, halogen, OR, NR R, SR, cycloalkyl of 3 to 8 atoms carbon, aryl (optionally substituted with one or more alkyl groups and / or halogen atoms, alkyl of 1 to 6 carbon atoms; or 2 R is a cycloalkyl group of 3 to 8 carbon atoms optionally substituted with one or more substituents selected from the group consisting of halogen, OR8, NR9R10, SR11, alkyl of 1 to 6 carbon atoms or phenyl radicals, these being two latter groups optionally substituted with one or more substituents that are selected from the group consisting of halogen radicals, N02, C (0) R8, OR8, SR11, NR12R13, a 5 or 6 membered saturated fused ring containing 1 or 2 atoms of oxygen, phenyl or alkyl of 1 to 6 carbon atoms, these last two groups being optionally substituted with radicals OR, NR R10 or one or more halogen atoms. Aryl groups include phenyl and naphthyl groups. Acyl groups include C (O) alkyl radicals of 1 to 6 carbon atoms such as acetyl and 1-oxopropyl. Preferably, R is an alkyl radical of 1 to 6 carbon atoms or a cycloalkyl group of 3 to 8 carbon atoms, optionally substituted with a phenyl. More preferably, R is a butyl or cyclopropyl group optionally substituted with a phenyl radical, the phenyl group itself being optionally substituted with one or more halogen atoms, alkyl radicals of 3 to 8 carbon atoms, alkoxy, phenoxy or phenyl. Suitably, one of R 3 and R 4 is a hydroxy radical and the other is a hydrogen atom, a hydroxy radical or NR R. Preferably, R and R are hydrogen.

Suitably, R is a group (CR R) mOR, where O or 1, R and R are independently a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms Phenyl, these last two groups optionally substituted with a halogen and R is a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms or (CR R) nR, wherein R and R are as defined above, n is 1 to 3 and R14 is COOH, OR15, NR16R17 or CONR16R17; or R is an alkyl radical of 1 to 4 carbon atoms or alkenyl of 2 to 4 carbon atoms, each of which is substituted with one or more groups which are selected from the group consisting of radicals = S, = 0, = NR or OR and optionally substituted with one or more groups which are selected from the group consisting of halogen radicals, alkyl of 1 to 4 carbon atoms, phenyl, SR 21, NO2 or NR 22R23 (wherein R21, R22 and R23 are independently a hydrogen atom, an alkyl radical of 1 to 4 carbon atoms or phenyl; R 20 is OR24 or NR25R26, wherein R24 is a hydrogen atom, an alkyl radical of 1 to 4 carbon atoms or phenyl, and R and R are independently a hydrogen atom, an alkyl radical of 1 to 4 carbon atoms, aryl, acyl of 1 to 6 carbon atoms, arylsulfonyl or arylcarbonyl.

Preferred R groups include OH, CH 2 OH, CH 2 CH 2 OH, OCH 2 CH 2 OH, CH 2 OCH 2 C (CH 3) 2 OH and 0 CH 2 C (CH 3) 2 OH radicals. Particularly preferred compounds of the present invention include those exemplified herein, both in the form of free bases and in the form of pharmaceutically acceptable salts and solvates. According to the present invention, there is provided a process for the preparation of a compound of the Formula (I) comprising: (a) reacting a compound of the Formula (II): wherein R, R1, R and R are as defined in Formula (I) or are protected derivatives thereof or R 3 and R 4 together form a bond and L is a leaving group, with a compound of Formula (III): R 2 NH 2 (III) wherein &Z is as defined in Formula (I) or is a protected derivative of same, or (b) reacting a compound of Formula (IV): wherein R1 and R2 are as defined in Formula (I) or are protected derivatives thereof and P and P2 are protective groups or hydrogen, with a suitable reagent to introduce a substituent R group, or, for compounds where m is 0: (c) the hydroxylation of a compound of the Formula (V): wherein R 1, R 2 and R 7 are as defined in Formula (I) or are protected derivatives thereof and, optionally, after the steps of subsections (a), (b) or (c) and in any order: • transform one or more functional groups into additional functional groups • remove any protective group • form a pharmaceutically acceptable salt or solvate acceptable. The compounds of Formula (II) can be reacted with amines of Formula (III) in the presence of a base such as a tertiary organic amine, in an inert solvent such as dichloromethane, at room temperature or at elevated temperature. Other suitable bases include inorganic bases such as potassium carbonate. When one or both of R 3 and R 4 are hydroxy radicals, these can be protected in the form of groups OP 1 and OP2, where P1 and P2 are protective groups.

Examples of suitable protecting groups in the compounds of Formulas (II) and (IV) are alkyl radicals of 1 to 6 carbon atoms (preferably methyl), benzyl, (alkyl of 1 to 6 carbon atoms) 3 Si (preferably t-butyldimethylsilyl) and a C (O) alkyl group of 1 to 6 carbon atoms such as acetyl. When both of between R 3 and R4 they are hydroxy radicals, preferably the two groups P and P together with the atoms to which they are attached, form an alkylidene ring such as a methylidene or isopropylidene ring. Alternatively, P 1 and P 2 can form an alkoxymethylidene ring such as ethoxymethylidene. Protective groups can be added and removed using known reaction conditions. The use of protecting groups is described extensively in "Protective Groups in Organic Chemistry", edited by J.W.F. McOmie, Plenum Press (1973), and "Protective Groups in Organic Synthesis", 2nd edition, T.. Greene & P.G.M. Wutz, Wiley-Interscience (1991). The ester protecting groups can be removed by basic hydrolysis, for example using a metal hydroxide, preferably an alkali metal hydroxide such as sodium hydroxide or lithium hydroxide, or quaternary ammonium hydroxide in a solvent, such as aqueous ethanol or tetrahydrofuran aqueous, at a temperature of 10 to 100 ° C, preferably the temperature is about room temperature; or by acid hydrolysis using a mineral acid such as HCl or a strong organic acid such as trichloroacetic acid, in a solvent such as aqueous 1,4-dioxane. The trialkylsilyl protecting groups can be removed by using, for example, a fluoride ion source, for example tetra-n-butylammonium fluoride or hydrogen fluoride. When one or both of P 1 and P 2 are alkyl radicals of 1 to 6 carbon atoms, the deprotection can be carried out using gold tribromide. The benzyl groups can be removed by hydrogenolysis using a transition metal catalyst, for example palladium in carbon, under an atmosphere of hydrogen, at a pressure of 1 to 5 bar, in a solvent such as acetic acid. A compound of Formula (II) can be prepared by diazotizing a compound of Formula (VI): where R and R are as defined in 3 Formula (I) and L is as defined above, and R and R are as defined in Formula (I) or are protected derivatives thereof, or R and R together form a bond, with a metal nitrite for example a alkali metal nitrite, especially sodium nitrite in dilute aqueous acid, by 2 M HCl, or with an alkyl nitrite of 1 to 6 carbon atoms in an inert solvent, at a temperature of -20 to 100 ° C; the preferred conditions are isoamyl nitrite in acetonitrile at 80 ° C. A compound of Formula (VI) in R is CH2OH and R and R are hydroxyl or protected derivatives thereof, L is as defined above, can be prepared by reduction of a compound of Formula (VII) where R 1, L, P1 and P2 are as previously defined. The reduction of the nitro group can be carried out, for example, using hydrogenation with a transition metal catalyst, at a temperature around room temperature, for example palladium on carbon under a hydrogen atmosphere, preferably at a pressure from 1 to 5 atmospheres, in a solvent for example ethanol, or using iron in an acidic solvent such as acetic acid, at a temperature of about 100 ° C. The reduction of the lactam can be carried out using complex metal hydrides such as lithium aluminum hydride, in a solvent such as ether or, preferably, using sodium borohydride in a suitable solvent such as methanol. A compound of Formula (VII) can be prepared by the reaction of a compound of Formula (VIII) wherein L and R are as previously defined and L is a leaving group, for example a halogen atom, wherein L and L are preferably the same, with a compound of Formula (IX): wherein P 1 and P 2 are as previously defined, in the presence of a base such as C 6-alkyl-M or MH, wherein M is a metal ion, for example n-butyllithium, in an inert solvent such as tetrahydrofuran (THF), at a temperature of -10 to 100 ° C. Preferably, sodium hydride is used in THF at room temperature. Preferably, the compound of Formula (IX) has the following stereochemistry, such that the above reactions produce a compound of Formula (Ia): One or more functional groups can be transformed into other functional groups, using standard chemistry. For example, a compound where R is 7 hydrogen can be transformed into a compound where R is a CH2COOH group, by a treatment with a compound of the formula (X): R18OCOCH = N2 (X) wherein R, 18 is an alkyl radical of 1 to 6 carbon atoms, in the presence of rx acetate>. gave, followed by a hydrolysis of the resulting ester. A compound in which R is hydrogen can be transformed into a compound in 7] _4 where R is (CH2) n by a treatment with a base 14 followed by L (CH2) n where L is a leaving group and R is as previously defined or a version protected from it. The SR group can be interconverted, TM oxidation of the sulfur, for example using oxone or metachloroperbenzoic acid (AMCPB), followed by a treatment with a compound R -SM, where R is a different R1 group and M is a metal such as sodium. The compounds of Formula (IV) can be reacted with a suitable reagent to introduce the R group, using conventional chemistry. For example, the compounds of Formula (IV) can be reacted with Zn / H2SO4 to obtain a compound of the Formula (I) wherein R is COCH 2 OH; with Hl to obtain a compound of Formula (I) wherein R is COCH3; or with BF3 / R 'OH (eg, methanol) to obtain a compound of Formula (I) wherein R is COCH2OR', or with light followed by a reducing agent (eg, DIBAL-H) to obtain a compound of the Formula (I) wherein R is CH2CH2OH. The compounds of the Formula (IV) can be prepared from compounds of the Formula (XI): wherein R, R ^ P and P are as previously defined, by a treatment with an activating agent such as an acyl chloride, followed by diazomethane. The compounds of Formula (XI) can be prepared from compounds of Formula (VII) such as those defined above by reducing the nitro group followed by hydrolysis. The hydrolysis can be carried out using a mineral acid such as HCl or a strong organic acid such as trifluoroacetic acid. Preferably, the reduction and hydrolysis are carried out simultaneously using iron in an alcohol solvent, for example ethanol, containing an alkaline earth metal halide such as calcium chloride, at a temperature of about 80 ° C. The compounds of Formula (VI) can also be prepared by the treatment of a compound of Formula (XII): where R 3 and R 4 are as defined in 3 Formula (I) or are protected derivatives thereof, or R 4 and R together form a bond, with a compound of the Formula (VII) such as the one previously defined, followed by the reduction of the nitro group. The reaction is carried out in an inert solvent such as dichloromethane or 1,4-dioxane, in the presence of a non-nucleophilic base such as N, N-diisopropylamine, at a temperature of about -20 to about 150 ° C, preferably at room temperature. Preferably, the compound of Formula (XII) has the following stereochemistry, such that the above reactions produce a compound of Formula (la) such as the one defined above.

R3 (XHa) The compounds of Formula (VI) wherein R and R form a bond and L is SR, can be prepared by reacting a compound of Formula (XIII): wherein the R groups are as defined in Formula (I), with a compound of the Formula (XIV): wherein R is as defined in Formula (I). The reaction can be carried out in the presence of a transition metal complex, preferably tetrakistriphenylphosphine palladium (0). The compounds of Formula (XIII) can be prepared from compounds of Formula (XV): reacting a compound R 1X, where R1 it is as defined in Formula (I) and X is a leaving group such as a halo, followed by a czation. 2 Amines R NH2 can be prepared using the procedures described in H. Nishiyama et al. , Bull. Chem. Soc., Japan, 1995, 68, 1247, P. Neman, Optical Resolution Procedures for Chemical Compounds, Vol., 1, Mines and Related Compounds; Optical Resolution and Information Center: Manhattan College, Riverdale, NY, 1978, p. 120, J. Vallgarda et al. , J. Chem. Soc. Perkin, 1, 1994, 461. Certain amines R2NH2 are novel compounds and form a further aspect of the present invention. All the new intermediates form an additional aspect of the present invention. The salts of the compounds of the Formula (I) can be formed by reacting the free acid or a salt thereof, or the free base, or a salt or a derivative thereof, with one or more equivalents of the appropriate base ( for example ammonium hydroxide optionally substituted with an alkyl group of 1 to 6 carbon atoms, or an alkali metal or alkaline earth metal hydroxide) or an acid (for example a hydrohalic acid (especially HCl), sulfuric acid, oxalic acid or phosphoric acid). The reaction can be carried out in a solvent or in a medium in which the salt is insoluble or a solvent in which the salt is soluble, eg, water, ethanol, THF or diethyl ether, which can be removed under vacuum or by lyophilization. The reaction can also be a metathetic process or it can be carried out in an ion exchange resin. Non-toxic physiologically acceptable salts are preferred, although other salts, e.g., may be useful in the isolation or purification of the product. The compounds of the present invention act as antagonists of the l? 2t receptor. Accordingly, the compounds are useful in therapy, especially adjunct therapy, particularly they are indicated to be used as: inhibitors of platelet activation, aggregation and degranulation, promoters of platelet deaggregation, antithrombotic agents or in the treatment or prophylaxis of unstable angina , coronary angioplasty (PTCA), myocardial infarction, perithrombolysis, primary arterial thrombotic complications of atherosclerosis such as thrombotic or embolic attack, transient ischemic attacks, peripheral vascular disease, myocardial infarction with or without thrombolysis, arterial complications due to surgeries in disease atherosclerotic such as angioplasty, endoarterectomy, surgical fasteners placement, coronary surgery and other vascular grafts, thrombotic complications of surgical or mechanical damage such as tissue salvage after accidental or surgical trauma, surgery Reconstructive surgery including skin and muscle flaps, disorders with a diffuse thrombotic / platelet consumption component such as disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, haemolytic uremic syndrome, thrombotic complications of sepsis, adult respiratory distress syndrome, antiphospholipid syndrome, induced thrombocytopenia by heparin and preclamsia / eclamsia or venous thrombosis such as deep vein thrombosis, veno-occlusive disease, hematological disorders such as myoloproliferative disease, including thrombocythemia, sickle-cell anemia; or in the prevention of mechanically induced platelet activation in vivo, such as cardiopulmonary shunts and extracorporeal membrane oxygenation (prevention of microthromboembolism), mechanically induced platelet activation in vitro, such as use in the preservation of blood products, eg, platelet concentrates or occlusion of shunts such as in renal dialysis and plasmapheresis, thrombosis secondary to vascular damage / inflammation such as vasculitis, arteritis, glomerulonephritis, inflammatory bowel disease and rejection of grafted organs, disorders such as migraine, Raynaud's phenomenon, disorders in which Platelets can contribute to the process of underlying inflammatory disease in the vascular wall such as formation / progression of the atheromatous plaque, stenosis / restenosis and in other inflammatory disorders such as asthma, in which platelets and platelet-derived factors are involved in the ceso of immunological diseases. In accordance with the present invention there is further provided the use of a compound according to the invention in the manufacture of a medicament for the treatment of the aforementioned disorders. In particular, the compounds of the present invention are useful for the treatment of myocardial infarction, thrombotic attack, transient ischemic attacks, peripheral vascular disease and angina, especially unstable angina. The present invention also provides a method for the treatment of the above disorders, which comprises administering to a patient suffering from such disorder, a therapeutically effective amount of a compound according to the present invention. The compounds can be administered topically, e.g., to the lung and / or the respiratory tract, in the form of solutions, suspensions, HFA aerosols and dehydrated powder formulations; or systemically, eg, by oral administration in the form of tablets, pills, capsules, syrups, powders or granules, or by parenteral administration in the form of sterile parenteral solutions or suspensions, by subcutaneous administration, or by rectal administration in the form of suppositories or transdermally. The compounds of the present invention can be administered on their own or in the form of a pharmaceutical composition comprising the compound of the present invention, in combination with a pharmaceutically acceptable diluent, adjuvant or vehicle. Particularly preferred compositions do not contain materials capable of causing an adverse reaction, e.g. an allergic reaction The dehydrated powder formulations and pressurized HFA aerosols of the compounds of the present invention can be administered by oral or nasal inhalation. For the inhalation of the compound, it is desirable that it be finely pulverized. The compounds of the present invention can also be administered by means of a dehydrated powder inhaler. The inhaler can be a single dose or multiple dose inhaler and can be a dehydrated powder inhaler powered by respiration. One possibility is to mix the finely powdered compound with a carrier substance, e.g., a monosaccharide, disaccharide or polysaccharide, a sugar alcohol or another polyol. Suitable carriers include sugars and starch. Alternatively, the finely powdered compound can be coated with another substance. The powder mixture can also be distributed in hard gelatin capsules, each containing the desired dose of the active compound. Another possibility is to process the finely powdered powder into spheres that break during the inhalation process. The spheronized powder can be filled in a receptacle of a multi-dose inhaler, e.g., known as Turbuhaler®, in which a metering unit measures the desired amount which is subsequently inhaled by the patient. With this system, the active compound, with or without a carrier substance, is administered to the patient. The pharmaceutical composition comprising the compound of the present invention may conveniently be in the form of tablets, pills, capsules, syrups, powders or granules for oral administration.; sterile parenteral or subcutaneous solutions suspensions for parenteral administration or suppositories for rectal administration. For oral administration, the active compound can be mixed with an adjuvant or a vehicle, eg, lactose, sucrose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatin or polyvinyl pyrrolidone and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin and the like, and then compressed into tablets. If coated tablets are needed, the cores prepared in the manner described above can be coated with a concentrated sugar solution, which may contain, e.g., gum arabic, gelatin, talc, titanium dioxide and the like. Alternatively, the tablet can be coated with a suitable polymer dissolved either in a volatile organic solvent, or in an aqueous solvent. For the preparation of soft gelatine capsules, the compound can be mixed, e.g., with a vegetable oil or polyethylene glycol. Hard gelatin capsules may contain granules of the compound using any of the aforementioned excipients for the tablets, e.g., lactose, sucrose, sorbitol, mannitol, starches, cellulose derivatives or gelatin. Likewise, liquid or semi-solid formulations of the drug can be emptied into hard gelatin capsules. Liquid preparations for oral administration may be in the form of syrups or suspensions, for example solutions containing the compound, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally, such liquid preparations may contain coloring, flavoring, saccharin and carboxymethylcellulose agents as a thickening agent or other excipients known to those skilled in the art. The present invention is illustrated with the following Examples. In the Examples, the NMR spectra were measured on a Varian Unity Inova 300 or 400 spectrometer and the mass spectra (MS) were measured as follows: The El spectra were obtained with a VG 70-250S spectrometer or Finnigan Mat spectrometer Incos-XL, the FAB spectra were obtained on a VG70-250SEQ spectrometer, the ESI and APCI spectra were obtained on a Finnigan Mat SSQ7000 spectrometer or a Micromas Plarform spectrometer. Separations by Preparative high performance liquid chromatography (HPLC), usually performed using a Novapak®, Bondapak® or Hypersil® column, packed with reversed-phase silica gel BDSC-18. Rapid chromatography (indicated in the Examples as (SÍO2)) was carried out using Fisher Matrix silica gel, 35-70 μm. For the Examples that showed the presence of rotamers in the proton NMR spectra, only the chemical changes of the main rotamer were noted. For the compounds prepared by parallel synthesis, the products were collected in ethanol (500 μl) and analyzed using an analytical HPLC machine (HP1100), against a standard calibration curve, in order to estimate the concentration of the product. The ethanol was evaporated and the residue was collected with an appropriate volume of dimethyl sulfoxide (DMSO), based on the analysis by CLAR, to obtain a solution with a concentration 5 mM for the biological tests.

EXAMPLE 1 [ÍS- [la, 2a, 3ß, 5ß- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopenfcane-1,2-diol a) [3aR- [3aa, 4a, 6a (lR *, 2S * ), 6aa] -tetrahydro-2, 2-dimethyl-6- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] ] -pyrimidin-3-yl] -4H-cyclopenta-l, 3-dioxol-4-methanol N, N-diisopropylethylamine (21 ml) was added to a solution [3aR- (3aa, 4a, 6a, 6aa)] - 6- [7-chloro-5- (propylthio) -3Ji-l, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4J? -cyclopenta -l, 3-dioxol-4-methanol (prepared in the manner described in WO International Publication 97/03084) (55 g) and [R- < R *, R *] -2, 3-dihydroxybutanedioate of (IR-trans) -2-phenylcyclopropanamine (1: 1) (prepared in the manner described by L. A. Mitscher et al., J. Med. Chem., 1986, 29, 2044) (11.3 g) in dichloromethane (500 ml). The reaction mixture was stirred at room temperature during 3 hours, then washed with water, dried and evaporated. The residue was purified (SiO2, ethyl acetate / dichloromethane, 3: 7 as eluent), to obtain the subtitle compound (19 g). MS (APCI) 497 (M + H +, 100%). b) [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. A product solution from step (a) (18.5 g) in methanol (11) and 2N HCl (150 ml) was stirred at room temperature for 2 hours and concentrated in vacuo. Water (500 ml) was added and the product was collected by filtration and dried (16.7 g). MS (APCI) 457 (M + H +, 100%). NMR dH (d6-DMS0) 9.33 (H, d), 7.30-7.16 (5H, m), 4.72 (2H, m), 4.43 (1H, m), 3.87 (H, d), 3.48 (2H, m) , 3. 20 (ÍH,), 2.95 and 2.85 (2H, 2x m), 2.26 (ÍH, m), 2.12 (2H, m), 1.85 (HH, m), 1.49 (3H, m), 1.33 (HH, m), 0.82 (3H, t). EXAMPLE 2 [IR- (la, 2a, 3ß, 5ß)] -3- [7- [(cyclopropyl) -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5 d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol a) [3aR- (3aa, 4a-6a, 6aa)] -6- [7- [(cyclopropyl) -amino] ] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -fcefcrahydro-2,2-dimethyl-4H-cyclopenta-l, 3-dioxole -4- methanol. A solution of [3aR- (3aa, 4a-6a, 6aa)] -6- [7-chloro-5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin- 3-yl] -tetrahydro-2, 2-dimethyl-4i? -cyclopenta-l, 3-dioxol-4-methanol (0.5 g) and cyclopropanamine (0.3 ml) in 1,4-dioxane (20 ml) was heated to Reflux. The heat source was removed and the reaction mixture was stirred for 1 hour. The mixture was concentrated and the residue was purified (SiO2, ethyl acetate / isohexane, 1: 1 as eluent) to obtain the subtitle compound (0.4 g). MS (APCI) 421 (M + H +, 100%). b) [lR- (the, 2a, 3ß, 5ß)] -3- [7- [(cyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, -d] -pyrimidin-3-yl ] -5- (hydroxymethyl) -cyclopentane-1,2-diol. A solution of the product from step (a) (0.12 g) in trifluoroacetic acid (4 ml) / water (1 ml) was stirred at room temperature for 2 hours, emptied into an aqueous solution of sodium bicarbonate and subjected to to extraction with dichloromethane. The extract was concentrated and purified (SiO2, ethyl acetate as eluent) to obtain the title compound (0.10 g). MS (APCI) 381 (M + H +, 100%). NMR dH (d6-DMSO) 9.00 (HH, s), 5.00 (2H,), 4.70 (2H,), 4.45-4.40 (HH, m), 3.90 (HH, br s), 3.50-3.40 (2H, m ), 3.10-3.00 (3H, m), 2.25-2.20 (HH, m), 2.19-2.16 (HH, m), 1.90-1.80 (HH, m), 1.80-1.60 (2H, m), 1.00 (3H , t), 0. 90-0.60 (4H, m).

EXAMPLE 3 [IR- (la, 2a, 3ß, 5ß)] -3- [7- (butylamino) -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidine -3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. The title compound was prepared from [3aR- (3aa, 4a, 6a, 6aa)] -6- [7- (butylamino) -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3 -yl] -tetrahydro-2, 2-dimethyl-4Ji-cyclopenta-l, 3-dioxol-4-methanol (prepared in the manner described in International Publication WO 97/03084), in accordance with the method of Example 2 , step of subsection (b). MS (FAB) 397 (M + H +, 100%). NMR dH (d6-DMSO) 6.25 (H, m), 5.15 (H, s), 5.00 (HH, m), 4.45 (1H, m), 4.25 (HH, s), 3.90-3.60 (4,), 3.10 (2H, m), 2.94 (HH, s), 2.75 (HH, m), 2.45 (HH, m), 2.20 (HH, m) 2.05 (HH, m), 1.78 (2H, m), 1.65 (2H, m), 1.46 (2H, m), 1.07 (3H, t), 1.00 (3H , t). EXAMPLE 4 [IR- (la, 2a, 3β, 5b)] -3- [7- (butylamino) -5- [[4- (trifluoromethyl) -phenyl] -thio] -3H-1, 2, 3-triazolo - [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopenan-1,2, -diol. a) [3aR- (3aa, 4a, 6a, 6aa)] -6- [7- (butylamino) -5- (propylsulfonyl) -3H-1,2,3-triazolo- [4,5-d] -pyrimidine -3- ü] -betrahydro-2,2-dimet ^ l-4i? -ca.dLopenta-l, 3-oioxol-4 ^ pe3nol. 3-Chloroperoxybenzoic acid (1.0 g) was added to a solution of [3aR- (3aa, 4a, 6a, 6aa)] -6- [7- (butylamino) -5- (propylthio) -3H-1, 2, 3 -triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4i? -cyclopenta-l, 3-dioxol-4-methanol (0.88 g) in dichloromethane (100 ml) and the resulting solution was stirred at room temperature for 18 hours. The solution was washed with a solution of aqueous sodium metabisulfite (3 x 10 ml) and then dried and concentrated. Purification (SiO2, ethyl acetate as eluent) yielded the compound of 1 subtitle (0.3 g). MS (APCI) 469 (M + H +, 100%). b) [3aR- (3aa, 4a, 6a, 6aa)] -6- [7- (butylamino) -5- [[4- (trifl-orornethyl) -phenyl] -thio] -3H-1, 2,3- triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol. 4- (Trifluoromethyl) -thiophenol (0.18 g) was added to a suspension of sodium hydride (60%, 40 mg) in THF (10 ml). After 30 minutes, a solution of the product from step (a) (0.23 g) in THF (10 ml) was added dropwise and the reaction mixture was stirred for 45 minutes. The reaction mixture was added slowly to a solution of sodium chloride (10 ml) containing acetic acid (1 ml) and then the solution was extracted with ethyl acetate (50 ml). The organic phase was dried and concentrated and the residue was purified (SiO2, from diethyl ether to diethyl ether / ethane 9: 1 as eluent), to obtain the sub-title compound. MS (APCI) 539 (M + H +, 100%) c) [LR- (la-2a-3ß, 5ß)] -3- [7- (butylamino) -5- [[4- (trifluoromethyl) -phenyl] -thio] -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. This compound was prepared according to the method of Example 2, step of part (b), using the product of the step of part (b). MS (APCI) 469 (M + H +, 100%).

NMR dH (d6-DMSO) 9.08 (HH, m), 7.88-7.78 (4H, dd), . 00-4.91 (2H, m), 4.71-4.64 (2H, m), 4.36-4.30 (ÍH, m), 3. 80-3.75 (ÍH, m), 3.42-3.17 (1H, m), 3.29-3.15 (2H, m), 2.52-2.08 (3H, m), 1.80-1.70 (ÍH, m), 1.37-1.32 (2H , m), 1. 17-1.07 (2H, m), 0.77 (3H, t). EXAMPLE 5 2- [[[lR (la, 2ß, 4a)] -4- [7- (butylamino) -5- (propylthio) -3H-1, 2,3, -triazolo- [4,5-d] acid ] -pyrimidin-3-yl] -2,3-dihydroxy-cyclopentyl] -methoxy] -acetic acid. a) Ethyl ester of [3aR- (3aa, 4a, 6a, 6aa] -2- [6- [7- (butylamino) -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5] -d] - pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methoxy] -acetic.

A solution of [3aR- (4a, 6a, 6aa)] -2- [6- [7-chloro-5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidine] -3-yl] -tetrahydro-2, 2-dimethyl-4J? -cyclopenta-l, 3-dioxol-4-methanol (0.7 g) and rhodium acetate (0.39 g) in dichloromethane (20 ml) was treated with a solution of ethyl diazoacetate (0.21 ml) in dichloromethane (10 ml) for 3 hours. The reaction mixture was stirred at room temperature during 60 hours, it was concentrated and purified (SiO2, isohexane / ethyl acetate, 3: 1 as eluent). The resulting intermediate was taken up with 1,4-dioxane (10 ml), n-butylamine (0.2 ml) was added and the solution was stirred for 18 hours and then concentrated. Purification (SiO 2, from dichloromethane to dichloromethane / ethyl acetate, 8: 2 as eluent) yielded the subtitle compound (0.2 g). MS (FAB) 523 (M + H +, 100%). b) Ethyl ester of 2- [[[IR- (la, 2ß, 3ß, 4a)] -4- [7- (butylamino) -5-propylthio-3H-1, 2,3-triazolo- [4,5 -d] - pyrimidin-3-yl] -2,3-dihydroxycyclopentyl] -methoxy] -acetic acid. It was prepared in accordance with the method of Example 2, step of part (b) using the product of part (a). MS (FAB) 483 (M + H +, 100%). d) 2 - [[[R- (la, 2ß, 3ß, 4a)] -4- [7- (butylamino) -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5] -d] -pyrimidin-3-yl] -2,3-dihydroxycyclopentyl] -methoxy] -acetic acid. A mixture of the product from step (c) (96 mg) and lithium hydroxide monohydrate (8.5 mg) in tetrahydrofuran (10 ml) was stirred for 18 hours and then concentrated. Purification (SiO2, from dichloromethane to ethyl acetate to ethyl acetate / methanol, 9: 1 as elution gradient) yielded the title compound (0.04 g). MS (FAB) 455 (M + H +, 100%) dH NMR (d6-DMSO) 12.60 (H, m), 8.97 (H, m), 4.99. (2H, m), 4.82 (HH, m), 4.42 (2H, m), 4.04 (2H, m), 3.92 (2H, m), 3.60-3.51 (HH, m), 3.50-3.40 (3H, m ), 3.10-3.00 (2H, t), 2.30-2.20 (2H, m), 1.88 (HI, m), l ".67 (2H, m), 1.55 (4H, m), 1.33 (2H,), 1.07-0.83 (6H, m). EXAMPLE 6 1- [[ÍS- [la, 2ß-3β-4a- (ÍS *, 2R *)]] -2, 3-dihydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentyl] -2-hydroxyethanone. a) Acid [3aR- (3aa-4a, 6a, 6aa)] -6- [[5-amino-6-chloro-2- (propylthio) -4-pyrimidinyl] -amino] -tetrahydro-2, 2-dimethyl -4H-cislopenta-l, 3-dioxol-4-carboxylic acid. Powdered iron (10.0 g) was added to a stirring solution of [3aS- (3aa, 4ß, 7ß, 7aa)] -5- [6-chloro-5-nitro-2- (propylthio) -pyrimidin-4- il] -tetrahydro-4,7-methano-2,2-dimethyl-1,3-dioxolo- [4,5-c] -pyrimin-6- (3aIT) -one (prepared in the manner described in International Publication WO 07/03084) (10.0 g) and calcium chloride in ethanol (140 ml). The reaction mixture was heated to reflux temperature for 10 minutes and then filtered through celite, washed several times with hot ethanol. The filtrate was concentrated to obtain the subtitle compound (9.3 g). MS (FAB) 405, 403 (M + H +), 405 (100%). b) Acid [3aR- (3aa, 4a, 6a, 6aa) J -6- [7-chloro-5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin- 3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-carboxylic acid. Isoamyl nitrite (6.02 ml) was added to a solution of the product from step (a) (9.28 g) in acetonitrile (80 ml) and the solution was heated at 70 ° C for 1 hour. The reaction mixture was cooled, concentrated and purified (SiO2, ethyl acetate / isohexane, 2: 1 as eluent) to obtain the subtitle compound (7.9 g). MS (FAB) 416, 414 (M + H +), 414 (100%). c) Acid [3aR- (3aa, 4a, 6a, 6aa)] -tetrahydro-2,2-dimethyl-6- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -3-yl] -4H-cyclopenta-1,3-dioxol-4-carboxylic acid. It was prepared according to the method of Example 1, step of part (a) using the product of the step of part (b). MS (APCI) 511 (M + H +, 100%). d) l- [[lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -2,3-dihydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopen-yl] -2-hydroxyethanone. Isobutyl chloroformate (0.38 ml) was added to an ice-cooled solution of the product from step (c) (0.50 g) and N-methylmorpholine (0.11 ml) in tetrahydrofuran (20 ml). The solution was stirred at room temperature for 90 minutes before adding it to a solution of diazomethane (1.0 g) in ether (100 ml). The solution was stirred for 30 minutes, then concentrated and the diazoketone was purified (SiO2, isohexane / diethyl ether, 1: 1 as eluent). The diazoketone (0.25 g) was taken up with 1,4-dioxane (10 ml) / 2 N sulfuric acid (10 ml) and then heated at 40 ° C for 2 hours. The reaction mixture was subjected to extraction with ethyl acetate and the extracts were washed with water and then dried and concentrated. Purification (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, elution gradient from 70:30 to 0: 100 over a period of 15 minutes) yielded the title compound (0.09 g). MS (APCI) 485 (M + H +, 100%). NMR dH (d6-DMSO) 9.36 (1H, d), 7.31-7.15 (5H, m), . 24 (2H, t), 5.13 (HH, t), 5.01 (1H, m), 4.33 (HH, m), 4.23 (2H, m), 4.13 (1H, m), 3.18 (2H, m), 2.96 -2.94 (HH, m), 2.96-2.84 (HH, m), 2.30 (2H,), 2.13 (HH, m), 1.49 (3H,), 1.34 (ÍH, m), 0.81 (3H, t). EXAMPLE 7 1- [[ÍS- [la, 2ß, 3ß, 4a]] -4- [7- (butylamino) -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] ] -pyrimidin-3-yl] -2,3-dihydroxycyclopentyl] -2-hydroxyethanone. a) Acid [3aR- (3aa, 4a, 6a, 6aa)] -6- [7- (butylamino) -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] - pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxole-4-carboxylic acid. The title compound according to the method of Example 1, step of part (a) using the product of Example 6, step of part (b) and butylamine. MS (APCI) 411 (M + H +, 100%). b) l - [[lS- [la, 2ß-3ß-4a]] -4- [7 (butylamino) -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -2, 3-dihydroxy-cyclopentyl] -2-hydroxyethanone It was prepared according to the method of Example 6, step of part (d) using the product of the step of part (a). MS (APCI) 425 (M + H +, 100%). NMR dH (d6-DMS0) 9.00 (HH, t), 5.26 (HH, t), 5.24 (ÍH, t), 5.14 (ÍH, t), 5.03 (ÍH, m), 4.38 (ÍH, m), 4.21 (ÍH, m), 4.13 (ÍH, m), 3.51 (2H, m), 3.15 ( 1H, m), 3.09 (HH), 2.30 (2H, m), 1.73 (HH, m), 1.61 (2H, m), 1.38 (2H, m), 1.09 (3H, t), 0.91 (3H, t). EXAMPLE 8 l - [[lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -2, 3-dihydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentyl] -ethanone. Isobutyl chloroformate (2.54 ml) was added to an ice-cooled solution of the product of Example 6, step (c) (2.00 g) and N-methylmorpholine (0.52 ml) in tetrahydrofuran (50 ml). The solution was stirred at room temperature for 90 minutes before adding it to a solution of diazomethane (4.0 g) in ether (200 ml). The reaction mixture was stirred for 30 minutes and concentrated. The crude diazoketone (2.05 g) was dissolved in chloroform (50 ml), 47% aqueous Hl (25 ml) was added and the solution was stirred at room temperature for 10 minutes before adding a saturated solution of sodium thiosulfate (100 g. ml). The reaction mixture was extracted with dichloromethane and the extracts were washed with water, dried and concentrated. The residue was taken up in methanol (300 ml), filtered and the filtrate was concentrated to 1/4 volume before adding trifluoroacetic acid / water (1: 1) 50 ml). After 2 hours, the mixture was concentrated and the residue was purified (SiO2, ethyl acetate / dichloromethane, 1: 3 as eluent, then HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, elution gradient from 60:40 to 0: 100 over a period of 15 minutes) to obtain the title compound (0.11 g). MS (APCI) 469 (M + H +, 100%). NMR dH (d6-DMSO) 9.35 (lh, d), 7.31-7.15 (5H, m), . 21 (2H, m), 4.99 (HH,), 4.27 (HH,), 4.17 (1H, m), 3. 21 (HH, m), 3.10 (1H, m), 2.95-2.83 (2H, m), 2.35 (2H, m), 2.22 (3H, s), 2.13 (HH, m), 1.50 '(3H, m ), 1.33 (ÍH, m), 0. 81 (3H, t). EXAMPLE 9 1- [[ÍS- [la, 2ß-3ß, 4a] - [7- (butylamino) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidine -3-yl] -2, 3-dihydroxycyclopethyl] -ethanone. The title compound was prepared according to the method of Example 8, using the product of Example 7, step of part (a). MS (APCI) 409 (M + H +, 100%).

NMR dH (d6-DMSO) 8.98 (HH, t), 5.22 (2H, m), 5.00 (HH, q), 4.27 (HH, m), 4.19 (1H, m), 3.48 (2H, m), 3.13 (3H, m), 2.32 (2H, m), 2.23 (3H, s), 1.71 (2H, m), 1.63 (2H, m), 0.98 (3H, m), 0.91 (3H, t). EXAMPLE 10 [lS- [la, 2a, 3β, 5β- (lS * -2R *)]] -3- (1-hydroxy-1-methylethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. Methylmagnesium bromide (3 M solution in diethyl ether, 4 ml) was added to a solution of the product of Example 8 (0.15 g) in tetrahydrofuran and the solution was stirred at room temperature for 30 minutes before adding ice / water (10 ml. ), followed by 1 N hydrochloric acid (1 ml). The reaction mixture was extracted with ethyl acetate and the extracts were washed with water, dried and concentrated. Purification (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, elution gradient from 70:30 to 0: 100 over a period of 15 minutes) yielded the title compound (0.13 g). MS (APCI) 485 (M + H +, 100%). NMR dH (d6-DMS0) 9.34 (HH, d), 7.31-7.15 (5H, m), 4.90 (2H, m), 4.57 (HH, m), 4.35 (3H, m), 3.93 (1H, m) , 3.22 (ÍH, m), 2.97-2.51 (2H,), 2.07 (3H,), 1.95 (ÍH, s). 1. 51 (3H, m), 1.33 (ÍH, m), 1.31 (3H, s), 1.18 (3H, s), 0.8 (3H, t). EXAMPLE 11 [SS- [la, 2a-3β-5β- (1S *, 2R *)]] - 3 - (2-hydroxyethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- ( propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) Ethyl ester of [IR- [la, 2β, 3β, 4a- (1R *, 2S *)]] -2,3-dihydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentaneacetic acid. Isobutyl chloroformate (2.54 ml) was added to an ice-cooled solution of the product of Example 6, step (c) (2.00 g) and N-methylmorpholine (0.52 ml) in tetrahydrofuran (50 ml). The solution was stirred at room temperature for 90 minutes and then added to a solution of diazomethane (4.0 g) in ether (200 ml). The solution was stirred for 30 minutes and then concentrated. The crude diazoketone (1.50 g) was taken up in methanol (100 ml), cooled in ice / water and irradiated with a mercury lamp of 400 W for 10 minutes. The solution was concentrated and purified (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, elution gradient from 40:60 to 0: 100 over a period of 15 minutes) to obtain the subtitle compound (0.39). g). MS (APCI) 539 (M + H +, 100%). b) [ÍS- [la, 2a, 3β, 5β- (1S *, 2R *)] j -3- (2-hydroxyethyl) -5- [7- [(2-phenylcislopropyl) -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. DIBAL-H® (1.5 M solution in toluene, 2 ml) was added to an ice-cooled solution of the product from step (a) (0.35 g) in toluene (20 ml) and the solution was stirred at this temperature for 30 minutes before adding ethyl acetate (2 ml). The solution was concentrated and the residue was taken up with trifluoroacetic acid (15 ml) / water (15 ml) and stirred for 30 minutes. The reaction mixture was concentrated and the residue was taken up in methanol (10 ml) and an aqueous solution of 10% potassium carbonate (5 ml) was added. After 30 minutes, the reaction mixture was extracted with ethyl acetate and washed with water, dried and concentrated. Purification (HPLC, Novapak® column C18, 0.1% aqueous ammonium acetate / acetonitrile, elution gradient from 60:40 to 0: 100 over a period of 15 minutes) yielded the title compound (0.21 g). MS (APCI) 471 (M + H +, 100%). NMR dH (d6-DMSO) 9.33 (1H, d), 7.31-7.15 (5H,), . 00 (1H, d), 4.96 (ÍH, m), 4.77 (ÍH, d), 4.51 (ÍH, t), 4. 39 (HH, m), 3.76 (HH, m), 3.45 (2H, m), 3.18 (HH, m), 2. 87 (2H, m), 2.37 (HH,), 2.13 (HH,), 2.03 (HH, m), 1.75 (2H, m), 1.51 (4H, m), 1.34 (HH, m), 0.83 (3H , t). EXAMPLE 12 [lS- [la, 2β, 3β-4a- (lS *, 2R *)]] -4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2 , 3-triazolo- [4,5-d] -pyrimidin-3-yl] -syclopentane-1, 2,3-diol. a) (1S-ci-5) -4- [[6-chloro-5-nitro-2- (propylthio) -pyrimidin-4-yl] -amino-2-cyclopenten-1-ol. To a solution of 4,6-dichloro-5-nitro-2-propylthiopyrimidine (prepared in the manner described in International Publication WO 97/03084) (4.00 g) and triethylamine (2.00 ml) in anhydrous tetrahydrofuran (THF) (100 ml) was added a solution of [lS-cis] -4-amino-2-cyclopenten-1-ol (prepared in the manner described by SF Martin et al., Tetrahedron Lett., 1992, 33, 3583) (1.48 g) in THF / 1, 4-dioxane, 2: 1 (150 ml) by dripping over a period of 1 hour. The reaction mixture was filtered, concentrated and purified (SiO2, ethyl acetate / isohexane, from 1: 4 to 1: 1 as eluent) to the subtitle compound (3.18 g). MS (APCI) 313 (M-H20 + H +, 100%). b) (lS-cis) -4- [[5-amino-6-chloro-2- (propylthio) -pyrimidin-4-yl] -amino] -2-cyclopenten-1-ol. Iron powder (2.30 g) was added to a stirring solution of the product from step (a) (2.61 g) in acetic acid (100 ml). The reaction mixture was stirred at room temperature for 2 hours, concentrated to half the volume, diluted with ethyl acetate and washed with water. The organic phase was dried and concentrated to obtain the subtitle compound (2.28 g). NMR dH (d6-DMSO) 7.03 (HH, d), 5.93-5.90 (1H,), 5.85-5.82 (HH,), 5.05 (HH, d), 4.91-4.85 (2H, m), 4.66-4.60 ( ÍH, m), 2.94 (2H, t), 2.77-2.68 (ÍH, m), 1.69-1.57 (2H, sextuplete), 11.48-1.42 (ÍH, quintuplete), 0.94 (3H, t). c) (lS-cis) -4- [7-chloro-5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -2-cyclopenten- LOL . It was prepared in accordance with the method of Example 6, step of subsection (b) using the product of the step of subsection (b). MS (APCI) 312 (M + H +), 224 (100%). d) (lR-fcrans-N- [(2,4-dimethoxyphenyl) -methyl] -2-pheny1cycloppanamine A solution of [R- (R *, R *;] -2, 3-dihydroxybutanedioate of (IR-) trans) -2-phenylcyclopropanamine (1: 1) (prepared as described in LA Mitscher et al., J. Med. Chem., 1986, 29, 2044) (1.92 g) in 1 N aqueous NaOH (50 ml) was stirred for 10 minutes and it was extracted with dichloromethane. The extract was dried, evaporated and the residue was dissolved in methanol (30 ml). To this mixture was added 2,4-dimethoxybenzaldehyde (1.12 g) and the pH was adjusted to 5 with acetic acid. Sodium cyanoborohydride (0.46 g) was added. The mixture was stirred overnight, made basic with 2N NaOH and extracted with ethyl acetate. The extract was dried, evaporated and purified (SiO2, methanol / dichloromethane / O.880 ammonia, 2: 98: 0.1 as eluent) to obtain the title compound (1.10 g). NMR dH (d6-DMSO) 7.23-6.97 (6H, m), 6.49-6.41 (2H, m), 3.73 (3H, s), 3.69 (3H, s), 3.66 (2H, s), 2.21-2.16 ( ÍH, m), 1.82-1.76 (ÍH, m), 1.01-0.87 (2H, m). e) [ÍS- [la, 4a- (1S *, 2R *)]] -4- [N - [(2,4-dimethoxyphenyl) -methyl] - (2-phenylcyclopropyl) -amino] -5- (propylthio) ) -3H- 1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -2-cyclopen en-1-ol. A solution of the product of step of subsection (c) (0.73 g), the product from the step of part (d) (0.73 g) and N, N-diisopropylethylamine (815 μl) eh 1,4-dioxane (25 ml), was stirred at room temperature for 1 hour. The reaction mixture was concentrated and the residue was purified (SiO2, ethyl acetate / hexane, 1: 2 as eluent) to obtain the subtitle compound (1.18 g). MS (APCI) 559 (M + H +, 100%). f) [ÍS- [la, 2ß, 3ß, 4a- < 1S *, 2R *)]] -4- [7- [N - [(2,4-dimethoxyphenyl) -methyl] - (2-phenylcyclopropyl) -amino-5- (propylthio) -3H-1, 2, 3 -triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol.

To product solution of step of subsection (e) (0.50 g) in acetone (10 ml) and water (7 ml), was added N-methylmorpholine-N-oxide (0.38 g) followed by osmium tetraoxide (390 μl, 2.5% solution in t-butanol). The mixture was stirred at room temperature overnight and then treated with sodium hydrosulfite (0.90 g). The suspension was filtered through celite and the product was purified (SiO2, ethyl acetate / hexane, 1: 1 as eluent) to obtain the subtitle compound (0.22 g). 'MS (APCI) 593 (M + H +, 100%). g) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7- [2- (phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2 , 3- triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol. It was prepared in accordance with the method of Example 2, step of subsection (b) using the product of the step of subsection (f). Purification (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, 60:40) yielded the title compound (0.12 g). MS (APCI) 443 (M + H +, 100%). NMR dH (d6-DMS0) 7.29 (2H, m), 7.16 (3H, m), 5.11-4.91 (3H, m), 4.97 (H, q), 4.67 (H, m), 3.93 (H, br s ), 3.78 (1H, m), 3.22 (1H, quintet), 2.95-2.81 (2H, m), 2.58 (1H, m), 2.13 (H, m), 1.91 (H, m), 1.51 (3H, m), 1.31 (ÍH,), 0.81 (3H, t). EXAMPLE 13 Hemiamonium salt of 2- [[[S] - [la, 3β, 4a- (1S *, 2R *)]] - 3-hydroxy-4- [7- [(2-phenylcyclopropyl) -amino-5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentyl] -oxy] -acetic acid. a) 1,1-dimethylethyl ester of 2- [[[S] - [la, 4a- (1S *, 2R *)]] -4- [7- [N- [2,4-dimethoxyphenyl] -methyl] - (2-phenylcyclopropyl) -amino-5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -2-cyclopentenyl] -oxy] -acetic acid. To a solution of the product of Example 1 step of part (e) (1.20 g) in toluene (10 ml) was added aqueous NaOH (5N, 10 ml) followed by tetrabutylammonium bromide (0.10 g) and the mixture was stirred for 30 minutes. Dimethyl sulfoxide (670 μl) and tert-butyl bromoacetate (3.47 ml) were added and the reaction mixture was stirred for 1 hour. The organic phase was washed with water and with brine, dried and evaporated. The residue was purified (SiO2, ethyl acetate / hexane, from 15:85 to 3: 7 as eluent) to obtain the subtitle compound (0.96 g). MS (APCI) 673 (M + H +, 100%). b) 2-dimethylethyl ester of 2- [[[ÍS- [la, 3β, 4a- (1S *, 2R *)]] -4- [7- [N- [(2,4-dimethoxyphenyl) - methyl] - (2-phenylcyclopropyl) -amino] 5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -3-hydroxycyclopentyl] -oxy] - acetic acid and 1,1-dimethylethyl ester of 2 - [[[lS- [Ia, 2β, 4a- (1S *, 2R *)]] -4- [7- [N- [(2,4-dimethoxyphenyl) - methyl] - (2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -2- hydroxycyclopentyl] -oxy] -acetic A product solution from step (a) (1.08 g), in tetrahydrofuran (15 ml) at 0 ° C, was treated with a complex of borane-tetrahydrofuran (1 M solution in tetrahydrofuran, 8.02 ml) by dropping- The reaction mixture was stirred at 0 ° C for 16 minutes. hours. Methanol was added and the mixture was stirred at room temperature and then concentrated. The residue was dissolved in diglyme (10 ml) and then treated with trimethylamine-N-oxide (0.48 g). The reaction mixture was heated at 130 ° C for 2 hours and then diluted with ethyl acetate and washed with brine, with a 1N HCl solution and with an aqueous solution of sodium bicarbonate, dried and concentrated. Purification (SIO2, acetate / hexane, 3: 7 as eluent) yielded the following two products: (i) 1,1-dimethylethyl ester of 2- [[[S] - [la, 3ß, 4a- (IS *, 2R *)]] -4- [7- [N- [(2,4-dimethoxy-enyl) -methyl] - (2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo - [4,5-d] -pyrimidin-3-yl] -3-hydroxycyclopentyl] -oxy] -acetic acid (0.33 g). NMR dH (d6-DMS0) 7.27-7.11 (5H, m), 6.98 (HH, d), 6.54 (HH, d), 6.39 (1H, m), 5.23 (2H, br m), 5.03 (HH, d ), 4.80 (3H, m), 4.20 (HH, m), 3.95, (2H, s), 3.71 (3H, s), 3.66 (3H, s), 3.00-2.90 (3H, m), 2.65 (HH) , m), 2.38 (HH, br), 2.30-2.10 (2H, m), 1.95 (HH, m), 1.60 (2H, sextuplete), 1.45 (HH, m), 1.43 (9H, s), 0.90 ( 3H, t). (ii) 1,1-dimethylethyl ester of 2- [[[ÍS- [la-2β, 4a- (1S *, 2R *)]] -4- [7- [N- [(2,4-dimethoxyphenyl)] -methyl] - (2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -2- hydroxycyclopentyl] -oxi ] -acetic (0.21 g). NMR dH (d6-DMS0) 7.27-7.11 (5H, m), 6.98 (HH, d), 6.54 (HH, d), 6.40-6.36 (1H, m), 5.27 (2H,), 4.89 (HH, d ), 4.25 (HH, m), 4.04 (2H, s), 3.88 (HH, m), 3.71 (3H, s), 3.65 (3H, s), 3.00-2.90 (3H, m), 2.67 (HH, m), 2.37 (HH, m), 2.30-2.10 (2H, m), 1.61 (2H, sextuplete), 1.44 (HH, m), 11.43 (9H, s), 0.91 (3H, t). c) Hemiamonium salt of the acid 2- [[[ÍS- [la, 3β, 4a- (1S *, 2R *)]] - 3-hydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentyl] -oxy] -acetic acid. The title compound was prepared according to the method of Example 2, step of part (d) using the product of the step of part (b) (i). MS (APCI) 485 (M + H +, 100%). NMR dH (d6-DMSO) 7.31-7.15 (5H, m), 4.78-4.68 (2H, m), 4.17 (H, m), 3.90 (2H, s), 3.20 (1H,), 2.97-2.81 (2H ,), 2.65-2.52 (HH, m), 2.25-2.11 (3H,), 1.92-1.85 (1H, m), 1.55-1.45 (3H, m), 1.34 (HH, m), 0.81 (3H, t ). EXAMPLE 14 Hemiamonium salt of the acid 2- [[[ÍS- [la, 2ß, 4a- (1S *, 2R *)]] -2-hydroxy-4- [7- [(2-phenylcyclopropyl) -amino-5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentyl] -oxy] -acetic acid. The title compound was prepared according to the method of Example 2, step of item (b) using the product of the step of part (b) (ii). MS (APCI) 485 (M + H +, 100%). NMR dH (d6-DMSO) 7.31-7.16 (5H, m), 5.21 (HH, quintuplet), 4.28 (HH, m), 4.03-3.92 (2H, m), 3.82 (HH,), 3.19 (HH, m ), 2.96-2.83 (2H, m), 2.64 (HH, m), 2.41 (HH, 2.16-2.08 (3H, m), 1.54-1.47 (3H, m), 1.33 (HH, m), 0.82 (3H , t) EXAMPLE 15 Acid 2- [[[ÍS- (la, 2ß, 3ß-4a] -4- [7- (butylamino) -5- (propylthio) -3H-1, 2, 3-triazolo- [ 4, 5-d] -pyrimidin-3-yl] -2, 3-dihydroxycyclopentyl] -oxy] -acetic acid a) 5,7-bis- (propylthio) -1H-1, 2, 3-triazolo- [4, 5-d] - pyrimidine. A mixture of 4,5-diamino-2,6-dimercaptopyrimidine (25 g), potassium hydroxide (36.9 g) and propyl iodide (62.9 ml) in water (710 ml) was stirred for 72 hours. The product was collected by filtration, washed with water and dried. The material was collected with water (710 ml) / glacial acetic acid (710 ml), cooled to 0 ° C and a solution of sodium nitrite (9.38 g) in water (109 ml) was added, keeping the temperature below of 5 ° C. The mixture was allowed to reach room temperature and the product was collected by filtration, washed with water and dried (28.9 g). MS (El) 269 (M +). b) Mixture of (lS-cis) -4- [5,7-bis- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -2- cyclopenten-l-ol and (lS-cis) -4- [5,7-bis- (propylthio) -2H-1, 2,3-triazolo- [4,5- d] -pyrimidin-2-yl] - 2-cyclopenten-l-ol. To a solution of the product from step (a) (3.7 g), (lS-cis) -4-acetoxy-2-cyclopenten-l-ol (2.0 g) and triethylamine (6 ml) in THF (100 ml) at 60 ° C, tetrakis (triphenylphosphine) -palladium (0) (2.0 g) was added as a suspension in THF (50 ml). The reaction mixture was stirred at 60 ° C for 4.5 hours and purified (SiO2, ethyl acetate / hexane, 1: 3 as eluent) to the product as a 2: 1 isomer mixture. MS (APCI) 352 (M + H +, 100%). c) [3aR- (3aa, 4a, 6a, 6aa)] -6- [5,7-bis- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3 -yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-ol. A product mixture from step (b) (2.0 g), 4-methylmorpholine-N-oxide (1.27 g) and osmium tetraoxide (2.5% solution in tert-butanol, 2.9 ml) in acetone (110 ml) and water (25 ml) was stirred at room temperature for 16 hours. Sodium hydrosulfite (2.0 g) was added and the mixture was stirred for 1 hour and then filtered through celite, washing with ethyl acetate. The filtrates were combined and the combined was concentrated and the residue was dissolved in acetone (75 ml). Toic acid (1.08 g) and 1,1-dimethoxypropane (6 ml) were added and the mixture was stirred for 1 hour. The solution was concentrated and the residue was extracted by partition in dichloromethane and water. The organic phase was dried and concentrated and the residue was purified (SiO2, ethyl acetate / hexane, 1: 4 as eluent) to obtain the subtitle compound (1.08 g). MS (APCI) 426 (M + H +, 100%). d) 1, 1-dimethylethyl ester of 2- [[[3aR- (3aa-4a, 6a-6aa)] -6- [5,7-bis- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -te-rahydro-2,2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-yl] -oxy] -acetic acid. To product solution of step of subsection (c) (0.36 g) in THF (10 ml) at 0 ° C, sodium hydride (60% in oil, 37 mg) was added. The mixture was stirred at 0 ° C for 15 minutes and tert-butyl bromoacetate (0.14 ml) was added. The mixture was stirred at room temperature for 24 hours and purified (SiO2, ethyl acetate / hexane, 1:10 as eluent) to obtain the subtitle compound (0.16 g). MS (APCI) 482 (M + H +, 100%). e) 2- [[[3aR- (3aa-4a, 6a, 6aa] - [7- (butylamino) -5- (propylthio) -3H-1, 2,3-triazolo- [1,1-dimethylethyl ester] 4, 5-d] -pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4-phenyl-cyclopenta-l, 3-dioxol-4-yl] -oxi] -acetic acid, a mixture of the product of the step of the subsection (d) (0.15 g) and n-butylamine (5 ml) in 1,4-dioxane (10 ml) was stirred at room temperature for 1 hour, concentrated and purified (SiO2, ethyl acetate / hexane, 1: 5 as eluent ) to obtain the subtitle compound (0.14 g). MS (APCI) 537 (M + H +, 100%). f) Acid 2 - [[[lS- (la, 2ß, 3ß, 4a)] -4- [7- (butylamino) -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5 -d] -pyrimidin-3-yl] -2,3-dihydroxycyclopentyl] -oxy] -acetic acid. The product was prepared according to the method of Example 2, step of item (b) using the product of step (e). MS (ESI) 441 (M + H +, 100%). NMR dH (d6-DMSO) 9.01 (HH, t), 4.94 (1H, q), 4.53 (HH, m), 4.04 (2H, m), 4.00 (HH, m), 3.85 (HH, m), 3.50 (2H, q), 3.08 (2H, m), 2.64 (HH, m), 2.08 (HH, m), 1.65 (4H, m), 1.34 (2H, m), 0.99 (3H, t), 0.91 ( 3H, t). EXAMPLE 16 2- [[[ÍS- (la, 2ß, 3ß, 4a)] -4- [7- (butylamino) -5- (propylthio) -3H-1,2,3-triazolo- [4, 5 d] -pyrimidin-3-yl] -2, 3-dihydroxycyclopentyl] -oxy] -acetamide. To a solution of the product of Example 15 (0.21 g) in N, N-dimethylformamide (25 ml) was added a solution of ammonia in acetonitrile (5 ml) and bromo-tris-pyrrolidinophosphonium hexafluorophosphate (0.35 g). The mixture was stirred for 10 minutes and N, N-diisopropylethylamine (300 μl) was added. The reaction mixture was stirred at room temperature for 2 hours, concentrated and purified (silica gel Sep-pak® C18, elution gradient of water to acetonitrile, followed by CLAR column Novapak® C18, 0.1% aqueous trifluoroacetic acid / acetonitrile, 50:50) to obtain the title compound (0.9 g). MS (APCI) 440 (M + H +, 100%).

NMR dH (d6-DMSO) 8.99 (1H, t), 7.33 (1H, br s), 7.18 (1H, br s), 5.20-5.10 (2H, br s), 4.95 (H, q), 4.57-4.53 (ÍH, m), 4.04-4.02 (ÍH, m), 3.88 (2H, s), 3.81-3.79 (ÍH, m), 3. 49 (2H, q), 3.11-3.06 (2H, m), 2.70-2.60 and 2.15-2.01 (1H, m), 1.70 (2H, sextuplete), 1.63 (2H, quintuplete), 1.34 (2H, sextuplete), 0.99 (3H, t), 0.91 (3H, t). EXAMPLE 17 [ÍS- [la, 2β, 3β, 4a- (ÍS *, 2R *)]] -4- [[5- (methylthio) -7- [(2-phenylcyclopropyl) -amino-3H-1, 2 , 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopen-1, 2, 3-triol. a) [lS- [la, 2,3β, 4a- (lS *, 2R *)]] -4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylsulfonyl) -3H-1, 2 , 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. Prepared according to the method of Example 4, step of part (a) using the product of Example 12. MS (APCI) 475 (M + H +, 100%). b) [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [[5- (Methylthio) -7- [(2-phenylcislopropyl) -amino] -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. Sodium thiomethoxide (0.11 g) was added to a solution of the product from step (a) (0.34 g) in THF (20 ml), and the reaction mixture was stirred for 1 hour. The reaction mixture was concentrated and the residue was purified (SiO2, ethyl acetate as eluent) to obtain the title compound (0.20 g). MS (APCI) 415 (M + H +, 100%). NMR dH (d6-DMSO) 9.36 (1H, d), 7.31-7.16 (5H, m), . 11-5.10 (ÍH,), 5.04-5.01 (1H, m), 4.97 (ÍH, d), 4.94-4.93 (ÍH, m), 4.68-4.63 (ÍH, m), 3.94-3.92 (ÍH, m) , 3.79 (ÍH, s), 3.21-3.18 (ÍH, m), 2.62-2.57 (ÍH, m), 2.32 (3H, s), 2.15-2.11 (ÍH,), 2.14-2.10 (2H, m), 1.94-1.87 (ÍH, m), 1.51-1.47 (ÍH, m), 1.36-1.32 (ÍH, m). EXAMPLE 18 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [5- [(methylethyl) -thio] -7- [(2-phenylcyclopropyl) -amino] -3H -1,2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. It was prepared in accordance with __the method of Example 4, step of subsection (b) using the product of Example 17, step of subsection (a) MS (APCI) 443 (M + H +, 100%). NMR dH (d6-DMSO) 9.38 (HH, d), 7.31-7.16 (5H, m), 5.11 (1H, d), 5.04-4.96 (HH,), 4.93-4.91 (HH, m), 4.67-4.63 (ÍH, m), 3.94-3.92 (ÍH, m), 3.79 (ÍH, s), 3.61 (ÍH, septuplete), 3.20-3.16 (ÍH, m), 2.62-2.57 (ÍH, m), 2.11-2.07 (ÍH, m), 1.93-1.89 (ÍH, m), 1.60-1.54 (ÍH, m), 1.38-1.30 (ÍH, m), 1.13 (3H, d), 1.07 (3H, d). EXAMPLE 19 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (4-fluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) (lR-ais) -bis- (1,1-dimethyl) -4-hydroxy-2-cyclopentenylimidodicarbonate. To a suspension of ether taken up with sodium hydride (60% dispersion in oil, 0.31 g) in THF (30 ml) was added bis- (1,1-dimethylethyl) -ester of the imidodicarbonic acid (1.84 g). The mixture was stirred at 40 ° C for 1 hour. To the mixture, at room temperature, (lS-cis) -4-acetoxy-2-cyclopenten-l-ol (0.5 g) and tetrakis (triphenylphosphine) -palladium (Q) (0.185 g) were added. The reaction mixture was stirred for 24 hours and then purified (SiO2, ethyl acetate / hexane, 1: 9 as eluent) to obtain the subtitle compound as a colorless solid (0.9 g). NMR dH (d6-DMS0) 1.43 (18H, s), 1.61 (ΔI, ddd, "= 12.3, 7.7, 6.4 Hz), 2.54 (ΔI, dt, J = 12.6, 7.4 Hz), 4.51-4.57 ( ÍH,), 4.86 (1H, tq, "= 8.0, 1.8 Hz), 4.91 (ÍH, d, J = 5.4 Hz), 5.71-5.77 (2H, m). b) Bis (1, 1-dimethylethyl) -ester of [IR- (la, 2ß, 3ß, 4a)] -2,3,4-trihydroxycyclopenteniiimidodicarbonic acid. The subtitle compound was prepared according to the method of Example 12, step of part (f) using the product of the step of part (a). NMR dH (d6-DMSO) 1.44 (18H, s), 1.46-1.60 (HH, m), 1.97-2.05 (HH, m), 3.55-3.58 (HH, m), 3.66-3.73 (HH, m), 4.11-4.21 (2H,), 4.54 (HH, d, J = .8 Hz), 4.56 (HH, d, J5.9 Hz), 4.82 (HH, d, J = 4.6 Hz), c) [ lS- (la, 2ß, 3ß, 4a)] -4- [[6-chloro-5-nitro-2- (propylthio) -pyrimidin-4-yl] -amino] -2-sislopentane-l, 2,3 -triol. A mixture of the product from step (b) (0.68 g), methanol (10"ml) and hydrochloric acid (2 M, 5 ml) was stirred for 24 hours and then concentrated under reduced pressure. THF (10 ml) and N, N-diisopropylethylamine (1.78 ml), followed by 4,6-dichloro-5-nitro-2- (propylthio) -pyrimidine (prepared in the manner described in International Publication WO 97/03084) (0.82 g) The mixture was refluxed for 20 hours and then cooled and concentrated under reduced pressure The residue was purified (SiO2, ethyl acetate / hexane, 7: 3 as eluent) to obtain the sub-title compound. in the form of a yellow solid (0.47 g) MS (APCI) 365/367 (M + H +, 100%). d) [lS- (la, 2β, 3β, 4a] -4- [[5-amino-6-chloro-2- (propylthio) -pyrimidin-4-yl] -amino] -2-cyclopentane-1, 2 , 3-triol The subtitle compound was prepared according to the method of Example 12, step of part (b) using the product of step (c) of MS (APCI) 335/337 (M + H +, 100% e) [lS- (la, 2ß, 3ß, 4a)] -4- [7-chloro-5- (propylthio) -3tf-l, 2,3-triazolo- [4,5-d] -pyrimidine) -3-yl] -cyclopentane-1, 2,3-triol The subtitle compound was prepared according to the method of Example 12, step of part (c) using the product of step (d). MS (APCI) 346/348 (M + H +), 318 (100%). f) [3aS- [l- (£ 7), 3aa, 6a, 7aß]] - l- [3- (4-fluorophenyl) -l-oxo-2-propenyl] -hexahydro-8, 8-dimethyl-3H-3a, 6-methano-2, 1-benzisothiazole-2,2-dioxide. A mixture of 3- (4-fluorophenyl) -2-propenoic acid (3.0 g) and thionyl chloride (5.0 ml) was stirred at 70 ° C for 1 hour and then the reaction mixture was concentrated under reduced pressure. The residue was subjected to azeotropic distillation twice with dichloromethane and then dissolved in toluene (10 ml). To a suspension of sodium hydride (60% dispersion in oil (0.99 g) in toluene (40 ml) was added a solution of [3aS- (3aa, 6a, 7aß)] -hexahydro-8,8-dimethyl- 3i? -3a, 6-methane-2, 1-benzisothiazole-2, 2-dioxide (3.89 g) in toluene (40 ml) and the mixture was stirred for 30 minutes, then the reaction mixture was added to the reaction mixture. The above-described solution and the resulting suspension was stirred for 16 hours Water (200 ml) was added, the organic phase was collected and the aqueous phase was extracted with dichloromethane (3 x 100 ml) .The organic phases were combined and the The mixture was dried and concentrated, recrystallization (in ethanol) afforded the subtitle compound as colorless needles (5.92 g) MS (APCI) 364 (M + H +, 100%) g) [3aS- [1- (ÍS *, 2R *), 3aa, 6a, 7ab]] -1- [[2- (4- luoropheni1) - cyclopropyl] -carbonyl] -hexahydro-8,8-dimethyl-3H-3a, 6-methane 2, l-benzisothiazole-2, 2-dioxide. A solution of diazomethane (2.9 g) in ether (150 ml) (prepared in the manner described in Vogel's textbook of practical organic chemistry, fifth edition, Longman scientific and technical, p 432), was added to a solution of the product from the step of part (f) (5.90 g) and palladium (II) acetate (18 mg) in dichloromethane (350 ml) at 0 ° C and the reaction mixture was stirred at 0 ° C for 5 hours. Acetic acid (5 ml) was added and the reaction mixture was washed with a saturated solution of sodium bicarbonate (200 ml) and the organic phase was filtered through a plug of silica gel. After concentrating in vacuo, the residue was recrystallized (in ethanol) to obtain the subtitle compound in the form of colorless needles (3.81 g). MS (APCI) 378 (M + H +, 100%). h) (lR-trans) -2- (4-luo-phenyl) -cyclopropanecarboxylic acid. A suspension of the product from the passage of part (g) (3.74 g) and lithium hydroxide monohydrate (4.11 g) in tetrahydrofuran (100 ml) and water (3 ml) was stirred at 50 ° C for 24 hours. The reaction mixture was concentrated in vacuo and the residue was dissolved in water (100 ml), acidified with 2 N HCl and extracted with dichloromethane (3 x 75 ml). The organic phases were combined and the combined was dried and concentrated. Purification (SIO2, isohexane / diethyl ether, 2: 1 as eluent) afforded the subtitle compound as a colorless solid (1.78 g). MS (APCI) 179 (M-H +, 100%). i) (lR-tzrans) -2- (4-fluorophenyl) -cyclopropanamine. To a solution of the product from step (h) (2.6 g) and triethylamine (2.7 ml) in acetone / water (10: 1, 33 ml) at 0 ° C, ethyl chloroformate (2.0 ml) was added over a period of time. 5 minutes The solution was kept at 0 ° C for 0.5 hours before adding sodium azide (1.52 g) in water (6 ml). After an additional hour, water (350 ml) was added and the reaction mixture was extracted with toluene (3 x 100 ml). The organic extracts were combined and the combined dried and refluxed for 2 hours behind a buffer screen.

After cooling the solution, 6 N HCl (50 ml) was added and the mixture was heated to reflux for 3 hours. Water (150 ml) was added and the aqueous phase was made basic with 2N NaOH (aq), and then extracted with dichloromethane. (3 x 100 ml). The organic phase was dried and concentrated to obtain the subtitle compound as a colorless oil (1.31 g). NMR dH (d6-DMSO) 0.88-0.95 (HH, m), 0.99-1.06 (1H, m), 1.81-1.87 (HH,), 2.47-2.52 (ÍÍ,), 6.90-7.00 (4H, m) . j) [ÍS- (la, 2ß, 3ß, 4a- (ÍS *, 2R *)] -4- [7- [[2- (4-fluorophenyl) -cyclopropyl] -amino] -5- (propylthio) - 3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol The title compound was prepared according to the method of Example 12, step of subsection (e) using two products from the steps of paragraphs (e) and (i) • MS (APCI) 461 (M + H +, 100%).

NMR dH (d6-DMSO) 0.99 (3H, t, J = 7.2 Hz), 1.29-2.15 (6H, m), 2.55-2.63 (ÍH, m), 2.81-3.15 (2H, m), 3.14-3.33 (ÍH, m), 3.78 (ÍH, br s), 3.93 (1H, br s), 4.66 (1H, br s), 4. 92-5.12 (4H, m), 7.11-7.26 (4H, m), 9.33 (ÍH, d, J = 4.2 Hz). EXAMPLE 20 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol a). Acid [IR- (trans)] -2- (4-methoxypheni1) -cyclopropanecarboxylic acid To a dimer solution of dichloro- (p-cymene) -ruthium (II) (250 mg) and 2,6-bis- [(4S ) -isopropyl-2-oxazolin-2-yl] -pyridine (240 mg) in dichloromethane (150 ml) at room temperature, 4-vinylanisole (25 g) was added. To this solution was added ethyl diazoacetate (5.0 g) over a period of 6 hours. The solution was kept at room temperature for 18 hours, then it was diluted with i-hexane (200 ml) and passed through a plug of silica (50 g) with an additional 250 ml of i-hexane / dichloromethane, 1: 1. The filtrate was concentrated and the residue was dissolved in methanol (100 ml) and LiOH (4 g) in water (10 ml) was added, then the mixture was refluxed for 4 hours. The resulting solution was concentrated to obtain a colorless solid, which was washed with ether / i-hexane, 1: 1 (100 mL). The solid was triturated with 2 N HCl and the precipitate was collected to obtain the subtitle compound (5.06 g). MS (APCI) 191 (M-H +, 100%). b) [R- (R *, R *)] -2,3-dihydroxybutanedioate of [IR- (trans)] -2- (4-methoxyphenyl) -cyclopropanamine, (1: 1) The amine was prepared in accordance with the method of Example 19, step of subsection (i) using the product of the step of part (a). The amine was dissolved in ethanol (5 ml) and a solution of L-tartaric acid (0.75 g) in ethanol (5 ml) was added. After 20 minutes, the solid was collected and recrystallized (isopropanol / water, 3: 1) to obtain the subtitle compound in the form of colorless needles. P.f. 192-193 ° C. NMR dH (d6-DMSO) 7.05 (2H, • d), • 6.85 (2H, d), 3.91 (2H, s), 3.71 (3h, S), 2.70-2.60 (HH, m), 2.15-2.07 (HH, m), 1.22-1.08 (HH, m), 1.03 (HH, dd). c) [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol. The title compound was prepared according to the method of Example 12, step of part (e) using the products of the step of part (b) and the product of Example 19, step of part (e).

MS (APCI) 473 (M + H, 100%) dH NMR (d6-DMSO) 0.83 (3H, t, J = 7.2 Hz), 1.20-2.25 (6H, m), 2.50-2.60 (ÍH, m), 2.81-3.04 (2H, m), 3.06-3.17 (ÍH, m), 3.33 (3H, s), 3.73 (ÍH, br s), 3.91-3.98 (ÍH, m), 4.60-4.70 (ÍH, m), 4.90-5.13 (4H, m), 6.86 ( 2H, d, J = 8.7 Hz), 7.14 (2H, d, J = 8.7 Hz), 9.30 (ÍH, d, J = 4.2 Hz). EXAMPLE 21 [lS- [the, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [7- [[2- (4-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopeno-1,2,3-triol a) Acid (IR-trans) -2- (4-methylphenyl) -cyclopropanecarboxylyl. It was prepared according to the method of Example 20, step of part (a) using 4-methyl-1-ethenylbenzene. MS (APCI) 175 (M-H +, 100%). b) [R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (4-methylphenyl) -cyclopropanamine, (1: 1) Prepared according to the method of Example 20, step of subsection (b) using the product of step of subsection (a). NMR dH (d6-DMSO) 7.8 (2H, d), 7.00 (2H, d), 3.98 (2H, s), 2.75-65 (HH, m), 2.50 (3H, s), 2.30-2.20 (HH, m), 1.30-1.22 (ÍH, m), 1.09 (ÍH, dd). c) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (4-methyl enyl) -cyclopropyl] -amino] -5- (propylthio) ) -3-l, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol. The title compound was prepared according to the method of Example 1, step of part (a), using the products of step (b) and Example 19, step of part (e). MS (APCI) 457 (M + H +, 100%). NMR dH (d6-DMSO) 0.99 (3H, t, J = 7.2 Hz), 1.30-1.40 (HH, m), 1.45-1.54 (HH, m), 1.50 and 1.70 (2H, sextuplet, J = 7.2 Hz) , 1. 87-1.94 (ÍH, m), 2.07-2.12 (1H, m), 2.27 (3H, s), 2.54- 2.61 (ÍH,), 2.83-2.99 (2H,), 3.15-3.17 (ÍH, m), 3.78 (1H, br s), 3.93 (ÍH, br s), 4.66-4.67 (1H, m), 4.91-5.11 (4H, m), 7.09 (4H, br s), 9.35 (ÍH, br s). EXAMPLE 22 [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (4-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) [IR- [la- (S *), 2ß]] -N- [2- (4-chlorophenyl) -cyclopropyl] -2-methoxy-2-phenylacetamide and [lS- [la- (R *), 2ß]] - N- [2- (4-chlorophenyl) -cyclopropyl] -2-methoxy-2-phenylacetamide. Oxalyl chloride (4.00 ml) was added to a solution of (S) -a-methoxyphenylacetic acid (2.00 g) in dichloromethane (100 ml) / DMF (10 ml). The reaction mixture was stirred at room temperature for 4 hours, then concentrated and the residue subjected to azeotropic distillation with dichloromethane (3 x 10 ml). The resulting oil was taken up in dichloromethane (4 ml) and treated with a solution of 2- (4-chlorophenyl) -cyclopropylamine (prepared in the manner described by C. Kaiser et al., J. Med. Pharm.

Bul., 1962, 5, 1243) (1.86 g) in pyridine (8 ml). The reaction mixture was stirred at room temperature during minutes, then subjected to extraction by partition in dichloromethane (500 ml) and water (500 ml). The organic phase was dried and concentrated and the residue was purified (SÍO2, isohexane / ethyl acetate / acetic acid, 66: 33: 1) to obtain [ÍS- [la- (R *), 2ß]] -N- [2- (4-chlorophenyl) -cyclopropyl] -2 -methoxy-2-phenylacetamide (1.23 g). MS (APCI, negative ionization) 314 (M-H +, 100%). Additional elution of the column yielded [1R- [la (S *), 2β]] - N - [2- (4-chlorophenyl) -cyclopropyl] -2-methoxy-2-phenylacetamide (1.40 g). MS (APCI, negative ionization) 314 (M-H +, 100%). b) (IR-rans) -2- (4-chloro-enyl) -cyclopropanamine A solution of [lR- [la (S *), 2ß]] -N- [2- (4-chlorophenyl) -cyclopropyl] -2 -methoxy-2-phenylacetamide (1.10 g) (prepared in the manner described in the step of part (a) in 1,4-dioxane (20 ml) containing 5 M HCl (aq) (40 ml), heated to reflux for 18 hours The reaction mixture was concentrated and the residue partitioned in water and diethyl ether The aqueous phase was treated with a 2 M aqueous sodium hydroxide solution (100 ml) and then extracted with ether diethyl ether (2 x 100 ml) The organic phase was concentrated to obtain the subtitle compound (0.55 g) Optical rotation -138.3 ° (c = 0.2, methanol) c) [IS- [la, 2β, 3β, 4a - (ÍS *, 2R *)]] -4- [7- [[2- (4-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4 , 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. The title compound was prepared according to the method of Example 12, step of item (e) using the products of the step of part (b) and of Example 19, step of part (e). MS (APCI) 477/479 (M + H +, 100%). NMR dH (d6-DMSO) 0.99 (3H, t, J = 7.2 Hz), 1.30-1.40 (HH, m), 1.48 and 1.68 (2H, sextuplet, J = 7.2 Hz), 1.52-1.60 (HH, m) , 1.87-1.94 (ÍH, m), 2.10-2.15 (ÍH, m), 2.50-2.60 (ÍH, m), 2.76-3.15 (2H, m), 3.13-3.21 (ÍH, m), 3.73 (ÍH, br s), 3.93 (ÍH, br s), 4.60-4.68 (ÍH, m), 4.89-5.11 (4H, m), 7.22 (2H, d, J = 8.4 Hz), 7.33 (2H, d, J = 8.4 Hz), 9.35 (ÍH, br s). EXAMPLE 23 2- [[[ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -2, 3-dihydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentyl] -oxy] -acetamide. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa)]] -6- [7- [N- [(2,4-dimethoxyphenyl) -methyl- (2-phenylcyclopropyl) -amino] -5- (propylthio) - 3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol To a solution of product of Example 12, step (f) (4.50 g) in acetone (100 ml), was added 2, 2-dimethoxypropane (12.60 ml) and p-toluenesulfonic acid (2.34 g) and the reaction mixture was stirred for 1 hour. Purification (SIO2, ethyl acetate / isohexane, 2: 7 as eluent) yielded the subtitle compound (4.34 g). MS (APCI) 633 (M + H +, 100%). b) 2- [[[3aR- [3a, 4a, 6a, 6aa- (1R *, 2S *)]] -6- [7- [N- (2,4-dimethoxyphenyl)] 1,1-dimethyl ethyl ester -methyl- (2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2,2-dimethyl -4H-cyclopenta-l, 3-dioxol-4-yl] -oxi] -acetic To a solution of the product from the step of the subsection (a) (0.40 g) in toluene (3.00 ml), 5 M NaOH (3.00 ml) and tetrabutylammonium bromide (31 mg) were added. The reaction mixture was stirred for 30 minutes, then dimethyl sulfoxide (0.18 ml) and 1,1-dimethylethyl-2-bromoacetate were added and stirring was continued for 4 hours. The toluene phase was separated and concentrated. Purification (SIO2, ethyl acetate / isohexane, 1: 3 as eluent) yielded the subtitle compound (0.41 g). MS (APCI) 747 (M + H +, 100%). c) Acid 2 - [[lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] - 2,3-dihydroxy-4- [6- [7- (2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl-cyclopent-1-yl] -oxy] -acetic acid. The subtitle compound was prepared according to the method of Example 2, step of part (b). MS (APCI) 501 (M + H +, 100%). d) 2 - [[[lS- [la, 2β, 3β, 4a- (lS *, 2R *)] j -2,3-dihydroxy-4- [7- [(2-phenylscyclopropyl) amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentyl] -oxy] -acetamide. It was prepared in accordance with the method of Example 16, using the product of the step of subsection (c). Purification (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, 63:37) yielded the title compound (0.04 g). MS (APCI) 501 (M + H +, 100%).

NMR dH (d6-DMS0) 9.35 (1H, d), 7.33-7.16 (7H, m), 5.20 (2H, br m), 5.00-4.90 (HH, q), 4.55 (HH, m), 4.05 (HH) , br 5), 3.85 (2H, 5), 3.80 (ÍH, m), 3.20 (ÍH, br m), 3.15 (ÍH.m), 3.00-2.90 (ÍH, m), 1.91 (ÍH, m), 1.51 (3H, m), 1.31 (1H, m), 0.81 (3H, t). EXAMPLE 24 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- (7- [(2- (3-methoxyphenyl) -cyclopropyl] -amino] -5- (propyl io) .}. -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol a) Hydrochloride of [3aR- (3aa, 4a , 6a, 6aa)] -6-aminotetrahydro-2,2-dimethyl-4H-cyclopen al, 3-dioxol-4-ol The product of Example 19, step of part (b) (17.37 g) in 6 M HCl (100 ml) and methanol (500 ml) was stirred for 18. The mixture was evaporated and then subjected to azeotropic distillation with toluene (4 x 200 ml), to obtain a colorless powder (8.67 g). in acetone (250 ml) containing 2,2-dimethoxypropane (25 ml) and concentrated HCl (0.2 ml) and then refluxed for 2 hours.The mixture was cooled, evaporated and subjected to azeotropic distillation with toluene (3 ml). x 200 ml) The residue was dissolved in 20% aqueous acetic acid and stirred for 2 hours.The mixture was evaporated and subjected to azeotropic distillation with toluene (4 x 2 00 ml), to obtain the subtitle compound (10.1 g). MS (APCI) 174 (M + H +, 100%). b) [3aR- (3aa, 4a, 6a, 6aa)] -6- [[6-sloro-5-nitro-2- (propylthio) -pyrimidin-4-yl] -amino] -tetrahydro-2, 2- dimethyl-4H-cyclopenta-l, 3-dioxol] -4-ol. A solution of the product from the step of part (a) (10.0 g) and N, N-diisopropylethylamine (35 ml) in THF (600 ml) was stirred for 1 hour. The mixture was filtered and the solution was added, over a period of 1 hour, to a solution of 4,6-dichloro-5-nitro-2- (propylthio) -pyrimidine (prepared in the manner described in International Publication WO 97/03084) (25.57 g) in THF (1000 ml) and stirred for another 2 hours. The volume of the solvent was reduced in vacuo and ethyl acetate (1000 ml) was added. The mixture was washed with water and the organic phases were dried (MgSO4), evaporated and purified (SiO2, isohexane / ethyl acetate as eluent) to obtain the subtitle compound (14.22 g). MS (APCI) 405 (M + H +, 100%). c) [3aR- (3aa, 4a, 6a, 6aa)] -6- [[5-amino-6-chloro-2-propylthiopyrimidin-4-yl] -amino] -tetrahydro-2,2-dimethyl-4H- cyclopenta-l, 3-dioxol-4-ol. The subtitle compound was prepared according to the method of Example 12, step of item (b) using the product of the step of part (b). MS (APCI) 375 (M + H +, 100%). d) [3aR- (3aa, 4a, 6a, 6aa)] -6- [7-chloro-5- (propylthio) -3H- 1, 2, 3- [4, 5-d] -pyrimidin-3-yl) ] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-ol. The subtitle compound was prepared according to the method of Example 12, subsection step (c) using the product of the step of subsection (c). MS (APCI) 386 (M + H +, 100%). ß) (lR-trans) -2- (3-methoxyphenyl) -cyclopropanamine hydrochloride. The subtitle compound was prepared according to the method of Example 19, step of the subsection (i) using (IR-trans) -2- (3-methoxyphenyl) -cyclopropanecarboxylic acid (prepared in the manner described by Vallgaarda et al., J. Chem. Soc., Perkin Trans. 1, 1994, 461-70) . The product was taken up in 2 N HCl and lyophilized to obtain the hydrochloride salt. MS (APCI) 164 (M + H +, 100%). f) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (3-mexy-phenyl) -cyclopropyl] -amino] -5- (propylthio) ) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-diol. To a suspension of the product from the passage of the subsection (d) (0.40 g) and the product from step (e) (0.28 g) in dichloromethane (20 ml), N, N-diisopropylethylamine (0.89 ml) was added, subsequently the resulting solution was stirred at room temperature for 7 hours.

The reaction mixture was concentrated and the residue was taken up in methanol (45 ml) / 2N HCl (5 ml), this solution was stirred at room temperature for 16 hours. The reaction mixture was concentrated and the residue partitioned in water (50 ml) and dichloromethane (50 ml) and the organic phase was dried (MgSO 4), filtered and concentrated. The product was purified (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, 50:50) to obtain the title compound (0.44 g). MS (APCI) 473 (M + H +, 100%) dH NMR (de-DMSO) 9.39 (H, d, J = 4.0 Hz), 7.23-6.81 (4H, m), 4.74-4.69 (H, m), 4.00 (ÍH, br s), 3.84 (ÍH, br s), 3.79 (3H, br s), 3.29-3.26 (ÍH, m), 3.06-2.87 (2H, m), 2.69-2.61 (ÍH, m) , 2.19-2.14 (HH, m), 2.00-1.94 (HH, m), 1.76-1.51 (3H, m), 1.42-1.29 (HH, m), 0.87 and 1.05 (3H, t, J = 7.6 Hz) . EXAMPLE 25 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (3-methyl enyl) -cyclopropyl] -amino] -5- (propylthio) ) -3H-l, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol a) Acid (IR-trans) -2- (3- methylphenyl) -cyclopropanecarboxylic acid. It was prepared according to the method of Example 12, step of part (a) using l-ethenyl-3-methylbenzene.

MS (APCI) 175 (M-H, 100%). b) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3-methylphenyl) -cyclopropanamine, (1: 1) Prepared according to the method of Example 20, step of subsection (b) using the product of step of subsection (a). NMR dH (de-DMSO) 7.17 (1H, t), 6.98 (H, d), 6.93-6.89 (2H, m), 3.93 (2H, s), 2.70-2.66 (H, m), 2.27 (3H, s), 2.13-2.08 (ÍH, m), 1.24-1.19 (ÍH, m), 1.19-1.09 (ÍH, m). c) [lS- [la-2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol. The title compound was prepared according to the method of Example 24, step of part (f), using the products of step "of part (b) and of Example 24, step of part (d)." MS (APCI) 457 (M + H +, 100%) NMR dH (d6-DMSO) 9.33 (1H, s), 7.19-7.14 (HH, m), 7.04-6.96 (3H, m), 5.12-5.10 (HH, m), 5.03 -4.97 (ÍH, m), 4.94-4.92 (ÍH,), 4.92-4.90 (ÍH, m), 4.69-4.64 (ÍH, m), 3.94-3.92 (ÍH, m), 3.78 (ÍH, s), 3.20-3.17 (ÍH, m), 2.97-2.85 (2H, m), 2.62-2.58 (2H,), 2.29 (3H, s), 2.05-2.10 (ÍH, m), 1.97-1.83 (ÍH, m), 1.54-1.47 (2H, m), 0.84- 0.79 (3H, t) EXAMPLE 26 [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopene-1,2,3-triol. a) [3aS- [l (E), 3aa, 6a, 7aβ]] -1- [3- (3-chlorophenyl) -l-oxo-2-propenyl] -hexahydro-8,8-dimethyl-3H-3a , 6-methane-2, 1-benzisothiazole-2, 2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (f) using 3- (3-chlorophenyl) -2-propenoic acid. MS (APCI) 382/380 (M + H +), 153 (100%). b) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7aß]] -1- [[2- (3-chloro-enyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8-dimethyl-3H-3a, 6-methane-2, l-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of subsection (g) using the product of the step of part (a). MS (APCI) 396/394 (M + H +), 195 (100%). c) (lR-trans) -2- (3-chlorophenyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of the step of part (b). MS (APCI) 195/197 (M-H +), 195 (100%). d) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of [IR- trans} -2- (3-chloroenyl) -cyclopropylamine, (1:). The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (c). NMR dH (de-DMSO) 1.13-1.23 (2H, m), 2.10-2.20 (HH, m), 2.70-2.74 (HH, m), 3.95 (2H, s), 7.08-7.32 (4H, m). e) [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-chloro-enyl) -syclopropyl] -amino] -5- (propylthio) ) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. The subtitle compound was prepared according to the method of Example 24, step of part (f) using the products of the step of part (d) and of Example 24, step of part (d). MS (APCI) 477/479 (M + H +), 477 (100%) - NMR dH (de-DMSO) 7.33-7.15 (4H, m) 5.00-4.93 (H, m), 4.68-4.65 (H, m) ), 3.94 (ÍH, br s), 3.79 (ÍH, br s), 3.20 (ÍH, br s), 2.97-2.79 (2H, m), 2.64-2.56 (1H, m), 2.26-2.13 (ÍH, m), 1.92-1.88 (ÍH, m), 1.70-1.40 (4H,) 0.98 (3H, t, J = 7.2 Hz). EXAMPLE 27 [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-nitrophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) Acid (lR-trans) -2- (3-nor ro enyl) - cislopropanecarboxylic acid. It was prepared according to the method of Example 20, step of part (a) using 3-nitrostyrene. MS (APCI) 206 (M-H +, 100%). b) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3-nor rophenyl) -cyclopropanamine, (1: 1). It was prepared in accordance with the method of Example 20, step of item (b) using the product of step (a). NMR dH (de-DMSO) 8.06-7.98 (2H, m), 7.62-7.53 (2H, m), 4.00 (2H, s), 2.84-2.77 (H, m), 2.41-2.34 (H, m), 1.41-32 (ÍH, m), 1.32-1.23 (ÍH, m). c) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa]] -6- [7- [2- [(3-nitrophenyl) -cyclopropyl] -amino-5- (propylthio) - 3H-1,2,3-triazole- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4 H-cyclopentan-1,3-dioxol-4-ol. It was prepared according to the method of Example 1, step of part (a) using the product of the step of part (b) and of Example 24, step of part (b). d) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3-nitrophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazole- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol. It was prepared according to the method of Example 1, step of item (b) using the product of the step of part (c). P.f. 112-114 ° C. MS (APCI) 488 (M + H +, 100%) dH NMR (de-DMSO) 9.43 (H, d), 8.08-8.01 (2H, m), 7.70-7.56 (H, m), 5.13-4.87 (4H , m), 4.69-4.60 (ÍH, m), 3.97-3.76 (2H, m), 3.31-3.04 (ÍH, m), 2.93-2.77 (2H, m), 2.54-2.51 (ÍH, m), 2.38-2.28 (ÍH, m), 1.97-1.88 (2H, m), 1.63-1.38 (3H, m), 0.76 (3H, t). EXAMPLE 28 [lS - [(la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (4-phenoxyphenyl) -cyclopropyl] -amino-5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol a) Acid (IR-trans) -2- (4-phenoxyphenyl) ) - cyclopropanecarcarboxylic acid. It was prepared in accordance with the method of Example 20, step of part (a) using l-ethenyl-4-phenoxybenzene. b) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (4-phenoxy) -1-cyclopropanamine, (1: 1). It was prepared in accordance with the method of Example 20, step of subsection (b) using the product of step of part (a). c) [ÍS- (la, 2ß, 3ß, 4a- (ÍS *, 2R *)] -4- [7- [[2- (4-enoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) - 3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol.

It was prepared in accordance with the method of Example 24, step of part (f) using the product of the step of part (b) and the product of Example 24, step (d).

MS (APCI) 534 (M + Ht, 100%) dH NMR (de-DMSO) 9.35 (H, d), 7.41-7.35 (2H, m), 7.25- 7.22 (2H, m), 7.14-7.09 (H) , m), 6.99-6.94 (4H, m) 5.12- 5.11 (1H, m), 5.04-5.01 (ÍH, m), 4.94-4.91 (2H, m), 4.67-4.64 (1H, m), 3.94- 3.92 (ÍH, m), 3.80 (ÍH, s), 3.20-3.17 (ÍH,), 2.99-2.87 (2H, s), 2.62-2.57 (ÍH, m), 2.19-2.10 (ÍH, m), 1.99-1.90 (ÍH, m), 1.56-1.49 (2H, m), 1.32-1.30 (ÍH, m), 0.85 (3H, t). EXAMPLE 29 [ÍS- [la, 2ß, 3ß-4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-phenoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-, 3-triol. a) l-ethenyl-3-enoxibenzene. A suspension of triphenylmethylphosphonium bromide (25.23 g) and potassium tert-butoxide (1M solution in tetrahydrofuran) (75.67 ml) was stirred at 0 ° C for 0.5 hour. A solution of 3-phenoxybenzaldehyde (10.0 g) in THF (10 ml) was added to the mixture and the reaction was stirred at 0 ° C for 4 hours. A solution of ammonium chloride was added and the mixture was extracted with diethyl ether. The organic extracts were combined and the combined was washed with water, dried and concentrated. Purification (SIO2, isohexane / ethyl acetate, 4: 1 as eluent) yielded the subtitle compound (7.12 g). NMR dH (CDCl3) 7.78-7.65 (HH, m), 7.58-7.41 (HH, m), 7.36-7.26 (3H, m), 7.16-7.06 (2H, m), 7.04-7.00 (2H, m), 6.92-6.88 (HH, m), 6.72-6.62 (HH, m), 5.75 (HH, d), 5.27 (1H, m). b) Acid (IR-rans) -2- (3-enoxy-i1) -cyclopropanecarboxylic acid. It was prepared in accordance with the method of Example 20, step of subsection (a) using the product of step of part (a). MS (APCI) 523 (M-H +, 100%). c) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3-phenoxyphenyl) -cyclopropanamine, (1: 1). It was prepared according to the method of Example 20, step of part (b) using the product of the step of part (b). NMR dH (de-DMSO) 7.42-7.36 (2H, m), 7.31-7.25 (H, m), 7.16-7.11 (H, m), 7.00-6.96 (2H, m), 6.90-6.88 (H, m) ), 6.81-6.77 (2H, m), 3.94 (2H, s), 2.71-2.66 (HH, m), 2.14-2.11 (HH, m), 1.26-1.20 (HH, m), 1.15-1.11 (HH) , m). d) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3-phenoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. It was prepared according to the method of Example 24, step of part (f) using the product of the step of part (c) and the product of Example 24, step of part (d). MS (APCI) 534 (M + Ht, 100%) dH NMR (de-DMSO) 9.35 (1H, d), 7.41-7.36 (2H, m), 7.32-7.27 (1H, t), 7.15-7.10 (1H) , m), 7.01-6.95 (3H, m), 6.90 (HH, m), 6.82-6.79 (HH, m), 5.12-5.10 (HH, m), 5.03-5.01 (HH, m), 4.93-4.91 (2H, m), 4.68-4.64 (HH, m), 3.94-3.92 (1H, m), 3.78 (HH, s), 3.20 (HH, m), 2.97-2.85 (2H, m), 2.61-2.57 (ÍH, m), 2.18-2.13 (ÍH, m), 1.96-1.92 (ÍH,), 1.55-1.47 (2H, m), 1.35-1.32 (ÍH, m), 0.83 (3H, t). EXAMPLE 30 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)] -4- [7- [[2- (3-amino enyl) -cyclopropyl] -amino-5- (propylthio) - 3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. A suspension of 5% palladium on carbon (40 mg) and the product of Example 27, step of part (d) (114 mg) in ethanol (10 ml) was stirred under two atmospheres of hydrogen pressure for 20 hours. The mixture was filtered and purified (Si02, isohexane / acetone, 1: 1 as eluent) to obtain the title compound (71 mg). P.f. 105-107 ° C. MS (APCI) 458 (M + H +, 100%) dH NMR (de-DMSO) 9.27 (H, d), 6.91 (H, t), 6.39-6.29 (3H, m), 5.16-5.07 (H, m) ), 5.06-4.88 (5H, m), 4.70-4.59 (ÍH, m), 3.95-3.90 (ÍH,), 3.84-3.75 (ÍH, m), 3.21-2.83 (3H, m), 2.64-2.53 ( ÍH, m), 2.02-1.87 (2H, m), 1.72-1. 11 (4H, m) 0.86 (3H, t). EXAMPLE 31 [ÍS- (la, 2a, 3ß, 5ß)] -3- [7- (butylamino) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidine -3-yl] -5- (3-hydroxypropoxy) -cyclopentane-1,2-diol. a) N-Butyl- (2,4-dimethoxyphenyl) -methanamine. The subtitle compound was prepared according to the method of Example 12, subsection step (d) using butylamine. NMR dH (CDCl 3) 0.90 (3H, t, J = 7.2 Hz), 1.33 (2H, sextet, J = 7.2 Hz), 1.48 (2H, m), 2.57 (2-H, m), 3.71 (2H, m ), 3.80 (3H, s), 3.81 (3H, s), 6.41-6.46 (2H, m), 7.12 (H, d, J = 8.1 Hz). b) (lS-cis) -4- [7- [N-butyl- [(2,4-dimethoxyphenyl) -methyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [ 4, 5-d] -pyrimidin-3-yl] -2-cyclopenten-l-ol. The subtitle compound was prepared according to the method of Example 12, subsection step (e) using the products of the step of subsection (a) and of Example 12, step of subsection (c). MS (APCI) 499 (M + H +, 100%). c) [3aR- (3aa, 4a, 6a, 6aa)] - 6- [7- [N-butyl - [(2,4-dimethoxyphenyl) -methyl] -amino] -5- (propylthio) -3H-1 , 2,3- triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-ol. The subtitle compound was prepared according to the method of Example 15, step of item (c) using the product of the step of part (b). MS (APCI) 573 (M + H +, 100%). d) [3aS- (3aa, 4a, 6a, 6aa)] -N- [2,4- (dimethoxyphenyl) -methyl] -3- [[[(tetrahydro-2H-pyran-2-yl) -oxi] - propyl] -oxi] -2,2- dimethyl-4H-cyclopenta-l, 3-dioxol-4-yl] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidine-7-amine. The subtitle compound was prepared according to the method of Example 13, step of part (a) using the product of step (c) and 2- (3-bromopropoxy) -2i-tetrahydropyran, except that the reaction was left proceed for 18 hours at reflux temperature. MS (APCI) 715 (M + H +, 100%). e) [ÍS- (la, 2a, 3ß, 5ß)] -3- [7- (butylamino) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidine -3-yl] -5- (3-hydroxypropoxy) -cyclopen-1,2-diol. The title compound was prepared according to the method of Example 2, step of item (b) using the product of the step of part (d).

MS (APCI) 441 (M + H +, 100%) dH NMR (de-DMSO) 0.91 (3H, t, J = 7.5 Hz). 0.99 (3H, t, J = 7.5Hz), 1.34 (2H, sextet, J = 7.2 Hz), 1.58-1.74 (6H, m), 2.02 (ÍH,), 2.62 (ÍH, M), 3.08 (2H, M), 3.44-3.56 (6H, m), 3.70 (1H, m), 3.91 (lh, m), 4.40 (H, t, J = 5.1Hz), 4.54-4.59 (H, M), 4.95 (H) , q, J = 9.0 Hz), 5.03 (HH, d, J = 6.3 Hz), 8.97, and 8.60 (HH, t, J = 5.4 Hz). EXAMPLE 32 [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethoxy) -5- [7- [(2-phenylcyclopropyl) -amino] -5- ( propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) N- [2,4- (dimethoxy-enyl) -methyl] -N- (2-enylcyclopropyl) -3- [[3aS- [3aa, 4a- (lS *, 2R *), 6a, 6aa]] - [[[(Tetrahydro-2H-pyran-2-yl) -oxy] -ethyl] -oxy] -2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-7-amine. The subtitle compound was prepared according to the method of Example 31, step of part (d) using the product of Example 23, step of part (a) and 2- (2-bromoethoxy) -2H-tetrahydropyran (prepared in accordance with the method of KF Bernardy et al., J. Org. Chem., 1979, 44, 1438). MS (APCI) 761 (M + H +, 100%). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] - 3- (2-hydroxyethoxy) -5- [7- [(2-enylcyclopropyl) -amino] -5- ( propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2-diol. The title compound was prepared according to the method of Example 2, step of item (b) using the product of the step of part (a). MS (APCI) 487 (M + H +, 100%) dH NMR (DMSO-dβ) 9.36 (ΔH, d, 4.0Hz), 7.31-7.27 (2H, m), 7.20-7.16 (3H, m), 5.13 ( HH, d, J = 6.4Hz), 5.06 (HH, d, J = 4.0Hz), 4.97 (HH, q, J = 9.2Hz), 4.63-4.55 (2H, m), 3.94 (HH, br), 3.75 (HH, m), 3.52-3.47 (4H, m), 3.21 (HH, m), 2.96-2.93 (HH, m), 2.85-2.82 (HH, m), 2.58-2.70 (HH, m), 2.13 (HH, m), 2.03 (HH, m), 1.54-1.46 (3H, m), 1.36-1.31 (HH, m), 0.80 (3H, t, J = 7.6Hz). EXAMPLE 33 [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopen-ano-1,2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -tetrahydro-6- [7- [[2- (4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) ) -3H- 1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of Example 20, step of part (b).

MS (APCI) 527 (M + H +, 100%). b) [ÍS- [la, 2a, 3β-5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 1, step of item (b) using the product of the step of part (a). MS (APCI) 487 (M + H ", 100%) dH NMR (de-DMSO) 9.28 (ΔI, d), 7.14 (4H, d) 6.85 (2H, d), 5.00-4.95 (2H, m), 4.75-4.68 (2H, m), 4.47-4.40 (ÍH, m), 3.88 (ÍH, q), 3.73 (3H, s), 3.50-3.40 (2H, m), 3.13-2.80 (3H, m), 2.27-2.02 (3H, m), 1.90-1.77 (ÍH,), 1.60-1.40 (3H, m), 1.28-1.20 (ÍH, m), 2.85 (3H, t). EXAMPLE 34 [IR- [la, 2a, 3b- (1R *, 2S *), 5b]] -3- [7- [[2- (4-chloro-enyl) -cyclopropyl)] -amino] -5- (propylthio) -3H-1, 2 , 3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cislopentane-1,2-diol a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [[2 - (- 4-chlorophenyl) -cyclopropyl] -amino-5- (propylthio) -3H-1,2,3-triazolo- [4,5-d ] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-methanol was prepared according to the method of Example 1, step of part (a) using the product of Example 22, step of item (b) and 1,4-dioxane as solvent MS (APCI) 531 (M + H +, 100%) dH NMR (CDCl 3) 7.31 (4H, m), 5.82-5.15 (2H) , m), 4.72-4.69 (ÍH, m), 3 .82-3.65 (2H, t), 3.06-3.01 (2H, m), 2.62-2.45 (2H, m), 2.45-2.28 (ÍH, m), 2.21-2.071, 2.01-2.00 (ÍH, m), 1.68-1.60 (ÍH, m), 1.58 (3H, s), 1.40-1.35 (2H, m), 1.33 (3H, s), 0.94 (3H, t). b) [IR- [la, 2a, 3b- (IR *, 2S *), 5b]] -3- [7- [[2- (4-chloro-enyl) -cyclopropyl)] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -syclopentane-1,2-diol. It was prepared according to the method of Example 1, step of item (b) using the product of the step of part (b). MS (APCI) 491 (M + H +, 100%) dH NMR (de-DMSO) 9.33 (1H, d), 7.35-7.21 (4H, dd), 5.00-4.95 (2H, m), 4.73-4.70 (2H , m), 4.43-4.40 (ÍH, m), 3.88-3.87 (ÍH, m), 3.45 (2H, m), 3.15-3.05 (ÍH, m), 3.00-2.80 (2H, m), 2.27-2.00 (HH, m), 2.17-2.00 (2H,), 1.90-1.80 (HH, m), 1.60-1.40 (4H, m), 1.40-1.30 (HH, m), 0.82 (3H, t). EXAMPLE 35 [IR- [la, 2a, 3β- (ÍS *, 2R *), 5β]] -3- [7- [[2- (3-chloro-enyl) -cyclopropyl] -amino] -5- (propylthio) ) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (IR *, 2S *), 6aa] -6- [7- [[2- (3-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) - 3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta, 1,3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of 26, step of part (d) and 1,4-dioxane as solvent.MS (APCI) 531 (M + H +, 100%). b) [lR- [la, 2a, 3β- (lS *, 2R *) - 5β]] - 3- [7 - [[2- (3-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cidopentano-1,2-diol. It was prepared in accordance with the method of Example 1, step of item (b) using the product of the step of part (a). MS (APCI) 491 (M + H +, 100%) dH NMR (d6-DMSO) 9.34 (H, m), 7.28-7.10 (4H, m), 5.05-4.93 (2H, m), 4.78-4.71 (2H, m), 4.48-4.40 (1H, m), 3.86-3.80 (HH,), 4.50-4.40 (2H, m), 3.24-3.18 (HH, m), 3.00-2.80 (2H,), 2.34-2.21 (1H, m), 2.20-2.00 (2H, m), 1.90-1.80 (ÍH, m), 1.60-1.38 (4H, m), 0.82 (3H, t). EXAMPLE 36 [ÍS- [la, 2a, 3ß-5β- (1S *, 2R *)]] -3- (methoxymethyl) -5- [7- [(2-phenylcyclopropyl) -apino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [(2,4-dimethoxyphenyl) -methyl- (2-phenylcyclopropyl) -a ino] -5 - (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-l, 3-dioxol-4- methanol It was prepared according to the method of Example 1, step of part (a) using the product of Example 12, step of part (d). MS (APCI) 647 (M + H +, 100%). b) [3aS- [3aa, 4a- (lS *, 2R *), 6a, 6aa]] -N- [(2,4-dimethoxyphenyl-methyl] -3- [6- (methoxymethyl) -2, 2- dimethyltetrahydro-4H-cyclopenta-1,3-dioxolan-4-yl] -N- (2-phenylcyclopropyl) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidine -3-yl] -7-amine Sodium hydride (31 mg 60% in oil) was added to a solution of the product from step (a) (0.26 g) and methyl iodide (0.15 ml) in N , N-dimethylformamide (1.5 ml) and the resulting mixture was stirred for 2 hours, water was added and the mixture was extracted with ethyl acetate and the extracts were washed with water, dried, concentrated and purified (SiO2). , ethyl isohexane / acetone, 4: 1 as eluent) to obtain the subtitle compound (0.12 g).

MS (APCI) 661 (M + H, 100%; c) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] - 3- (methoxymethyl) -5- [7 - [( 2- phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 2, step of subsection (b) using the product of the step of subsection (b). P.f. ' 149-150 ° C. MS (APCI) 471 (M + H +, 100%) dH NMR (de-DMSO) 9.33 (HH, m), 7.20 (5H, m), 5.02 (HH, m), 4.81 (HH, m), 4.41 ( HH, m), 3.85 (HH, m), 3.40, (2H, m), 3.28 (3H, m), 3.20 (HH, m), 2.90 (2H, m), 2.25 (2H, 'm), 2.13 (ÍH, m), 1.86 (2H, m), 1.52 (2H, m), 1.49-1.32 (2H, m), 0.83 (3H, t, J = 7Hz). EXAMPLE 37 [ÍS- [la, 2a-3β-5β- (1S *, 2R *)]] -3- (hydroxymethyl) -5- [5- (methylthio) -7- [(2-phenylcyclopropyl) -amino] -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylsulfonyl) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared according to the method of Example 4, step of part (a) using the product of Example 1, step of part (b).

MS (APCI) 489 (M + H, 100%). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] - 3- (hydroxymethyl) -5- [5- (methylthio) -7- [(2-phenylcyclopropyl) -amino] -3H-1, 2, 3- triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 17, step of subsection (b) using the product of step of part (a). MS (APCI) 429 (M + H +, 100%) dH NMR (de-DMSO) 9.33 (1H, m), 7.31-7.15 (5H, m), 5.03-4.97 (2H, m), 4.74-4.71 (2H) , m), "4.47-4.40 (ÍH, m), 3.91-3.878 (HH, m), 3.51-3.46 (2H, m), 3.19-3.18 (HH, m), 2.33 (3H, s), 2.29-2.24 (HH, m), 2.14-2.10 (2H, m), 1.92 -1.80 (ÍH, m) 1. 51-1.47 (ÍH, m) 1.35-1.32 (ÍH, m). EXAMPLE 38 [lS- [la, 2a, 3β-5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- [(1 -methylethyl) -thio] -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. The title compound was prepared according to the method of Example 4, step of part (b) using the product of Example 37, step of part (a) and 1-methylethanethiol. MS (APCI) 457 (M + H +, 100%) dH NMR (de-DMSO) 9.35 (H, s), 7.26-7.19 (5H, m), 5.00-4.97 (2H, m), 4.72 (2H, s), 4.41 (HH, s), 3.87 (HH, s), 3.60- 3.64 (1H, m), 3.47 (2H, s), 3.17 (HH, s), 2.23-2.27 (HH, m), 2.09 (2H, s), 1.83-1.85 (HH, m), 1.53-1.55 (HH, m), 1.23-1.36 (HH, m), 1.15 (3H, d), 1.09 (3H, d) EXAMPLE 39 [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (prop-2-enylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [ÍS- [la, 2a-3β-5β- (1S *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino-5- (prop-2 -enthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. The title compound was prepared according to the method of Example 4, step of item (b) using the product of Example 37, step of part (a) and 2-propen-1-thiol. MS (APCI) 455 (M + H +, 100%) dH NMR (de-DMSO) 9.00 (H, s), 7.30-7.16 (5H,), 5.95-5.80 (ÍH, m), 5.22 (ÍH, d), 5.04-4.98 (2H, m), 4.67 (ÍH, d), 4. 47-4.38 (3H, m), 3.91 (HH, q), 3.75-3.65 (2H, m), 3.55- 3.48 (2H, m), 2.30-2.12 (3H, m), 1.93-1.86 (HH, m ), 1.50-1.45 (ÍH, m), 1.34-1.28 (ÍH, m) EXAMPLE 40 [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)]] -3- (hydroxymethyl) -5 - [5- (4-methylphenylthio) -7- [(2-phenylcyclopropyl) -amino] -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1 , 2-diol.

It was prepared according to the method of Example 4, step of item (b) using the product of Example 37, step of part (a) and p-thiocresol. MS (APCI) 505 (M + Ht, 100%) dH NMR (de-DMSO) 9.28 (H, m), 7.48-7.44 (2H, m), 7.32-7.11 (7H, m), 4.94-4.88) ( 2H, m), 4.64-4.60 (2H, m),, 4.32-4.27 (ÍH, m), 3.30-3.20 (2H, m), 3.13-3.10 (1H, m), 2.34 (3H, s), 2.22 -2.15 (2H, m), 2.02-1.98 (HH, m), 1.70-1.60 (HH, m), 1.42-1.38 (HH, m), 1.20-1.15 (HH, m). EXAMPLE 41 [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -tetrahydro-2,2-dimethyl-6- [7- [[2- (4-methylphenyl) -cyclopropyl] -amino ] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -4 H -cyclopenta-l, 3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of item (a) using the product of Example 21, step of item (b) and 1,4-dioxane as solvent. MS (APCI) 511 (M + H +, 100%). b) [ÍS- [Ia, 2a, 3β, 5β- (1S *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 1, step of item (b) using the product of the step of part (a). MS (APCI) 471 (M + Ht, 100%) dH NMR (de-DMSO) 9.30 (1H, d), 7.09 (4H, s), 5.30-4.92 (2H,), 4.71 (2H, s), 4.42. -4.36 (HH, m), 3.84 (HH, s), 5.56-3.41 (2H, m), 3.20-3.10 (1H, m), 3.00-2.80 (2H, m), 2.27 (3H, s), 2.25 -2.20 (HH, m), 2.15-2.05 (2H, m), 1.89-1.81 (HH, m), 1.60-1.40 (3H, m), 1.28 (HH, dd), 0.84 (3H, t). EXAMPLE 42 [lS-la, 2a, 3β, (R *), 5β- (lS *, 2R *)]] -3- (1-hydroxymethyl) -5- [7- [(2-phenylscyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. Sodium borohydride (0.50 g) was added to a solution of the product of Example 8 (2.10 g) in methanol (100 ml). The mixture was stirred for 1 hour and then poured into water (300 ml). The mixture was extracted with diethyl ether, washed with water, dried and concentrated. Purification (HPLC, Chiralpak AD, isohexane / ethanol, 8: 2 as eluent) yielded the title compound (0.16 g). The stereochemistry of the secondary alcohol was determined by the method of B Trost et al. , J. Org. Chem., 1086, 51, 2370.

MS (APCI) 471 (M + H +, 100%) dH NMR (de-DMSO) 9.31 (ΔI, d), 7.31-7.15 (5H, m), 4.91 (2H, m), 4.62 (ΔI, d), 4.57 (HH, d), 4.37 (HH, m), 3.84 (HH, m), 3.74 (1H, m), 3.18 (HH, m), 2.96-2.81 (2H, m), 2.11 (3H,), 1.96 (HH, m), 1.54 (3H, m), 1.35 (1H, m), 1.01 (3H, d), 0.79 (3H, t). EXAMPLE 43 [lS- [la, 2a, 3β, (S *), 5β- (lS *, 2R *)]] -3- (1-hydroxyethyl) -5- [7- [(2-phenylcyclopropyl) -amino] ] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol.

It was prepared according to the method of Example 42, but the additional elution (HPLC, Chiralpak AD, isohexane / ethanol, 8: 2) yields the title compound (0.18 g). The stereochemistry of the secondary alcohol was determined by the method of B Trost-et al. , J. Org. Chem., 1986, 51, 2370. MS (APCI) 471 (M + H ", 100%) dH NMR (de-DMSO) 9.33 (ÍH, d), 7.30-7.16 (5H, m),, 4.956 (2H , m), 4.68 (1H, m), 4.62 (HH, d), 4.37 (HH, m), 4.02 (HH, m), 3.62 (HH, m), 3.21 (HH, m), 2.96-2.82 ( 2H, m), 2.13 (2H, m), 1.89 (2H, m), 1.48 (3H, m), 1.33 (1H, m) 1.15 (3H, d), 0.82 (2H, t), EXAMPLE 44 [IR - [la, 2a, 3ß- (1R *, 2S *) -5β]] -3- [5- (ethylthio) -7- [[2-enylcyclopropyl] -amino] -3H-1,2,3-triazolo - [, 5-d] -pyrimidin-3-yl] -5-hydroxymethyl-cyclopentane-1,2-diol a) [3aR- [3aa, 4a, 6a- (IR *, 2S *), 6aa] - 6- [5- (ethylthio) -7- [[2- phenylcyclopropyl] -amino-3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2 dimethyl-4H-diclopenta-1,3-dioxol-4-methanol was prepared according to the method of Example 4, step of item (b) using the product of Example 37 step (a) and ethanethiol. (APCI) 483 (M + H +, 100%) b) [IR- [la, 2a, 3β- (IR *, 2S *), 5β]] -3- [5- (ethylthio) -7- [[ 2- phenylcyclopropyl] -amino-3H-l, 2,3-tri azolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 1, step of item (b) using the product of the step of part (a). MS (APCI) 443 (M + Ht, 100%) dH NMR (de-DMSO) 9.34 (1H, d), 7.31-7.15 (5H, m), 5.01-4.97 (2H, m), 4.73-4.70 (2H) , m), 4.45-4.41 (HH, m), 3.88 (HH, q), 3.51-3.45 (2H, m), 3.21-3.17 (HH, m), 2.90-2.86 (2H, m), 2.28-2.23 (ÍH,), 2.11-2.08 (2H, m), 1.90-1.82 (ÍH, m), 1.54-1.51 (ÍH,), 1.35-1.30 (ÍH,), 1.09 (3H, t). EXAMPLE 45 [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- [(1,1'-biphenyl) -4-yl] -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) Acid (lR-fcrans) -2 - [(1, 1-biphenyl) -4-yl] -cyclopropanecarboxylic acid. It was prepared according to the method of Example 20, step of part (a) using l-ethenyl-4-phenylbenzene. NMR dH (CDCl 3) 7.50-7.30 (7H, m), 7.19 (2H, d), 2.70-2.60 (HH, m), 1.99-1.93 (HH, m), 1.75-1.68 (HH, m), 1.47- 1.41 (ÍH, m). b) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- [(1,1'-bi-enyl) -4-yl] -cyclopropanamine, (1: 1) ). It was prepared in accordance with the method of Example 20, step of item (b) using the product of step (a). MS (APCI) 210 (M + H +, 100%). c) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [[2- [(1,1'-bi-enyl) -4-yl] -cyclopropyl] -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4-yl-cyclopenta-l, 3 -dioxol-4-methanol. Prepared according to the method of Example 1, step. of part (a) using the product of step (b) and 1,4-dioxane as solvent.

MS (APCI) 573 (M + H, 100%). d) [IR- [la,, 2a, 3ß- (IR *, 2S *), 5ß]] -3- [7- [[2- [(1,1'-phenyl) -4-yl] -cyclopropyl ] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5-hydroxymethyl) -cyclopentane-1,2-diol. It was prepared according to the method of Example 1, step of item (b) using the product of the step of part (c). MS (APCI) 433 (M + Ht, 100%) dH NMR (de-DMSO) 9.38 (1H, d), 7.64 (2H, d), 7.59 (2H, d), 7.46 (2H, t), 7.33 ( ÍH, t), 7.27 (2H, d), 5.10-5.00 (2H, m), 4.78 (2H, s), 4.47-4.40 (ÍH, m), (3H, t) 3 (ÍH, m), 3.50 -3.40 (2H, m), 3.27-3.20 (ÍH, m), 3.00-2.80 (2H, m), 2.35-2.04 (3H,), 1.89-1.80 (ÍH,), 1.70-1.39 (4H,), 0.79 (3H, t). EXAMPLE 46 [IR- (la, 2a, 3ß, 5ß)] -3- [7-butylamino) -5- (cyclopenicthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidine -3-yl] -5- (hydroxymethyl) -cyclopene-1,2-diol. It was prepared in accordance with the method of Example 4, step of part (b) using the product of Example 4, step of part (a) and cyclopentanethiol, followed by the method of Example 2, step of subsection (b). P.f. 187-188 ° C MS (APCI) 437 (M + Ht, 100%) dH NMR (de-DMSO) 8.96 (ΔH, t), 4.98-4.96 (2H, dd), 4.73-4.69 (2H, m), 4.46-4.39 (ÍH, m), 3.90-3.85 (ÍH,), 3.47 (ÍH, br s), 3.52-3.43 (4H,), 2.25-1.28 (17H,), 0.91 (3H, t). EXAMPLE 47 [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- [4- (tri luoromethyl) -phenylthio [-3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. The title compound was prepared according to the method of Example 4, step of part (b) using the product of Example 37, step of part (a) and 4- (trifluoromethyl) -thiophenol. P.f. 100-102 ° C MS (APCI) 559 (M + Ht, 100%) dH NMR (de-DMSO) 9.44 (1H, d), 7.83 (2H, d), 7.61 (2H, d), 7.29-7.08 ( 5H, m), 4.90 (2H, m), 4.62 (2H, m), 4.32 (HH, m), 3.75 (HH, m), 3.39-3.27 (2H, m), 3.06 (HH, m), 2.21 (2H, m), 2.01 (HH, m), 1.72 (HH, m), 1.40 (ÍH, m), 1. 19 (ÍH, m). EXAMPLE 48 [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] - 3-hydroxymethyl) -5- [7 - [[2- (4-phenoxyphenyl) -cyclopropyl] -amino] - 5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [lR- (la, 2a, 3ß, 5ß)] -3- [7-chloro-5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3 -yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. A solution of [3aR- (aa, 4a, 6a, 6aa)] -6- [7-chloro-5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin- 3-yl] -tetrahydro-2,2-dimethyl-4-yl-cyclopenta-l, 3-dioxol-4-methanol (0.50 g) in acetonitrile (20 ml) was stirred with Dowex® 50WX8-200 (form H) which is an ion exchange resin (0.49 g) at 60 ° C for 7 hours and then at room temperature overnight. The resin was removed by filtration and the filtrate was concentrated. The crude product was purified by chromatography (SiO2, ethyl acetate as eluent) to obtain the subtitle compound as a colorless solid (0.31 g). MS (APCI) 360 (M + H +, 100%). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-phenoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopene-1,2-diol. It was prepared according to the method of Example 1 , step of subsection (a) using the products of the step of subsection (a) and of Example 28, step of subsection (b) and acetonitrile as solvent.

MS (APCI) 549 (M + Ht, 100%) dH NMR (de-DMSO) 9.33 (ΔI, d), 7.42-7.34 (2H,), 7.27-7.17 (2H, m), 7.12 (1H, m) , 7.01-6.92 (4H, m), 5.06-4.95 (2H, m), 4.75-4.68 (2H, m), 4.48-4.38 (1H, m), 3.91-3.85 (HI, m), 3.56-3.40 ( 2H, m), 3.21-3.13 (HH, m), 3.05-2.83 (2H, m), 2.32-2.19 (HH, m), 2.18-2.03 (2H, m), 1.91-1.79 (HH, m), 1.61-1.46 (3H, m), 1.36-1.26 (1H, m), 0.85 (3H, t). EXAMPLE 49 [lR- [la, 2a, 3β- (lS *, 2R *), 5β]] -3- [7- [[2- (2-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopene-1,2-diol. a) Acid (IR-trans) -2- (2-chlorophenyl) -cyclopropanecarboxylic acid. It was prepared in accordance with the method of Example 20, step of part (a) using 2-chloro-1-ethenylbenzene. MS (APCI) 195 (M-H, 100%). b) [R- (R *, r *)] -2,3-dihydroxybutadioate of (IR-rans) -2- (chlorophenyl) -cyclopropanamine, (1: 1). It was prepared in accordance with the method of Example 20, step of item (b) using the product of step (a). MS (APCI) 166 (M + H +, 100%). c) [3aR- [3aa, 4a, 6a- (IR *, 2S *), 6aa] -6- [7- [[2- (2-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) - 3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol. It was prepared in accordance with the method of Example 1, step of part (a) using the product of the step of part (b) and 1,4-dioxane as solvent. MS (APCI) 531 (M + H +, 100%). d) [IR- [la, 2a, 3β- (ÍS *, 2R *), 5β]] -3- [7- [[2- (2-chloro-enyl) -cyclopropyl] -amino-5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. It was prepared according to the method of Example 1, step of item (b) using the product of the step of part (c). (Resonance enters *) EXAMPLE 50 [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)]] -3- (2-hydroxyethoxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] ] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -N- [(2,4-dimethoxyphenyl) -methyl] -3- [6- [[2- [(1, 1-dimethylethyl) -dimethylsilyl] -oxy] -ethoxymethyl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-yl] -N- (2-phenylcyclopropyl) -5- (propylthio ) -3H- 1, 2, 3-triazolo- [4,5-d] -pyrimidin-7-amine. Sodium hydride (35 mg, dispersion at 60% in oil) and (2-bromoethoxy) -tert-butyldimethylsilane (0.2 ml) was added to a solution of the product of Example 36, step (b) (333 mg) in toluene (3 ml) and the reaction mixture was heated at 65 ° C for 6 hours and then 100 ° C for 16 hours. Then more sodium hydride (35 mg) and silane (0.2 ml) were added and the mixture was heated for 6 hours. A solution of ammonium chloride was added and the mixture was extracted with ethyl acetate. The organic extracts were dried, concentrated and purified (SiO2, petroleum / ether, 2: 1 and petroleum / ethyl acetate, 4: 1 as eluents) to obtain the subtitle compound (77 mg). NMR dH (CDCl 3) 7.27-7.12 (6H, m), 6.40-6.28 (2H, m), 5.37-5.17 (3H, m), 3.79 (1H, m), 3.78-3.73 (5H, m), 3.6-3.51 (7H, m), 3.1-2.95 (2H, m), 2.6-2.1 (2H, m), 1.68-1.61 (2H, m), 1.59-1.57 (6H, m), 1.48-1.41 (ÍH) , m), 1.30-1.21 (5H, m), 0.94 (3H, t), 0.86 (9H, s) 0.06 (6H, s). b) [1 S- [la, 2a, 3β, 5β- (lS *, 2R *)]] - 3- (2-hydroxyethoxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- ( propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopene-1,2-diol. It was prepared in accordance with the method of Example 2, step of subsection (b) using the product of step of part (a). Purification (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, isocratic elution with 35% MeCN over a period of 30 minutes) yielded the title compound (33 mg). MS (APCI) 501 (M + H *, 100%) NMR dH (de-DMSO) 9.35 (H, s), 7.38-7.05 (5H, m), 5.09-4.92 (2H, m), 4.81 (HH, d), 4.63-4.54 (HH, m), 4.47-4.38 (HH,), 3.90-3.84 (HH, m), 3.6-3.3 (8H,), 3.24-3.16 (ÍH, m), 3. 01-2.79 (2H, m), 2.35-2.08 (3H, m), 1.90-1.78 (ÍH, m), 1.56-1.44 (2H, m), 1.37-1.27 (ÍH,), 0.80 (3H, t) . EXAMPLE 51 [1- R- [la, 2β, 3β, 4a- (lR *, 2S *)]] - 3-hydroxy-2-methoxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentanemethanol. a) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3-. { 7- [N- (2,4-dimethoxyphenylmethyl) - (2-phenylcyclopropyl) -a ino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3 -yl] - 5- (hydroxymethyl) -cyclopentane-1,2-diol. A solution of the product of Example 36, step of part (a) (1.39 g) in trifluoroacetic acid (1.5 ml) / methanol (15 ml) was stirred for two days. Ethyl acetate was added and the mixture was concentrated. A solution of sodium hydrogen carbonate was added and the mixture was extracted with ethyl acetate. The organic extracts were dried, concentrated and purified (SiO2, petroleum / acetone, 1: 1 as eluent) for the subtitle compound (1.11 g). MS (APCI) 607 (M + H +, 100%). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] - 5- [7- [N- (2,4-dimethoxyphenylmethyl) - [(2-phenylcyclopropyl) -amino]] -5- (propyl io) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] - 3 - [[[(1,1-dimethylethyl) -diphenylsilyl] -oxi ] -methyl] -cyclopentane-1,2-diol. A solution of the product from step (a) (1.11), imidazole (417 mg) and tert-butylchlorodiphenylsilane (0.75 ml) in anhydrous DMF (4 ml) was stirred for 18 hours.

Water was added and the mixture was extracted with ethyl acetate. The organic extracts were dried, concentrated and purified (SiO2, petroleum / acetone, 3: 1 as eluent) to obtain the subtitle compound. (1.16 g). NMR dH (CDCl 3) 7.70-7.04 (16H, m), 6.44-6.30 (2H, m), 5.83- 5.63 (2H, m), 5.45-5.31 (HH, m), 5.04-4.78 (HH, m), 4.50- 4.40 (1H, m), 4.32-4.27 (1H, m), 3.86-3.52 (8H, m), 3.13-2.63 (4H, m), 2.53-2.17 (3H, m), 1.79-1.40 (4H , m), 1.01 (9H, s) 0.97 (3H, t). c) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] - 5- [7- [N- (2,4-dimethosyphenylmethyl) - [(2-phenylcyclopropyl) -amino]] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -3- [[[(1,1-dimethylethyl) -diphenylsilyl] -oxi] -methyl] -2- methoxycyclopentane. Sodium hydride (65.3 mg) was added to a solution of the diol from step (b) (1.23 g) and methyl iodide (0.13 ml) in DMF (4 ml) and the mixture was stirred for 4 hours. A solution of ammonium chloride was added and the mixture was extracted with ethyl acetate. The organic extracts were dried, concentrated and purified (SÍO2, petroleum / acetone, 4: 1 and petroleum / ethyl acetate, 2: 1 as eluents) to obtain the subtitle compound (676 mg) in the form of a 1: 2.5 mixture with the regioisomeric compound [IR- [la, 2a, 3β, 5β- (1R *, 2S *)]] -3- [7- [N- (2, -dimethoxyphenylmethyl) - (2-phenylcyclopropyl) -amino]] -5-propylthio-3i? -l, 2, 3-triazolo- [4,5-d] -pyrimidine -3-yl] -5- [[[(1,1-dimethylethyl) -diphenylsilyl] -oxy] -methyl] -2-methoxycyclopentanol. NMR dH (CDCl 3) 7.5-7.0 (16H, m), 6.43-6.31 (2H,), 5.84-4.60 (4H, m), 4.35-4.27 (H, m), 3.82-3.12 (11H, m), 3.15 -2.85 (2H, m), 2.64-2.58 (HH, m), 2.53-1.97 (2H, m), 1.77-1.22 (5H, m), 1.01 (9H, s), 0.97 (3H, t). d) [LR- [la, 2β, 3β, 4a- (lR *, 2S *)]] - 3-hydroxy-2-methoxy-4- [7- [(2-phenylscyclopropyl) -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopene-amethanol. A solution of the mixture of compounds from step (c) (676 mg) in trifluoroacetic acid / water (9: 1) (3 ml) was stirred for 20 hours. The solvent was removed in vacuo and the residue was dissolved in THF (1 ml) and treated with tetrabutylammonium fluoride in THF (2 ml, 1 M solution) and stirred for 4 hours. The solvent was removed in vacuo and the residue was purified (SiO2, petroleum / acetone, 2: 1, dichloromethane / methanol, 29: 1 and petroleum / ethyl acetate, 1: 2 as eluents) to obtain two factions: Fraction 1, 161 mg of [IR- [la, 2β, 3β, 4a- (1R +, 2S *)]] - 3-hydroxy-2-methoxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentanemethanol. Fraction 2, 330 mg of [IR- [la, 2ß, 3ß, 4a- (1R *, 2S *)]] -2-hydroxy-3-methoxy-4- [7- [(2-phenylcyclopropyl) -amino] -5-propylthio-3i? -l, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentammethanol; which was further purified in Example 52. Further purification of fraction 1 (HPLC, Novapak column C18, aqueous ammonium acetate 0. 1% / acetonitrile, isocratic elution with 45% MeCN over a period of 40 minutes), afforded the title compound (58.9 mg). MS (APCI) 471 (M + H *, 100%) dH NMR (d6-DMSO) 9.33 (ΔH, bs), 7.34-7.13 (5H, m), 5.10-4.69 (3H, m), 4.60-4.49 ( ÍH, m), 3.68-2.79 (6H, m), 3.37 (3H, s), 2.32-2.07 (3H,), 1.92-1.80 (ÍH, m), 1.60-1.47 (3H, m), 1.38-1.28 (ÍH, m), 0.80 (3H, t). EXAMPLE 52 [IR- [la, 2β, 3β, 4a- (IR *, 2S *)]] -2-hydroxy-3-methoxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopene-amethanol. Purification of fraction 2 of Example 51 (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, isocratic elution with 45% MeCN over a period of 40 minutes) yielded the title compound (133.5 mg). MS (APCI) 471 (M + H *, 100%) dH NMR (de-DMSO) 9.35 (H, s), 7.34-7.13 (5H,), 5.14 (H, q), 4.79 (H, s), 4.23-4.05 (2H, m), 3.57-3.25 (5H, m), 3.25-3.18 (H, m), 3.04-2.79 (2H, m), 2.37-2.06 (3H, m), 1.92-1.80 (H) , m), 1.60-1.47 (3H, m), 1.38-1.28 (ÍH, m), 0.83 (3H, t). EXAMPLE 53 [ÍS- [la, 2a, 3ß (£), 5β- (ÍS *, 2R *)]] -3- (3-hydroxyprop-1-enyl) -5- [7- [(2-phenylcyclopropyl)] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) Methylester of 3- [[3aR- [3aa, 4a (£ 7), 6a- (1R *, 2S *), 6aa]] -6- [7- [(cyclopropyl) -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-ylJ-tetrahydro-2,2-dimethyl-4H-cyclopenta-l, 3-dioxol--yl] -2 -propenoic A solution of the product of Example 1, step of part (a) (1.6 g) in dimethyl sulfoxide (15 ml) was treated with pyridine (0.25 g) followed by trifluoroacetic acid (0.18 g). To this mixture was added 1,3-dicyclohexylcarbodiimide (1.99 g). After stirring for 5 hours, the reaction mixture was treated with methyl- (triphenylphosphoroanilidene) -acetate (1.72 g) and then stirred for a further 18 hours. The mixture was poured into ethyl acetate (300 ml) and treated with oxalic acid. (1.59 g). After stirring for 30 minutes, the mixture was filtered and the ethyl acetate solution was washed with a dilute aqueous solution of sodium bicarbonate and then with dilute aqueous brine, before being dried and concentrated. Purification (Si02, ethyl acetate / isohexane, 1: 4 as eluent) yielded the subtitle compound (1.5 g). MS (APCI) 551 (M + H +, 100%). b) 3- [[R- [la- (E), 2ß, 3ß, 4a- (1R *, 2S *)]] -2,3-dihydroxy-4- [7- [(2-enylcyclopropyl)] methyl ester ) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentyl] -2-propenoic acid. It was prepared according to the method of Example 2, step of item (b) using the product of step (a). MS (APCI) 511 (M + H +, 100%). c) [lS- [la, 2a, 3β- (E), 5β- (1S *, 2R *)]] -3- (3-hydroxyprop-1-enyl) -5- [7- [(2-phenylcislopropyl) ) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. A product solution from step (b) (0.7 g) in tetrahydrofuran (25 ml) at -78 ° C, was treated with DIBAL-H® (1.5 M solution in toluene, 8.2 ml). Then, the mixture was stirred at 0 ° C for 1 hour before being stopped with methanol (1 ml) and then it was poured into dilute aqueous sodium hydroxide (50 ml). This mixture was extracted with ethyl acetate (200 ml), the extract was dried and concentrated. Purification (SIO2, ethyl acetate as eluent) yielded the title compound (0.2 g) -MS (APCI) 483 (M + Ht, 100%) dH NMR (de-DMSO) 9.34 (1H, d), 7.31- 7.15 (5H, m), 5.80-5.70 (ÍH,), 5.66-5.58 (ÍH, m), 5.09 (ÍH, d), 4.98 (ÍH, q), 4.88 (ÍH, d), 4.67 (ÍH, t ), 4.33 (1H, q), 3.93 (2H, t), 3.84 (HH, q), 3.22-3.18 (HH, m), 3.00-2.80 (2H, m), 2.65- 5.60 (HH, m), 2.42-2.38 (ÍH,), 2.15-2.10 (ÍH,), 2.00-1.85 (ÍH, m), 1.55-1.47 (3H, m), 1.35-1.30 (ÍH, m), 0.85-0.80 (3H, m ). EXAMPLE 54 [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (3-hydroxypropyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- ( propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopene-1,2-diol. A solution of the product of Example 53, step of part (c) (0.2 g) and triisopropylbenzenesulfonyl hydrazide (0.3 g) in tetrahydrofuran (10 ml), was heated at 70 ° C for 4 hours. Subsequently, the mixture was purified (SiO2, ethyl acetate as eluent) to obtain the title compound (0.13 g). MS (APCI) 485 (M + Ht, 100%) dH NMR (de-DMSO) 9.32 (1H, d), 7731-7.15 (5H, m), 5.00-4.95 (2H, m), 4.71 (1H, d ), 4.42-4.36 (2H, m), 3.73 (HH, q), 3.41 (2H, q), 3.20-3.17 (HH, m), 2.97-2.83 (2H, m), 2.37-2.33 (HH, m ), 2.13-2.11 (ÍH, m), 1.95-1.85 (ÍH, m), 1.77-1.31 (9H, m), 0.83 (3H, t). EXAMPLE 55 l - [[lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 2,3-dihydroxy-4- [7 - [(2-enylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentyl] -2-methoxyethanone. Boron trifluoride etherate (1.0 ml) was added to a solution of the diazoketone prepared in the manner described in Example 8 (0.60 g) in methanol (50 ml) and the solution was heated at 50 ° C for 1 hour. The reaction mixture was subjected to extraction with ethyl acetate and the extracts were washed with water and then dried and concentrated. Purification (SIO2, ethyl acetate / dichloromethane, 2: 3 as eluent) yielded the title compound (0.16 g). MS (APCI) 499 (M + H +, 100%) dH NMR (de-DMSO) 9.36 (HH, d), 7.31-7.16 (5H, m), 5.25 (2H,), 4.99 (HH, m), 4.30. (HH, m), 4.24 (2H, m), 4.13 (HH,), 3.31 (3H, s), 3.19 (HH, m), 3.13 (HH, m), 2.96-2.83(2H, m), 2.35 (2H,), 2.14 (ÍH, m), 1.51 (3H, m), 1.34 (1H, m), 0.81 (3H, t). EXAMPLE 56 • - [lS- (la, 2a, 3ß, 5ß)] -3- (hydroxymethyl) -5- [7- [[(fcrans) -2- (3,4-methylenedioxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a, 6aa] -tetrahydro-2,2-dimethyl-6- [7- [[(trans) -2- (3,4-methylenedioxyphenyl) -cyclopropyl] -amino] - 5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -4 H -cyclopenta-1,3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using (trans) -2- (3, -methylenedioxyphenyl) -cyclopropanamine hydrochloride. MS (APCI) 541 (M + H +, 100%). b) [1 S- (la, 2a, 3β, 5β)] -3-hydroxymethyl-5- [7- [[(trans) -2- (3,4-methylenedioxy enyl) -cyclopropyl] -amino] -5- (propyl io) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 1, step of item (b) using the product of the step of part (a). NMR dH (df-DMSO) 9.28 (ΔI, d), 6.84-6.80 (2H,), 6.61-6.69 (ΔI, m), 5.96 (2H, s), 5.01-4.97 (2H, m), 4.73-4.71 (2H, m), 4.44-4.40 (ÍH, m), 3.87 (ÍH, q), 3.51-3.44 (2H,), 3.10-3.07 (ÍH, m), 3.00-2.90 (2H, m), 2.27- 2.23 (ÍH, m), 2.08-2.05 (2H, m), 1.86-1.83 (ÍH, 'm), 1.59-1.53 (2H, m), 1.45-1.42 (ÍH, m), 1.29-1.24 (ÍH, m), 0.86 (3H, t). EXAMPLE 57 [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (3-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] cyclopene-1, 2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -tetrahydro-6- [7- [[2- (3-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) ) -3H- 1,2,3-triazolo- [4,5-dJ-pyrimidin-3-yl] -2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol.

It was prepared according to the method of Example 1, step of part (a) using the product of Example 24, step of part (e). MS (APCI) 527 (M + H +, 100%). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] - 3- (hydroxymethyl) -5- [7 - [[2- (3-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane A solution of the product from step (b) (0.29 g) in a 80% aqueous acetic acid solution (10 ml) was heated at 80 ° C for 1 hour. The solution was concentrated in vacuo and purified by chromatography (SiO2, methanol / dichloromethane, 5:95 as eluent), to obtain the crude product. Further purification (HPLC, column Novapak © C18, acetate of 0.1% aqueous ammonium / acetonitrile, isocratic elution with 45% MeCN in a period of 15 minutes), produced the title compound as a colorless solid (0.19). g) MS (APCI) 487 (M + H +, 100%) dH NMR (de-DMSO) 9.32 (ΔI, d), 7.19 (ΔI, t), 6.78-6.72 (3H, m), 5.04-4.95 ( 2H, m), 4.75-4.69 (2H, m), 4.47-4.38 (HH, m), 3.91-3.84 (HH, m), 3.75 (3H, s), 3.55-3.41 (2H, m), 3. 24-3.17 (ÍH, m), 3.01-2.92 (ÍH, m), 2.90-2.81 (ÍH,), 2. 31-2.19 (ÍH,), 2.14-2.04 (2H, m), 1.90-1.79 (ÍH, m), 1.59-1.45 (3H,), 1.37-1.30 (ÍH,), 0.83 (3H, t). EXAMPLE 58 [ÍS- [la, 2a, 3ß, 5ß- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-hydroxyphenyl) -cyclopropyl] -a ino ] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) (lR-trans) -2- (4-hydroxyphenyl) -cyclopropanamine hydrobromide. A solution of the free base of the product of Example 20, step (b) (300 mg) in 47% aqueous hydrobromic acid (9 ml) was heated at 100 ° C for 2 hours. The reaction mixture was concentrated and the residue was subjected to azeotropic distillation with toluene (3 x 30 ml). The residue was taken up in ethanol (30 ml) and the product was precipitated by the addition of ether (100 ml) to obtain the subtitle compound 4.290.mg). NMR dH (de-DMSO) 6.98 (2H, m), 6.74 (2H, m), 2.68 (HH,), 2.25 (HH, m), 1.25 (HH, m), 1.14 (HH, m). b) [3aR- [3aa, 4a, 6a- (IR *, 2S *), 6aa] -te rahydro-6- [7- [[2- (4-hydroxyphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-l, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of the step of part (a) and tetrahydrofuran as the solvent. MS (APCI) 513 (M + H, 100%) c) [ÍS- [Ia, 2a, 3β, 5β- (1S *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[ 2- (4-hydroxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2 -diol. It was prepared in accordance with the method of Example 57, step of subsection (b) using the product of the step of subsection (b). MS (APCI) 473 (M + H% 100%) dH NMR (de-DMSO) 9.25 (1H, d), 7.05 (2H, dd), 6.69 (2H, dd), 6.62 (4H, m) 5.00 (1H) , m), 4.41 (ÍH, m), 3.87 (ÍH, m), 3. 45 (2H, m), 3.05 (HH, m), 2.95 (2H,), 2.27 (HH,), 2. 06 (2H, m), 1.86 (HH, m), 1.54 (2H, m), 1.39 (HH, m), 1. 20 (ÍH, m), 0.87 (3H, t). EXAMPLE 59 [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (3-methyl enyl) -cyclopropyl] -amino ] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -2, 2-dimethyl-4H-cyclopenta-1,3-dioxol- - methanol It was prepared in accordance with the method of Example 1, step of part (a) using the product of Example 25, step of subsection (b). MS (APCI) 511 (M + H +, 100%). b) [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyridin din-3-yl] -cyclopentane-1,2-diol. It was prepared according to the method of Example 57, step of item (b) using the product of the step of part (a). (Resonance enters *) EXAMPLE 60 [ÍS- [la, 2a, 3ß, 5ß- (1S *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (3-phenoxyphenyl) - cyclopropyl] -amino] -5- (propylthio-3ff-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, a) [3aR- [ 3aa, 4a, 6a- (lR *, 2S *), 6aa] -tetrahydro-2,2-dimethyl-6- [7- [[2- (3-phenoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) ) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -4 H -cyclopenta-l, 3-dioxol-4-methanol. It was prepared in accordance with the method of Example 1, step of part (a) using the product of Example 29, step of part (c). MS (APCI) 589 (M + H +, 100%). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (3-phenoxyphenyl) -cyclopropyl] -amino ] -5- (propylthio) -3H-1,2,3-riazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared according to the method of Example 57, step of item (b) using the product of the step of part (a). MS (APCI) 549 (M + H +, 100%). NMR dH (de-DMSO) 9.32 (1H, d), 7.41-7.38 (2H, m), 7.30 (1H, t), 7.01-6.96 (3H, m), 6.95 (1H, s), 6.80 (1H, dd), 5.01-4.96 (2H, m), 4.72-4.70 (2H, m), 4.45-4.38 (H, m), 3.51-3.45 (2H, m), 3.20-3.18 (H, m), 3.03- 2.81 (2H, m), 2.31-2.22 (HH, m), 2.15-2.06 (2H, m), 1.89-1.91 (HH, m), 1.56-1.49 (3H,), 1.33-1.30 (HH, m) 0.84 (3H, t). EXAMPLE 61 [1R-Ila, 2a, 3β- (1R *, 2S *), 5β]] -3- [7- [[2- (4-fluorophenyl) -cyclopropyl] -amino] -5- (propylthio) - 3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5-. { hydroxymethyl) -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [[2- (4-fluorophenyl) -cyclopropyl] -amino] -5- (propylthio) - 3H-1,2,3-triazolo- [4,5-d] -pyrimidi? -3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of Example 19 step of part (1). MS (APCI) 515 (M + H +, 100%). b) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (4-luo-phenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol.

It was prepared according to the method of Example 57, step of item (b) using the product of the step of part (a). MS (APCI) 475 (M + H +, 100%). NMR dH (d6-DMSO) 9.33 (ΔI, d), 7.29-7.17 (2H, m), 7.17-7.07 (2H, m), 5.05-4.95 (2H, m), 4.76-4.68 (2H, m), 4.48-4.38 (ÍH, m), 3.92-3.84 (ÍH, m), 3.55-3.41 (2H, m), 3.18-3.05 (1H,), 3.01-2.81 (2H, m), 2.31-2.19 (ÍH, ), 2.18-2.04 (2H, m), 1.91-1.79 (HH, m), 1.58-1.46 (3H, m), 1.36-1.28 (HH, m), 0.83 (3H, t). EXAMPLE 62 [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (3-nitrophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol a) [3aR- [3aa, 4a, 6a - (lR *, 2S *), 6aa] -tetrahydro-2,2-dimethyl-6- [7- [[2- (3-nitro-enyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -4 H -cyclopenta-l, 3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of Example 27, step of part (b). MS (APCI) 542 (M + H +, 100%). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (3-nitrophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared according to the method of Example 57, step of item (b) using the product of the step of part (a). MS (APCI) 502 (M + H +, 100%). NMR dH (de-DMSO) 8.10-8.00 (2H, m), 7.71-7.55 (2H, m), 5.06-4.9-2- (2H, m), 4.82-4.64 (2H, br), 4.47-4.37 ( ÍH, m), 3.91-3.83 (ÍH, m), 3.55-3.41 (2H, m), 3.28-3.20 (ÍH, m), 2.97-2.72 (2H, m), 2.37-2.17 (2H, m), 2.16-2.03 (ÍH, m), 1.92-1.77 (ÍH, m), 1.74-1.60 (ÍH, m), 1.59-1.39 (3H, m), 0.78 (3H, t). EXAMPLE 63 [IR- [la, 2a, 3β, 5β- (1R *, 2S *)]] -3- [7- [[2- (3-aminophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. It was prepared according to the method of Example 30, using the product of Example 62. MS (APCI) 472 (M + H +, 100%). NMR dH (de-DMSO) 6.91 (ÍH, t), 6.42-6.29 (3H, m), 5.07-4.86 (ÍH, m), 4.49-4.38 (ÍH, m), 3.91-3.85 (ÍH, m), 3.56-3.40 (2H, m), 3.23-3.15 (HH, m), 3.14-2.84 (2H, m), 2.32-2.18 (ÍH, m), 2.17-2.05 (ÍH,), 2.05-1.96 (ÍH, m), 1.91-1.78 (HH, m), 1.64-1.50 (2H, m), 1.46-1.36 (HH, m), 1.25-1.13 (HH, m), 0.87 (3H, t).

EXAMPLE 64 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3,5-dimethoxyphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2, 3-riol. a) 3- (3,5-Dimethoxy-enyl) -2-propenoic acid. To a solution of 3,5-dimethoxybenzaldehyde (12.5 g) in pyridine (20 ml) was added malonic acid (8.61 g) and piperidine (1 ml). The resulting solution was heated at 100 ° C for 16 hours, cooled to room temperature, emptied on ice and acidified using concentrated HCl. The resulting precipitate was collected, subjected to extraction with a sodium bicarbonate solution and washed with isohexane. The aqueous phase was acidified using concentrated HCl to obtain a white precipitate, which was filtered, washed. with . water and dried to obtain the subtitle compound (11.07 g). MS (APCI) 207 (M-H +, 100%). b) [3aS- [1- (E), 3aa, 6a, 7aβ]] -1- [3- (3-3,5-dimethoxyphenyl) -1- oxo-2-propenyl] -hexahydro-8, 8- dimethyl-3H-3a, 6-methano-2, l-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (f) using the product of the step of part (a). MS (APCI) 406 (M + H +, 100%). c) [3aS- [1 - ((1S *, 2R *), 3aa, 6a, 7ab]] -1- [[2- (3,5-dimethoxyphenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8 - dim il-3H-3a, 6-xnetane-2, 1-benzisothiazole-2,2-dioxide The subtitle compound was prepared according to the method of Example 19, step of part (g) using the product of step of part (b) MS (APCI) 418 (M-H +, 100%) d) Acid (IR-trans) -2- (3,5-dimethoxy-enyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of step (c). MS (APCI) 221 (M-H +, 100%). e) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of [IR-trans] -2- (3,5-dimethoxyphenyl) -cyclopropanamine, (1: 1). The subtitle compound was prepared according to the method of Example 20, subsection step (b) using the product of the passage of subsection (d). NMR dH (de-DMSO) 6.32-6.31 (HH, m), 6.26-6.25 (2H, m), 3.92 (2H, s), 3.71 (6H, s), 2.73-2.66 (2H, m), 2.10- 2.03 (ÍH, m), 1.23-1.08 (2H, m). f) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3,5-dimethoxy-enyl) -cyclopropyl] -amino] -5- (propylthio) -3flT-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-riol. The title compound was prepared according to the method of Example 24, step of part (f) using the products of step (e) and Example 24, step of part (d). MS (APCI) 503 (M + H +, 100%). NMR dH (de-DMSO) 6.35-6.30 (3H, m), 5.10 (HH, bs), 5.00-4.91 (3H,), 4.67-4.63 (HH, m), 3.93 (HH, s), 3.78-3.77 (HH, m), 3.73 (6H, s), 3.22-3.17 (HH, m), 3.01-2.84 (2H, m), 2.62-2.61 (HH, m), 2.08-2.05 (HH, m), 1.91 -1.87 (ÍH, m), 1.53-1.46 (2H, m), 1.35-1.32 (1H, m), 0.85-0.80 (3H, s). EXAMPLE 65 [lS- [la, 2a, 3b, 5b- (lS *, 2R *)]] -3- [(2-hydroxy-2,2-dime-yl) -ethoxy] -5- [7- [( 2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) 2- [[[3aR- [3aa, 4a- (IR *, 2S *), 6a, 6aa]] -6- [7- [N- [(2, 4-dimethoxyphenyl) -methyl] -2- . { phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1 , 3-dioxol-4-yl] -oxi] -1, 1-dimethylethanol. To a solution of the product of Example 23, step (b) (1.15 g) in tetrahydrofuran (25 ml) at 0 ° C, was added methylmagnesium bromide (0.45 ml, 3 M solution in THF). The reaction mixture was stirred for 1 hour and then quenched with a 10% ammonium chloride solution and the reaction mixture was partitioned into ethyl acetate and water. The organic phase was separated, dried and concentrated. Purification (SIO2, ethyl acetate / hexane, 1: 3 as eluent) yielded the subtitle compound (0.80 g). MS (APCI) 705 (M + H +, 100%). b) [lS- [la, 2a, 3b, 5E- (lS *, 2R *)]] -3- [(2-hydroxy-2,2-dimethyl) -ethoxy] -5- [7- [(2 phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. The title compound was prepared according to the method of Example 2, step of item (b) using the product of step (a) MS (APCI) 705 (M + H +, 100%). NMR dH (de-DMSO) 9.35 (ΔI, t, J = 4.5 Hz), 7.31-7.27 (2H, m), 7.21-7.15 (3H, m), 5.13 (ΔI, d, J = 6.3 Hz), 5.05 (ÍH, d, J = 3.9 Hz), 4.98 (ÍH, q, J = 9.0 Hz), 4.63-4.56 (ÍH, m), 3.94 (ÍH, s), 3.74 (ÍH, s), 3.27 (ÍH, d, J = 8.7 Hz), 3.21 (HH, d, J = 9.0 Hz), 3.21 (HH, m), 2.97-2.81 (2H, m), 2.63 (HH, m), 2.13 (HH, m), 2.04 (HH, m), 1.52 (2H, m), 1.48 (HH, m), 1.34 (HH, m), 1.10 (3H, s), 1.09 (3H, t, J = 7.5 Hz).

EXAMPLE 66 [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] - 3- (hydroxymethyl) -5- [7 - [[2- [4- (1-methylethyloxy) -phenyl] -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) 1-ethenyl-4- (1-meletoxy) -benzene. It was prepared according to the method of Example 29, step of part (a) using 4- (1-methylethoxy) -benzaldehyde. MS (El) 162 (M +, 100%). b) Acid (IR-trans) -2- [4- (1-methylethoxy) -phenyl] -cyclopropane-aarboxylic acid. It was prepared in accordance with the method of Example 20, step of part (a) using the product of the step of part (a). MS (APCI) 219 (M-H +, 100%). c) (IR-rans) -2- [4- (1-methylethoxy) -phenyl] -cyclopropanamine. It was prepared according to the method of Example 19, step of item (i) using the product of the step of part (b). NMR dH (de-DMSO) 7.00 (2H, d), 6.76 (2H, d), 4.51 (1H, septete), 2.30-2.25 (1H, m), 1.67-1.61 (H, m), 1.21 (6H, d), 0.85-0.75 (2H, m). d) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -tetrahydro-2,2-dimethyl-6- [7- [[2- [4- (1-m-tiletoxy) - phenyl] -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -4H-cyclopenta-1,3-dioxol- 4-methane It was prepared in accordance with the method of Example 1, step of part (a) using the product of the step of part (c). MS (APCI) 219 (M + H +, 100%). e) [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- [4- (1-methylethyloxy) -phenyl] -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared according to the method of Example 57, step of item (b) using the product of the step of part (d). NMR dH (de-DMSO) 9.28 (ÍH, d), 7.11 - < 2H, d), 6.82 (2H, m), 5.01-4.97 (2H,), 4.74-4.70 (2H, m), 4.55 (1H, sept), 4.46-4.39 (H, m), 3.89-3.85 (H) , m), 3.51-3.45 (2H, m), 3.14-3.07 (HH, m), 3.03-2.82 (2H, m), 2.30-2.20 (HH, m), 2.09-2.06 (2H, m), 1.89 -1.79 (1H, m), 1.59-1.49 (HH, m), 1.47-1.41 (HH, m), 1.24 (7H, m), 0.99 (3H, t). EXAMPLE 67 [ÍS- [la, 2a, 3b, 5b- (ÍS *, 2R *)]] -3- (3-hydroxypropoxy) -5- [7- [(2-phenylcyclopropyl) -amino] -5- ( propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [3aS- [3aa, 4a- (lS *, 2R *), 6a, 6aa]] -N- [2,4- (dimethoxyphenyl) -methyl] -3- [2, 2-dimethyl-6- [ [[3- (tetrahydro-2H-pyran-2-yl) -oxi] -propyl] -oxi3 -4H-cyclopenta-l, 3-dioxol-4-yl3-N- (2-phenylscyclopropyl) -5- (propylthio) ) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -7-amine. The subtitle compound was prepared according to the method of Example 31, step of part (d) using the product of Example 23, step of part (a) and 2- (3-bromopropoxy) -2iT-tetrahydropyran. MS (APCI) 775 (M + H +, 100%). b) [lS- [la, 2a, 3b, 5b- (lS *, 2R *)]] -3- (3-hydroxypropoxy) -5- [7- [(2-phenylcyclopropyl) -amino] -5- ( propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. The title compound was prepared according to the method of Example 2, step of item (b) using the product of the step of part (a). MS (APCI) 501 (M + H +, 100%). NMR dH (de-DMSO) 9.34 (ΔI, d, J = 4.0 Hz), 7.32-7.25 (2H, m), 7.22-7.15 (3H, m), 5.11 (ΔI, d, J = 3.3 Hz), 5.04 (HH, d, J = 3.8 Hz), 4.97 (HH, q, J = 9.1 Hz), 4.62-4.52 (1H, m), 4.40 (HH, t, 5.2 Hz), 3.95-3.92 (HH, m) , 3.75-3.66 (HH,), 3.59-3.41 (4H, m), 3.25-3.14 (HH, m), 3.13-2.78 (2H, m), 2.70-2.55 (HH, m), 2.30-1.95 (2H ,), 1.73-1.61 (2H,), 1.57-1.28 (4H, m), 0.82 (3H, t, J = 7.5 Hz).

EXAMPLE 68 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7- [t2- (3,4-difluorophenyl) -cyclopropyl] -amino3 -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) [3aS- [l- (E), 3aa, 6a, 7aβ]] -1- [3- (3,4-difluorophenyl) -1- oxo-2-propenyl] -hexahydro-8, 8-dimethyl- 3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (f) using 3- (3,4-difluorophenyl) -2-propenoic acid. MS (APCI) 382 (M + H +, 100%). b) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7ab]] -l- [[2- (3,4-difluorophenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8- dimethyl-3H-3a, 6-methane-2, l-bensisothiazole-2, 2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of subsection (g) using the product of the step of part (a). MS (APCI) 396 (M + H +, 100%). c) Acid (IR-trans) -2- (3,4-di luoro-enyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of the step of part (b). NMR dH (CDCl3) 7.68 (ΔI, dd, J-10.0, J = 8.5 Hz), 7.46-7.31 (2H, m), 3.12-3.03 (ΔH, m), 2.37 (ΔI, dt, J-8.5, J = 4.4 Hz), 2.17 (HH, dt, J = 9.2, J = .8 Hz), 1.86 (HH, ddd, J-8.5, J-6.9, J = 5.3 Hz). d) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-fcrans) -2- (3,4-difluorophenyl) -cyclopropanamine, (1: 1). The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (c). MS (APCI) 170 (M + H +, 100%). e) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3,4-difluorophenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. The title compound was prepared according to the method of Example 24, step of part (f) using the products of step (d) and Example 24, step of subsection (d). MS (APCI) 479 (M + H +, 100%). NMR dH (de-DMSO) 9.36 (H, d, J = 4.2 Hz), 7.40-7.22 (2H, m) 7.10-7.00 (H, m), 5.13-4.90 (4H, m), 4.68-4.60 (H) , m), 3. 97-3.90 (ÍH, m), 3.82-3.76 (ÍH,), 3.20-2.80 (3H, m), 2. 62-2.50 (ÍH, m), 2.32-2.04 (ÍH, m), 1.96-1.83 (ÍH,), 1. 75-1.36 (4H, m), 0.82 (3H, t, J = 7.5 Hz).

EXAMPLE 69 [R- [la, 2a, 3β- (lS *, 2R *), 5β]] -3- [7- [[2- (3,4-difluorophenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [[2- (3,4-difluorophenyl) -cyclopropyl] -amino] -5- (propylthio) ) -3H- 1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of Example 68, step of part (d). MS (APCI) 533 (M + H +, 100%). b) [R- [la, 2a, 3β- (lS *, 2R *), 5β]] -3- [7- [[2- (3,4-difluorophenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. It was prepared according to the method of Example 57, step of item (b) using the product of the step of part (a). NMR dH (de-DMSO) 9.36 (HH, d), 7.39-7.27 (2H, m), 7.10-7.05 (HH, m), 5.05-4.95 (2H, m), 4.74-4.71 (2H, m), 4.46-4.39 (ÍH, m), 3.90-3.86 (ÍH, m), 3.53-3.41 (2H, m), 3.18-3.12 (ÍH, m), 3.00-2.81 (2H, m), 2.31-2.21 (ÍH) , m), 2.16- 2.06 (2H, m), 1.90-1.79 (HH, m), 1.58-1.46 (3H, m), 1.41-1.34 (HH, m), 0.83 (3H, t). EXAMPLE 70 [lS- [la, 2β, 3β-4a- (lS *, 2R *)]] - 4- [7 - [[2- (3,5-difluorophenyl) -cyclopropyl] -amino-5- (propylthio ) -3H-1, 2,3-triazolo- [4,5-dJ-pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) [3aS- [l- (B), 3aa, 6a, 7aß]] -1- [3- (3, 5-di-luo-phenyl) -1-oxo-2-propenyl] -hexahydro-8, 8-dimethyl -3fí-3a, 6-methano-2, l-bencisothiazol-2, 2-dioxide. The subtitle compound was prepared according to the method of Example 19, subsection step (f) using 3- (3,5-difluorophenyl) -2-propenoic acid. MS (APCI) 382 (M + H +, 100%). b) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7ab]] -1- [[2- (3,5-difluorophenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8- dimethyl-3H-3a, 6-methane-2, l-benzisothiazole-2, 2-dioxide. The subtitle compound was prepared according to the method of Example 19, subsection step (g) using the product of step (a). MS (APCI) 396 (M + H +, 100%). c) Acid (lR-fcrans -) - 2- (3,5-difluorophenyl) -cyclopropanecarboxylic acid The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of the step of part ( b) MS (APCI) 197 (M-H +, 100%). d) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of [IR- (trans)] -2- (3,5-di-luo-phenyl) -cyclopropanamine, (1: 1). The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (c). NMR dH (de-DMSO) 7.00-6.84 (3H, m), 3.98 (2H, m), 2.16-2.10 (1H, m), 1.28-1.15 (2H, m). e) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3,5-difluorophenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. The subtitle compound was prepared according to the method of Example 24, step of part (f) using the products of step (b) and Example 24, step of part (d). MS (APCI) 479 (M + H +, 100%). NMR dH (de-DMSO) 9.38 (ΔI, d, J = 4.2 Hz), 7.01-6.95 (3H, m), 5.11-4.91 (4H, m), 4.68-4.64 (1H, m), 3.94-3.91 ( ÍH, m), 3.77 (ÍH, bs), 3.20-2.80 (3H, m), 2.65-2.55 (ÍH,), 2.20-2.10 (ÍH, m), 1.95-1.85 (ÍH, m), 1.63-1.43 (4H, m), 0.81 (3H, t, J = 7.5 Hz). EXAMPLE 71 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- [l, 1-biphenyl] -3-yl3-cyclopropyl] -amino ] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) [3aS- [1- (E), 3aa, 6a, 7aß]] -1- [3- [[1, 1'-biphenyl] -3-yl] -1-oxo-2-propeni1] -hexahydro -8, 8-dimethyl-3H-3a, 6-methano-2, l-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (f) using 3- (3,5-difluorophenyl) -2-propenoic acid. M? (APCI) 422 (M + H +, 100%). b) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7ab]] -1- [[2- [[1,1'-biphenyl) -3- yl] -cyclopropyl] -carbonyl] hexahydro-8,8-dimethyl-3H-3a, 6-methane-2, l-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of subsection (g) using the product of the step of part (a). MS (APCI) 436 (M + H +, 100%). c) (lR-trans) -2- [[1,1'-biphenyl] -3-yl] -syclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of the step of part (b). MS (APCI) 237 (M-H +, 100%). d) [R- (R *, R *)] -2,3-dihydroxybutanedioate of [IR- (rans)] - 2- [[1,1'-biphenyl] -3-yl] -cyclopropanamine, (1: 1) The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (c). MS (APCI) 210 (M-H +, 100%). e) [lS- [la, 2β, 3β-4a- (lS *, 2R *)]] - 4- [7 - [[2 - [[1, 1-biphenyl] -3-yl] -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol. The title compound was prepared in accordance with the method of Example 24, step of item (f) using the products of the step of part (d) and of Example 24, step of part (d). MS (APCI) 519 (M + H +, 100%). NMR dH (de-DMSO) 9.37 (OH, d, J = 4.2 Hz), 7.70-7.18 (9H, m), 5.12-4.91 (4H, m), 4.67-4.64 (lH, "m), 3.94-3.93 (ÍH,), 3. 78 (ÍH, bs), 3.28-2.80 (3H, m), 2.62-2.50 (ÍH, m), 2.25- 2.15 (ÍH, m), 1.95-1.85 (ÍH, m), 1.59-1.41 (4H, m ), 0.75 (3H, t, J = 7.5 Hz). EXAMPLE 72 [R- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- [1, 1 '-biphenyl] -3-yl] -cyclopropyl] - amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) [3aR- [3aa-4a, 6a- (IR *, 2S *) -6aa] -6- [7- [[2- [1, 1-biphenyl] -3-yl] -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -te rahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxole -4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of Example 71, step of part (d). MS (APCI) 573 (M + H +, 100%). b) [IR- [la, 2a, 3β- (IR *, 2S *), 5β]] -3- [7- [[2- [1, 1 '-biphenyl] -3- yl] -cyclopropyl] - amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -syclopentane-1,2-diol. It was prepared according to the method of Example 57, step of item (b) using the product of the step of part (a). MS (APCI) 533 (M + H +, 100%). NMR dH (de-DMSO) 9.35 (HH, m), 7.-68 (2H, dd), 7.49-7.44 (4H, m), 7.41-7.33 (2H, m), 7.19 (HH, d), 6.80 (HH, dd), 5.05-4.95 (2H, m), 4.74-4.71 (2H, m), 4.46-4.39 (HH,), 3.90-3.87 (HH, m), 3.51-3.45 (2H, m); 3.27-3.20 (ÍH, m), 3.00-2.77 (2H, m), 2.30-2.17 (2H, m), 2.12-2.04 (ÍH, m), 1.90-1.79 (ÍH, m), 1.60-1.53 (ÍH) , m), 1.50-1.41 (3H,), 0.77 (3H, t). EXAMPLE 73 N-ethyl- [[[lls- [la, 2β, 3β, 4a- (lS *, 2R *)]] -2, 3-dihydroxy-4- [7- [(2-f-enylcyclopropyl) -amino] ] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentyl] -oxy] -acetamide. a) Acid [lS- [la, 4a- (lS *, 2R *)]] - 2 - [[4- [7 - [(2-phenylcyclopropyl) -a ino] -5- (propylthio) -3H-1 , 2,3- triazolo- [4,5-d] -pyrimidin-3-yl] -2-cyclopentenyl] -oxy] -acetic acid. The subtitle compound was prepared according to the method of Example 2, step of the subsection (b) using the product of Example 13, step of the subsection (a) MS (APCI) 467 (M + H, 100%). b) N-ethyl-2- [[[lS- [la, 4a- (lS *, 2R *)]] -4- [7- [2-phenylcyclopropyl] -amino] -5- (propylthio) -3H- 1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -2-cyclopentenyl] -oxy] -acetamide. The subtitle compound was prepared according to the method of Example 16, using the product of the step of part (a) and 40% aqueous ethylamine. MS (APCI) 494 (M + H +, 100%). c) N-ethyl- [[[ÍS- [la, 2β, 3β, 4a- (ÍS *, 2R *)]] -2, 3-dihydroxy-4- [7- [(2-phenylsopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentyl] -oxy] -acetamide. The title compound was prepared according to the method of Example 12, step of part (f) using the product of step (b) MS (APCI) 528 (M + H +, 100%). DMSO) 9.36 (HH, m), 7.75-7.68 (HH, m), 7.31-7.26 (2H, m), 7.21-7.15 (3H, m), 5.23-5.18 (2H, m), 5.00-4.92 (HH) , m), 4.60-4.53 (ÍH,), 4.05-4.01 (ÍH, m), 3.93-3.78 (3H, m), 3.24-3.08 (3H, m), 2.98-2.90 (ÍH, m), 2.87- 2.79 (HH, m), 2.69-2.61 (HH, m), 2.30-2.06 (2H, m), 1.72-1.29 (4H, m), 1.04 (3H, t, J = 7.1 Hz), 0.80 (3H, t, J = 7.2 Hz) EXAMPLE 74 [ÍS- [la, 2ß, 3ß4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-methoxy-4-methylphenyl) -cyclopropyl) ] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol a) Acid 3 - (3-methoxy-4-methylphenyl) -2-propenoic acid. The subtitle compound was prepared according to the method of Example 64, step of part (a) using (3-methoxy-4-methyl) -benzaldehyde. MS (APCI) 191 (M-H +, 100%). b) [3aS- [l- (E), 3aa, 6a, 7aβ]] -hexahydro-1- [3- (3-methoxy-4-methylphenyl) -l-oxo-2-propenyl] -8,8- dimethyl-3H-3a, 6-methane-2, l-benzisothiazole-2, 2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (f) using the product of the step of part (a).

MS (APCI) 390 (M + H +, 100%). c) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7ab]] -hexahydro-1- [[2- (3-methoxy-4-methylphenyl) -cyclopropyl] -carbonyl] -8, 8-dimethyl-3H-3a, 6-methane-2, 1-benzyl-iazol-2, 2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (g) using the product of the step of part (b). MS (APCI) 404 (M + H +, 100%). d) (lR-trans) -2- (3-methoxy-4-methylphenyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, subsection step (h) using the product of step (c). NMR dH (CDCl3) 7.04 (ΔI, d, J = 7.3 Hz), 6.60 (ΔI, s), 6.59 (ΔH, d, J = 7.3 Hz), 3.82 (3H, s), 2.63-2.55 (ΔI, m), 2.18 (3H, s), 1.89 (HH, ddd, J = 9.2, J = 5.2, J = 4.2 Hz), 1.64 (HH, dt, J = 9.4, J = 4.6 Hz), 1.40 (HH, ddd, J = 11.3, J = 6.7, J = 4.6 Hz). e) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of [IR- (fcrans)] -2- (3-methoxy-4-methylphenyl) -cyclopropanamine, (1: 1) The compound of The subtitle was prepared in accordance with the method of Example 20, step of subsection (b) using the product of step (b). MS (APCI) 178 (M + H +, 100%). f) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3-methoxy-4-ethylphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d3-pyrimidin-3-yl3-cyclopentane-1, 2,3-triol. The title compound was prepared according to the method of Example 24, step of part (f) using the products of step (e) and Example 24, step of part (d). MS (APCI) 487 (M + H +, 100%). NMR dH '(de-DMSO) 9.31 (HH, d, J = 4.2 Hz), 7.03 (HH, d, J = 7.7 Hz), 6.77 (HH, m), 6.64 (HH, dd, J = 7.7, J = 1.2 Hz), 5.12-4.89 (4H, m), 4.70-4.62 (HH, m), 3.97-3.89 (HH, m), 3.80 (3H, s), 3.81-3.76 (HH, m), 3.22- 2.80 (3H, m), 2.64-2.53 (HH, m), 2.10 (3H, s), 2.27-2.06 (HH, m), 1.96-1.87 (HH, m), 1.73-1.27 (4H, m), 0.82 (3H, t, "J = 7.5 Hz). EXAMPLE 75 [1- R- [la, 2a, 3β- (lR *, 2S *), 5β] 3 -3- [7- [[2- (4-N, N-dimethylaminophenyl) -cyclopropyl] -amino} -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5-hydroxymethylcyclopentane-1,2-diol. a) [3aS- [l- (E), 3aa, 6a, 7aβ]] -1- [3- (4-N, N-dimethylaminophenyl) -1-oxo-2-propenyl] -hexahydro-8, 8- dimethyl-3H-3a, 6-methane-2, l-benzyl-iazol-2, 2-dioxide. It was prepared according to the method of Example 19, step of part (f) using (£) -3- (4-N, N-dimethylaminophenyl) -2-propenyl chloride (prepared according to the method of K. Venkataraman et al., Tetrahedron Lett., 1979, 32, 3037. MS (APCI) 389 (M + H +, 100%) b) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7ab] ] -1- [[2- (4-N, N-dimethylanephenyl) -cyclopropylcarbonyl-3-hexahydro-8,8-dimethyl-3H-3a, 6-methano-2, l-benzisothiazole-2, 2-dioxide . It was prepared in accordance with the method of Example 19, step of subsection (g) using the product of step of part (a). MS (APCI) 403 (M + H +, 100%). c) Acid (IR-trans) -2- (4-N, N-dimethylamino enyl) -cyclopropanecarboxylic acid. It was prepared according to the method of Example 19, step of part (h) using the product of the step of part (b). MS (APCI) 206 (M + H +, 100%). d) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (lR-fcrans) -2- (4-N, N-dimethylamino enyl) -syclopropanamine, (1: 1). It was prepared in accordance with the method of Example 20, step of subsection (b) using the product of step (c).

NMR dH (de-DMSO) 6.95 (2H, d), 6.64 (2H, d), 3.91 (2H, s), 2.84 (6H, s), 2.61-2.56 (H, m), 2.12-2.05 (H, m), 1.21-1.14 (ÍH, m), 1.06-0.98 (ÍH, m). e) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [[2- (4-N, N-dimethylaminophenyl) -cyclopropyl] -amino-5- ( propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of the step of part (d). MS (APCI) 540 (M + H +, 100%). f) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (4-N, N-dimethylamino enyl) -cyclopropyl] -amino] - 5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5-hydroxymethylcyclinepentane-1,2-diol. It was prepared according to the method of Example 1, step of subsection (b) using the product of the step of subsection (e). MS (APCI) 500 (M + H +, 100%). NMR dH (de-DMSO) 9.25 (1H, d), 7.04 (2H, d), 6.67 (2H, d), . 01-4.96 (2H, m), 4.73-4.70 (2H, m), 4.46-4.41 (ÍH,), 3. 88 (ÍH, q), 3.51-3.44 (2H, m), 3.10-2.90 (3H, m), 2.85 (6H, s), 2.27-2.23 (ÍH, m), 2.08-2.01 (2H, m), 1.87-1.82 (ÍH, m), 1.60-1.53 (2H, m), 1.40-1.37 (ÍH, m), 1.21-1.18 (ÍH,), .086 (3H, t). EXAMPLE 76 [R- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3-luoro-4-methoxyphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) [3aS- [l- (JE), 3aa, 6a, 7aβ]] -1- [3- (3-fluoro-4-methoxyphenyl) -oxo-2-propenyl] -hexahydro-8, 8-dimethyl- 3H-3a, 6-methano-2,2-benzisothiazole-2,2-dioxide. It was prepared in accordance with the method of Example 19, step of part (f) using (E) -3- (3-fluoro-4-methoxyphenyl) -2-propenoic acid. MS (APCI) 394 (M + H +, 100%). b) [3aS- [1- (1S *, 2S *), 3aa, 6a, 7ab]] -1- [[2- (3-fluoro-4-methoxyphenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8-dimethyl-3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. It was prepared according to the method of Example 19, step of item (g) using the product of the step of part (a). MS (APCI) 498 (M + H +, 100%). c) Acid (IR-trans) -2- (3-fluoro-methoxyphenyl) -cyclopropanecarboxylic acid. It was prepared according to the method of Example 19, step of part (h) using the product of the step of part (b). NMR dH (CDCl 3) 6.91-6.81 (3H, m), 3.87 (3H, s), 2.58-2.51 (HH, m), 1.86-1.80 (HH, m), 1.66-1.60 (HH, m), 1.37- 1.25 (ÍH, m). d) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of [IR- (trans)] -2- (3-fluoro-4-methoxyphenyl) -cyclopropanamine, (1: 1). It was prepared according to the method of Example 20, step of subsection (b) using the product of the step of part (c). NMR dH (de-MDSO) 7.08-6.91 (3H, m), 3.93 (2H, S), 3.79 (3H, s), 2.67-2.62 (HH, m), 2.14-2.08 (HH, m), 1.23- 1.17 (1H, m), 1.11-1.05 (ÍH, m). e) [3aR- [3aa, 4a, 6a- (IR *, 2S *) -6aa] -6- [7- (3-luoro-4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) - 3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclope, 3-dioxol-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of the step of part (d). MS (APCI) 545 (M + H +, 100%). f) [lR- [la, 2a, 3β- (lR *, 2S *), 5β] J -3- [7- [[2- (3-fluoro-4-methoxyphenyl) -cyclopropyl] -amino] -5 - (propylthio-3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5-hydroxymethyl) -cyclopentane-1,2-diol.

It was prepared according to the method of Example 1, step of item (b) using the product of step (e). MS (APCI) 505 (M + H +, 00%). NMR dH (de-DMSO) 9.30 (1H, d), 7.11-6.98 (3H,), 5.04-4.97 (2H, m), 4.73-4.70 (2H, m), 4.46-4.39 (H, m), 3.89 -3.86 (ÍH, m), 3.81 (3H, s), 3.51-3.45 (2H, m), 3.11-3.09 (ÍH,), 3.00-2.85 (2H, m), 2.27-2.20 (ÍH, m), 2.09-2.06 (2H, m), 1.90-1.83 (HH, m), 1.57-1.47 (3H, m), 1.33-1.27 (HH, m), 0.84 (3H, t). EXAMPLE 77 [ÍS- [la, 2a, 3ß, 5ß- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-methoxy-3-methylphenyl) -cyclopropyl) ] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [3aS- [1- (E) -, 3aa, 6a, 7aβ]] -1- [3- (4-methoxy-3-methylphenyl) -l-oxo-2-propenyl] -hexahydro-8, 8 -dimethyl-3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. It was prepared according to the method of Example 19, step of part (f) using (£) -3- (4-methoxy-3-methylphenyl) -2-propenoic acid. MS (APCI) 390 (M + H +, 100%). b) [3aS- [l- (lS *, 2S *) -3aa, 6a, 7ab]] - l - [[2- (4-methoxy-3-methylphenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8- dimethyl-3H-3a, 6-methane-2, l-benzisothiazole-2,2-dioxide. It was prepared according to the method of Example 19, step of item (g) using the product of the step of part (a). MS (APCI) 404 (M + H +, 100%). c) Acid (IR-rans) -2- (4-methoxy-3-methylphenyl) -cyclopropanecarboxylic acid. It was prepared according to the method of Example 19, step of part (h) using the product of the step of part (b). NMR dH (de-DMSO) 6.94-6.89 (2H, m), 6.74 (HH, d), 3.81 (3H, s), 2.57-2.51 (HH, m), 2.19 (3H, s), 1.85-1.79 ( ÍH, m), 1.63-1.57 (ÍH, m), 1.38-1.32 (ÍH, m). d) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (4-methoxy-3-methylphenyl) -cyclopropanamine, (1: 1). It was prepared according to the method of Example 20, step of subsection (b) using the product of the step of part (c). NMR dH (de-DMSO) 6.93-6.90 (2H, m), 3.83-6.80 (HH, m), 3.92 (2H, s), 3.74 (3H, s), 2.64-2.59 (HH, m), 2.13- 2.07 (4H, m), 1.22-1.16 (ÍH, m), 1.08-1.01 (ÍH, m). e) [3aR- [3aa, 4a, 6a- (IR *, 2S *), 6aa] -6- [7- [(2- [4-methoxy-3-methylphenyl] -cyclopropyl) -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of the step of part (d). MS (APCI) 541 (M + H +, 100%). f) [ÍS- [la, 2a, 3ß, 5ß- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-methoxy-3-methylphenyl) -cyclopropyl) ] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 1, step of subsection (b) using the product of the step of subsection (e). MS (APCI) 501 (M + H +, 100%). NMR dH (de-DMSO) 9.27 (1H, d), 7.04-6.98 (2H, m), 6.83 (1H, d), 5.01-4.97 (2H, m), 4.73-4.71. { 2H, m), 4.46-4.42 (1H, m), 3.88 (HH, q), 3.75 (3H, s), 3.51-3.45 (2H, m), 3.09- 3.06 (HH, m), 3.02-2.99 ( ÍH, m), 2.91-2.88 (ÍH, m), 2.27-2.24 (ÍH, m), 2.14 (3H, s), 2.13-2.03 (2H,), 1.90-1.81 (ÍH, m), 1.59-1.53 (2H, m), 1.43-1.41 (ÍH, m), 1.25-1.22 (ÍH,), 0.85 (3H, t). EXAMPLE 78 [IR- [la, 2a, 3b- (IR *, 2S *), 5b]] -3- [7- [[2- (3,4-dichloro-enyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) [3aS- [l - (- S), 3aa, 6a, 7aß]] -1- [3- (3,4-dichlorophenyl) -1-oxo-2-propenyl] -hexahydro-8, 8-dimethyl -3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. It was prepared according to the method of Example 19, step of part (f) using (2?) -3- (3,4-dichlorophenyl) -2-propenoic acid. P.f. 198-200 ° C. MS (APCI) 414 (M + H +, 100%). b) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7ab] -1- [[2- (3,4-dichlorophenyl) -cyclopropyl] -carbonyl] -hexahydro-8,8-dimethyl -3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. It was prepared according to the method of Example 19, step of item (g) using the product of the step of part (a). P.f. 162-163 ° C. MS (APCI) 429 (M + H +, 100%). c) Acid (lR-fcrans) -2- (3,4-dichlorophenyl) -cyclopropanecarboxylic acid. It was prepared according to the method of Example 19, step of part (h) using the product of the step of part (b). NMR dH (CDCI) 7.40-7.30 (2H, m), 7.20 (H, d), 6.96-6.93 (1H, dd), 2.57-2.51 (H, m), 1.92-1.85 (H, m), 1.71- 1.65 (ÍH, m), 1.41-1.34 (ÍH, m). d) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-ans) -2- (3,4-dichlorophenyl) -cyclopropanamine. (1: 1) It was prepared according to the method of Example 20, step of subsection (b) using the product of the step of part (c). NMR dH (de-DMSO) 7.53-7.51 (H, d), 7.41-7.40 (H, d), 7.14-7.11 (H, d,), 3.77 (2 H, s), 2.73-2.68 (H, m), 2.16-2.10 (ÍH, m), 1.27-1.14 (2H, m). e) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [[2- (3,4-dichlorophenyl) -cyclopropyl] -amino] -tetrahydro-2, 2- dimethyl-5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -4H-cyclopenta-1,3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of the step of part (d). MS (APCI) 565 (M + H +, 100%). NMR dH (CDCl 3) 7.40-7.33 (2H, m), 7.20-7.01 (1H, m), 5.21- 5.15 (2H, m), 4.73-4.70 (H, m), 3.80-3.75 (2H, m), 3.20- 3.00 (3H, m), 2.61-2.34 (4H, m), 2.21-2.09 (HH,), 2.03-1.93 (HH, m), 1.75-1.61 (HH, m), 1.58 (3H, s) , 1.45-1.35 (2H, m), 1.28 (3H, s), 1.05-0.82 (4H, m). f) [IR- [la, 2a, 3b- (IR *, 2S *), 5b]] - 3- [7. [[2- (3,4-dichlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -syclopentane-1,2-diol.

It was prepared according to the method of Example 1, step of item (b) using the product of step (e). MS (APCI) 526 (M + H +, 100%). NMR dH (de-DMSO) 9.38-9.36 (HH, d), 7.55-7.52 (2H, m), 7.22-7.19 (HH, dd), 5.01-4.70 (2H, m), 4.72-4.70 (2H, m) ), 4.42-4.40 (HH, m), 3.90-3.85 (HH, m), 3.50-3.40 (2H, m), 3.20-3.16 (HH, m), 3.02-2.70 (2H, m), 2.71-2.43 (HH, m), 2.14-2.09 (1H, m), 2.18-2.03 (HH, m), 1.90-1.81 (HH, m), 1.90-1.81 (HH, m), 1.90-1.41 (4H, m) 0.80 (3H, t). EXAMPLE 79 ÍS- [la, 2a-3β, 5β, - (ÍS *, 2R *)] -3- [(2-amino) -ethoxy] -5- [7- (2-phenylcyclopropyl) -amino] -5 -propylthio-3H- [1, 2, 3] -triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. To a solution of the product of Example 23 (0.50 g) in tetrahydrofuran (20 ml) was added diborane (10 ml, 1 M solution in THF). The reaction was refluxed for 1 hour, cooled and methanol (5 ml) was added. The solvent was evaporated and the residue was dissolved in methanol (25 m) / concentrated hydrochloric acid (0.50 ml) and then heated to reflux for 1 hour. The solvent was evaporated and the residue was purified (HPLC, Novapak® C18 column, 0.1% aqueous trifluoroacetic acid / methanol, 50:50) to obtain the title compound (198 mg). MS (APCI) 486 (M + H +, 100%).

NMR dH (de-DMSO) 9.37 (ΔI, d, J = 4.2 Hz), 7.83 (3H, s), 7.29 (2H,), 7.16 (3H, m), 4.96 (ÍH, q, J = 8.7 Hz), 4.57-4.53 (ÍH, m), 4.00 (ÍH, m), 3.66 (2H, m), 3.21 (1H, m), 3.03 (2H,), 3.01-3.92 (2H,), 2.82 (HH, m), 2.10 (HH, m), 2.05 (1H, m), 1.55-1.44 (3H, m), 1.32 (HH, q, J = 7.8 Hz), 0.80 (3H, t, J = 7.5 Hz). EXAMPLE 80 [R- (la, 2a, 3β- (lR *, 2S *), 5β)] -3- [7- [[2- (3,4-dimethylphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) 3- (3,4-Dimethylphenyl) -prop-2-enoic acid. It was prepared according to the method of Example 64, step of part (a) using 3,4-dimethylbenzaldehyde. MS (APCI) 175 (M-H +, 100%); - • b) [3aS- [l- (E), 3aa, 6a, 7aß]] -1- [3- (3,4-dimethylphenyl) -1 -oxo-2-propenyl] -hexahydro-8,8-dimethyl-3H-3a, 6-methano-2, 1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (f) using the product of the step of part (a). MS (APCI) 374 (M + H +, 100%). c) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7aß]] -l- [[2- (3,4-dimethylphenyl) -cyclopropyl-3-carbonyl] -hexahydro-8,8-dimethyl -3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (g) using the product of the step of part (b). MS (APCI) 388 (M-H +, 100%). d) Acid (IR-trans) -2- (3, -dimethylphenyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of step (c). MS (APCI) 189 (M-H +, 100%). e) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3,4-dimethylphenyl) -cyclopropanamine. (1: 1) The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (d). NMR dH (de-DMSO) 7.03-7.01 (H, s), 6.84-6.81 (H, m), 3.92 (2 h, s), 2.67-2.61 (H, m), 2.18 (3 H, s), 2.16 ( 3H, s), 2.13-2.06 (lh, m), 1.24-1.17 (ÍH, m), 1.10-1.03 (ÍH, m). f) [R- (la, 2a, 3β- (lR *, 2S *), 5β)] -3- [7- [[2- (3,4-dimethylphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. The title compound was prepared according to the method of Example 1, step of part (a) using the products of the step of part (e) followed by the method of Example 1, step of part (b). MS (APCI) 485 (M + H +, 100%) dH NMR (de-DMSO) 9.29-9.28 (H, d), 7.04-7.01 (2H,) 6.91-6.88 (H, m), 5.01 (2H, m ), 4.73-4.70 (2H, m), 4.43-4.41 (HH, m), 3.88-3.86 (HH, m), 3.51-3.45 (2H, m), 3.13-3.11 (HH, m), 2.98-2.85 (2H,), 2.26-2.21 (ÍH,), 2.20 (3H, s), 2.17 (3H, s), 2.8-2.4 (2H, m), 1.91-1.82 (ÍH, m), 1.53-1.42 (2H , m), 1.27-1.23 (ÍH, m), 0.85-0.80 (3H, s). EXAMPLE 81 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (3, 4-dimethylphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa]] -6- [7- [2- [(3,4-dimethylphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-ol. The subtitle compound was prepared according to the method of Example 1, step of part (a) using the product of Example 24, step of part (d) and the product of Example 80, step of part (e). MS (APCI) 511 (M + H +, 100%). b) [1 S- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3,4-dimethylphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. The title compound was prepared according to the method of Example 1, step of item (b) using the product of the step of part (a). P.f. 175-76 ° C MS (APCI) 471 (M + H +, 100%) NMR dH (de-DMSO) 9.29 (OH, d), 7.03-6.87 (3H, m), 5.09 (OH, d), 5.02 (OH, d), 4.95 (HH, d), 4.90 (HH, d), 4.68 (HH, m), 3.93 (HH, m), 3.77 (1H, m), 3.13 (1H, m), 3.01-2.81 (2H, m ), 2.61 (HH, m), 2.19 (3H, s), 2.16 (3H, s), 2.06 (HH, m) 1.90 (HH, m), 1.52-1.42 (2H, m), 1.43 (HH, m ), 1.26 (ÍH, m) 0.81 (3H, t). EXAMPLE 82 - [lR- (la, 2a, 3ß, 5ß)] - [7- (cyclopropylamino) -5- [[4- (tri-luomomethyl) -phenyl] -thio] -3H-1, 2, 3-triazolo - [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) [3aR- (3aa, 4a, 6a, 6aa)] -6- [7- (cyclopropylamino) -5- (propylsulfonyl) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidine -3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol. It was prepared according to the method of Example 4, step of part (a) using the product of Example 2, step of part (a). MS (APCI) 453 (M + H +, 100%). b) [3aR- (3aa, 4a, 6a, 6aa] -6- [7- (cyclopropylamino) -5- [[4- (trifluoromethyl) -phenyl3-thio3 -3H-1, 2, 3-triazolo- [4 , 5-d3-pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol was prepared according to the method of Example 4, step (b) ) using the product of step (a), MS (APCI) 523 (M + H +, 100%) c) [IR- (la, 2a, 3ß, 5ß)] -3- [7- (cyclopropylamino) -5- [[4- (trifluoromethyl) -phenyl] -thio] -3H, 1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5-. { hydroxymethyl) -cilcopentane-1,2-diol. It was prepared according to the method of Example 1, step of item (b) using the product of the step of part (b). MS (APCI) 483 (M + H +, 100%) dH NMR (de-DMSO) 9.23 (1H, d), 7.90 (2H, d), 7.70 (2H, d), 4.95-4.90 (2H, m), 4.67-4.60 (2H, m), 4.32- .30 (HH, m), 3.72-3.70 (1H, m), 3.32 (2H, m), 2.81-2.79 (HH, m), 2.22-2.16 (HI, m), 2.05-2.00 (lH, m), 1.80-1.60 (ÍH, m), 1.00-0.60 (2H,). EXAMPLE 83 [ÍS- [la, 2β, 3β, 4a- (1S *, 2R *)]] -4- [7- [[2- (3,5-dichlorophenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) [3aS- [l- (E), 3aa, 6a, 7aß]] -l- [3- (3,5-dichlorophenyl) -1-oxo-2-propenyl] -hexahydro-8, 8-dimethyl- 3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, subsection step (f) using 3- (3,5-dichlorophenyl) -2-propenoic acid. M? (APCI) 414/416/418 (M + H +), 153 (100%). b) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7aß]] -l- [[2- (3,5-dichlorophenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8- dimethyl-3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, subsection step (g) using the product of step (a). MS (APCI) 428/430/432 (M + H +), 364 (100%). c) (lR-trans) -2- (3,5-dichlorophenyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of the step of part (b). NMR dH (CDCL3) 1.26-1.42 (HH, m) 1.65-1.72 (HH, m), 1.89-1.95 (lH.m), 2.51-2.58 (HH, m), 6.99 (2H, d, J = 1.08 Hz ). d) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-fcrans) -2- (3,5-dichlorophenyl) -cyclopropanamine. (1: 1) The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (c). NMR dH (de-DMSO) 1.19-1.29 (2H, m), 2.13-2.20 (1H, m), 2.71-2.8K1H, m), 4.00 (2H, s), 7.22 (2H, d, J-1.08 Hz ). e) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3,5-dichlorophenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. The title compound was prepared in accordance with the method of Example 24, step of item (f) using the products of the step of part (d) and of Example 24, step of part (d). MS (APCI) 511/513/515 (M + H +), 511 (100%) dH NMR (de-DMSO) 9.39 (ΔI, d, J = 4, 2 Hz), 7.40 (ΔI, t, J = 1 .8 Hz), 7.30 (2H, D, J = 1.8 Hz), 5.11-4.91 (4H, m), 4.68-4.62 (ÍH, m), 3.93 (1H, br s), 3.78 (1H, br s), 3.20 (1H, br s), 2.99-2.78 (2H, m), 2.64-2.54 (ÍH, m), 2.17-2.10 (1H, m), 1.95-1.85 (1H, m) 1.62-1.45 (4H.m) , 0.81 (3H, t, J = 7.2 Hz). EXAMPLE 84 [lR- [la- (lS *, 2R *), 2β, 3β, 4a]] -N- [3- [2- [[3- (2,3,4-trihydroxycyclopentyl) -5- (propylthio ) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -methanesulfonamide. a) 1,1-dimethylethyl ester of (IR-rans) -N- [2- (3-nitrophenyl) -cyclopropyl] -carbamism acid. A solution of the acid of Example 27, step of part (a) (1.72), diphenylphosphorylazide (2.1 ml) and triethylamine (1.4 ml) in tert-butanol (15 ml) and toluene (35 ml), was heated to 85 ° C. for 5 hours. Water was added and the mixture was extracted with ether. The organic phases were dried, evaporated and purified (SiO2, petroleum / ether, 1: 1 as eluent) to obtain the subtitle compound as a colorless solid (1.91 g). NMR dH (CDCl 3) 8.03 (1H, d); 7.98-7.95 (ÍH, m), 7.55-7.50 (ÍH, m), 7.43 (1H, t) 4.83 (1H, s) 2.78-2.75 (ÍH, m), 2.21-2.12 (ÍH, m) 1.46 (9H , s) .1.29-1.23 (2H, m). b) (lR-trans) -N- [2- (3-aminophenyl) -cyclopropyl] -carbamic acid 1,1-dimethylethyl ester. A platinum suspension in charcoal (5%, 374 mg) and the product from step (a) (1.90 g) in ethanol (40 ml) was stirred under 1.1 atmospheres of hydrogen pressure for 4 hours. The mixture was filtered and purified (SiO 2, isohexane / ether, 1: 3 as eluent), to obtain the subtitle compound (1.60 g). NMR dH (CDCl 3) 7.04 (1H, t), 6.53-6.45 (3H, m), 4.81 (1H, s), 3.61 (2H, s), 2.72-2.70 (lH, m), 1.98-1.91 (ÍH, m), 1.46 (9H, s), 1.19-1.06 (2H, m). c) 1,1-dimethylethyl ester of (IR-trans) -N- [2- [3- [(methylsulfonyl) -amino] -phenyl] -cyclopropyl] -carbamic acid. A product solution from step (b) (592 mg), methanesulfonyl chloride (0.225 ml) and pyridine (0.35 ml) in dichloromethane (5 ml), was stirred for 3 hours. Water was added and the mixture was extracted with dichloromethane. The organic phases were dried, evaporated and purified (SiO2, isohexane / ether, 1: 3 as eluent) to obtain the subtitle compound (724 mg). MS (APCI) 325 (MH ", 100%) d) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (lS-trans) -N- 3- [(2-aminociclopropyl) - phenyl] -methanesulfonamide, (1: 1). A solution of the product from the step of part (c) (722 mg) in trifluoroacetic acid (3 ml) was stirred for 3 hours. The solvent was removed in vacuo and the residue was basified with a sodium bicarbonate solution and extracted with ethyl acetate. The organic phases were dried and evaporated. The resulting amine was dissolved in ethanol (10 ml) and a solution of L-tartaric acid (332 g) in ethanol (20 ml) was added. The solvent was removed in vacuo to obtain the subtitle compound (867 mg). NMR (de-DMSO) 7.30-6.81 (4H, m), 4.05 (2H, s), 2.97 (3H, s), 2. 97 (3H, s), 2.74-2.70 (lH, m), 2.23-2.18 (ÍH, m), 1.34-1.27 (1H, m), 1.17-1.05UH, m). e) [3aS- [3aa, 4a- (IR *, 2S *), 6a, 6aa] -N- [3- [2- [[3- (2,2-dimethyl-6-hydroxytetrahydro-4H-cyclopenta- 1, 3-dioxol-4-yl) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -metansulfonamide. The subtitle compound was prepared according to the method of Example 1, step of part (a) using the products of step (b) and Example 24, step of part (d). MS (APCI) 576 (M + H +, 100%). f) [lR- [la- (lS *, 2R *), 2β, 3β, 4a]] - N- [3- [2 - [[3- (2,3,4-trihydroxycyclopentyl) -5- (propylthio ) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -methanesulfonamide. It was prepared in accordance with the method of Example 1, step of subsection (b) using the product of the step of subsection (e). P.f. 170-172 ° C MS (APCI) 536 (M + H +, 100%) dH NMR (de-DMSO) 9.67 (H, s), 9.34 (H, d), 7.25 (1H, t), 7. 06-6.98 (2H, m), 6.92 (HH, d), 5.11 (HH, d), 5.04-.98 (HH, m), 4.94-4.91 (2H, m), 4.68-4.61 (1H, m) , 3.95-3.90 (ÍH, m), 3. 80-3.75 (lH, m), 3.24-3.20 (ÍH, m), 2.98 (3H, s), 2.97-2.85 (2H, m), 2.62-2.57 (HH, m), 2.18-2.06 (HH, m), 1.97-1.87 (1H,), 1.54-1.22 (4H, m), 0.82 (3H, t). EXAMPLE 85 [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *) 33-4- [7 - [[2- (3,4-dimethoxyphenyl) -cyclopropyl-3-amino-5- (propylthio)] -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) [3aS- [l- (E), 3aa, 6a, 7aß]] -1- [3- (3, -dimethoxyphenyl) -1- oxo-2-propeni1] -hexahydro-8, 8-dimethyl-3H 3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, subsection step (f) using 3- (3,4-dimethoxyphenyl) -2-propenoic acid. MS (APCI) (M + H +), 153 (100%). b) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7aβ]] -1- [[2- (3,4-dimethoxyphenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8- dimethyl-3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, subsection step (g) using the product of step (a). MS (APCI) 420 (M + H +, 100%). c) (lR-trans) -2- (3,4-dimethoxyphenyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of the step of part (b).

NMR dH (CDCl 3) 1.34-1.41 (HH, m), 1.60-1.66 (HH, m) 1.83-1.88Í1H, m), 2.54-2.61 (HH, m), 3.86 (3H, s), 6.65-6.67 ( 2H, m), 6.79 (ÍH, d, J = 8.7 Hz). d) [R- (R *, R *) 3 -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3,4-dimethoxyphenyl) -cyclopropanamine. (1: 1) The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (c). NMR dH (de-DMSO) 1.03-1.22 (2H, m), 2.08-2.14 (HH, m), 2.63-2.68 (1H, m), 3.70 (3H, s), 3.74 (3H, s), 3.91 ( 2H, s), 6.23 (HH, dd, J = 8.01 Hz, J = 1.08 Hz), 6.70 (HH, d, J = 1.08 Hz), 6.8 (HH, d, J = 8.01 Hz). e) [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *) 33 -4- [7- [[2- (3,4-dimethoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) ) -3H- - 1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol The title compound was prepared according to the method of Example 24, step of subsection (f) using the products of the passage of subsection (d) and of Example 24, step of subsection (d). MS (APCI) 503 (M + H +, 100%) NMR dH (de-DMSO) 9.28 (ΔI, d, J = .5 hz), 6.86 (1H, d, J = 8.4 Hz), 6.8K1H, d, J = 2.1 Hz), 6.70 (1H, dd, J = 8.4 Hz, j * = 2.1 Hz), 5.10-4.90 (4H,), 4.68-4.64 (HH, m), 3.93 (1H, s), 3.76 (3H, s), 3.74 (HH, s), 3.71 (3H, s), 3.13-3.10 (HH, m), 3.05-2.82 (2H, m), 2.65-2.55 (HH, m), 2.10-2.00 (HH, m), 1.95-1.85 (1H, m) , 1.56-1.27 (4H, m), 0.82 (3H.t.J = 7.2 Hz). EXAMPLE 86 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (4-methoxy-3-methylphenyl) -cyclopropyl] -amino3 -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d3-pyrimidin-3-yl] -cyclopentane-1,2,3-triol a) [3aR- [3aa, 4a, 6a- ( LR *, 2S *), 6aa33-tetrahydro-6- [7- [2- [(4-methoxy-3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5] -d] -pyrimidin-3-yl] -2, 2-dimethyl-4ff-cyclopenta-l, 3-dioxol-4-ol. The subtitle compound was prepared according to the method of Example 1, step of part (a) using the products of Example 24, step of part (d) and Example 77, step of part (d). MS (APCI) 527 (M + H +, 100%). b) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (4-methoxy-3-methylphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol. The title compound was prepared according to the method of Example 1, step of item (b) using the product of the step of part (a). P.f. 135-136 ° C MS (APCI) 487 (M + H, 100%) dH NMR (e-DMSO) 9.28 (1H, d), 7.01-6.80 (3H, m), 5.09 (1H, d), 5.0K1H , d), 4.98 (1H, d), 4.90 (1H, d), 4.66 (1H, m), 3.91 (H, m), 3.76 (1H, m), 3.73 (3H, s), 3.06 (1H, m), 3.01-2.81 (2H.m), 2.58 (1H, m), 2.12 (3H, s), 2.02 (1H, m), 1.88 (1H, m), 1.56-1.49 (2H, m), 1.42 (1H, m), 1.23 (1H, m), 0.80. { 3h; t). EXAMPLE 87 [IR- [la- (IS *, 2R *) -2β, 3β, 4β]] -N- [3- [2- [[3- (2, 3, 4-trihydroxycyclopentyl) -5- (propylthio ) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -acetamide. a) 1,1-dimethylethyl ester of (IR-trans) -N- [2- (3-acetamidophenyl) -cyclopropyl] -carbamic acid. A solution of the product of Example 84, step of part (b) (582 mg), acetic anhydride (0.27 ml) and pyridine (0.35 ml) in dichloromethane (5 ml) was stirred for 18 hours. Water was added and the mixture was extracted with dichloromethane. The organic phases were dried, evaporated and purified (SiO2, isohexane / acetone, 2: 1 as eluent) to obtain the subtitle compound (703 mg). MS (APCI) 325 (M-H +, 100%). b) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (SS-trans) -N- 4- [(2-aminociclopropyl) -phenyl] -acetamide, (1: 1).

A product solution from step (a) (703 mg) in trifluoroacetic acid (3 ml), was stirred for 3 hours. The solvent was removed in vacuo and the residue was basified with a sodium bicarbonate solution and then extracted with ethyl acetate. The organic phases were dried and evaporated. The amine was dissolved in ethanol (10 ml) and a solution of L-tartaric acid (349 mg) in ethanol (25 ml) was added. The solvent was removed in vacuo to obtain the subtitle compound (828 mg). NMR dH (de-DMSO) 7.45-7.05 (3H, m), 6.82 (1H, d), 4.19 (2H, s), 2.77-2.71 (HH, m), 2.30-2.23 (HH,), 2.03 (3H , s), 1.39-1.31 (1H, m), 1.18-1.08 (ÍH, m). c) [3aS- [3aa, 4a- (IR *, 2S *), 6a, 6aa] -N- [3- [2- [[3- (2,2-dimethyl-6-hydroxytetrahydro-4H-cyclopenta- 1, 3-dioxol-4-yl) -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -asetamide. It was prepared according to the method of Example 12, step of part (e) using the product of the step of part (b). d) [IR- [la- (ÍS *, 2R *) -2β-3β-4a]] -N- [3- [2- [[3- (2,3,4-trihydroxycyclopentyl) -5- (propylthio ) -3H-1, 2,3-triazolo- [4,5-d3-pyrimidin-7-yl3-amino-3-cyclopropyl] -phenyl-acetamide. . It was prepared according to the method of Example 1, step of item (b) using the product of the step of part (c). P.f. 147-148 ° C. MS (APCI) 500 (M + H +, 100%), dH NMR (de-DMSO) 9.87 (H, s), 9.35 (H, d), 7.41-7.34 (2H, m), 7.18 (1H, t) , 6.84 (1H, d), 5.13-4.91 (4H, m), 4.66-4.61 (1H, m), 3.93-3.91 (HH, m), 3.82-3.75 (HH, m), 3.23-2.78 (4H, m), 2.62-2.51 (ÍH, m), 2.17-2.08 (ÍH, m), 2.02 (3H, s), 1.97-1.85 (lHm), 1.72-1.61 (ÍH, m), 1.57-1.09 (3H, m), 0.80 (3H, t). EXAMPLE 88 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[(2- (3,4-dichlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol a) [3aR- [3aa, 4a, 6a - (lR *, 2S *), 6aa]] -6- [7- [2- [(3,4-dichlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1,2,3- triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-ol. The subtitle compound was prepared according to the method of Example 1, step of part (a) using the products of Example 24, step of part (d) and Example 78, step of part (d). MS (APCI) 551 (M + H +, 100%). b) lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[(2- (3,4-dichlorophenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol was prepared according to the method of Example 1, step of subsection (b) using the product of step (a), mp 140-142 ° C. MS (APCI) 511 (M + H +, 100%) NMR dH (de-DMSO) 9.4 (1H, d), 7.54-7.50 (2H, m), 7.18 (1H, dd), 5.13-4.91 (4H, m), .68-4.60 (H, m), 3.94 -3.90 (HH, m), 3.78-3.755 (1H, m), 3.18-3.02 (HH, m), 2.91-2.76 (2H, m), 2.62-2.5K1H, m), 2.17-2.06 (1H, m ), 1.94-1.84 (ÍH, m), 1.71-1.37 (3H, m), 0.79 (3H, t). EXAMPLE 89 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (4-chloro-3-methylphenyl) -cyclopropyl] -amiho] -5 - (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol. a) 3- (4-Chloro-3-methylphenyl) -2-propenoic acid. The subtitle compound was prepared according to the method of Example 64, step of part (a) using (4-chloro-3-methyl) -benzaldehyde (prepared in accordance with International Publication WO 9603387). MS (APCI) 191 (M-H +, 100%). b) [3aS- [l (E), 3aa, 6a, 7aß]] - l- [3- (4-chloro-3-methyl enyl) -l-oxo-2-propenyl] -hexahydro-8, 8- dimethyl-3H-3a, 6-methano-2,1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (f) using the step product of part (a). MS (APCI) 392 (M-H +, 100%). c) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7aβ]] -1- [[2- (4-chloro-3-methylphenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8-dimethyl-3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. NMR dH (CDC13) 7.22 (ΔI, d, J = 8.1 Hz), 7.07 (ÍH, d, J-1.9 Hz), 6.96 (1H, dd, J = 8.1, J = 2.1 Hz), 3.92 (1H, dd, J = 7.5, J = 5.0 Hz), 3.51 (ÍH, d , J = 13.8 Hz), 3.44 (1H, d, J = 13.8 Hz), 2.33 (3H, s), 2.57-2.47 (2H, m), 2.20-2.02 (2H,), 1.98-1.82 (3H, m ), 1.79-1.73 (ÍH,), 1.44-1.29 (3H,), 1.20 (3H, s), 0.98 (3H, s). The subtitle compound was prepared according to the method of Example 19, step of part (g) using the product of the step of part (b). d) Acid (IR-trans) -2- (4-chloro-3-methylphenyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of the step of part (c). NMR dH CDCl3) 7.24 (HH, d, J = 8.3 Hz), 6.97 (HH, d, J = 1.5 Hz), 6.86 (1H, dd, J = 8.1, J = 1.9 Hz), 2.5 (HH, ddd, J = 10.6, J = 6.7, J = 4.2 Hz), 2.34 (3H, s), 1.86 (1H, ddd, J = 9.2, J = 5.2, J = 4.2 Hz), 1.65 (1H, dt, J = 9.2 , J = .8 Hz), 1.37 (ÍH, ddd, J = 11.3, J = 6.7, J = 4.8 Hz). e) [R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (4-chloro-3-methylphenyl) -cyclopropanamine, (1: 1). The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (d). MS (APCI) 182/184 (M + H +), 182 (100%). f) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (4-chloro-3-methylphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -syclopentane-1, 2,3-triol. The title compound was prepared according to the method of Example 24, step of part (f) using the product of the step of part (d). MS (APCI) 491/493 (M + H +), 491 (100%) dH NMR (de-DMSO) 9.35 (ΔI, d, J = 3.9 Hz), 7.30 (1H, d, J = 8.1 Hz), 7.22 (HH, d, J = 2.1 Hz), 7.04 (HH, dd, J = 8.1, J = 2.1 Hz), 5.1K1H, d, J = 4.2 Hz), 5.02 (1H, d, J = 6.6 Hz), 4.95 (HH, q, J = 8.7 Hz), 4.92 (HH, d, J = 4.2 Hz), 4.69-4.64 (1H, m), 3.97-3.90 (1H,), 3.81-3.75 (1H, m), 3.20-2.79 (3H, m), 2.62-2.50 (1H, m), 2.3K3H, s), 2.26-2.03 (HH, m), 1.97-1.83 (HH, m), 1.75-1.33 (4H, m) , 0.80 (3H, t, J = 7.5 Hz). EXAMPLE 90 [ÍS- [la, 2ß, 3ß, 4a- (trans)] 3 -4- [7- [[2- (phenylmethyl) -cyclopropyl-3-amino-5- (propylthio) -3H-1,2,3 -triazolo- [4,5-d3-pyrimidin-3-yl-3-cyclopentane-1,2,3-triol. a) (Trans) -2- (phenylmethyl) -cyclopropanecarboxylic acid. Prepared according to the method of Example 20, step of part (a) using 2- (phenylmethyl) -cyclopropanecarboxylic acid ethyl ester. MS (APCI) 175 (M-H +, 100%). b) (trans) -2- (3-Phenylmethyl) -cyclopropanamine. It was prepared according to the method of Example 19, step of item (i) using the product of step (a). NMR dH (CDC13) 7.33-7.17 (5H.m), 2.55 (2H >; d), 2.53-2.18 (HH, m), 1.03-0.96 (1H, m), 0.60-0.54 (HH, m), 0.45 (1H, m). c) [ÍS- [la, 2β-3β-4a- (trans)]] -4- [7- [[2- (phenylmethyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2 , 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. It was prepared in accordance with the method of Example 24, step of subsection (f) using the product of step of subsection (b). NMR dH (de-DMSO) 9.10-9.08 (HH, m), 7.35-7.27 (4H, m), 7.21-7.17 (1H, m), 5.11-5.10 (1H,), 5.03-5.01 (HH, m) , 4.97- 4.9K2H, m), 4.69-4.64 (HH, m), 3.94 (HH, s), 3.79 (1H, s), 3.20-3.06 (3H, m), 2.78-2.76 (HH, m), 2.60-2.52 (2H, m), 1.97-1.92 (ÍH, m), 1.76-1.66 (2H,), 1.37-1.32 (ÍH,), 0.99 (3H, t), 0.78-0.76 (lH, m). EXAMPLE 91 [R- [la, 2a, 3β- (lR *, 2S *), 5β33-3- [7- [[2- (4-chloro-3-methylphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [[2- (4-chloro-3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-methanol . It was prepared according to the method of Example 1, step of part (a) using the product of Example 89, step of part (e). MS (APCI) 545.547 (M + H +), 545 (100%). b) [R- [la, 2a, 3β- (lR *, 2S *), 5βJ] -3- [7- [[2- (4-sloro-3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 1, step of item (b) using the product of the step of part (a).

MS (APCI) 505, 507 (M + H +), 505 (100%) dH NMR (de-DMSO) 9.33 (H, d), 7.31-7.02 (3 H, m), 5.00 (H, q), 4.42 ( 1H, q), 3.89-3.86 (HI, m), 3.53-3.42 (2H,), 3.16-3.12 (1H, m), 2.98-2.82 (2H, m), 2.31 (3H, s), 2.27-3.86 (ÍH, m), 3.53-3.42 (2H, m), 3.16-3.12 (ÍH, m), 2.98-2.82 (2H, m), 2.3K3H, s), 2.27-2.20 (lH, m), 2.10- 2.06 (2H, m), 1.89-1.79 (1H, m), 1.54-1.45 (3H, m), 1.37-1.31 (HH, m), 0.82 (3H, t). EXAMPLE 92 [ÍS- [la, 2β, 3β-4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-dimethylamino enyl) -cyclopropyl] -amino] -5-. { propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol. a) 1,1-dimethylethyl ester of (IR-trans) -N- [2- (3-dimethylaminophenyl) -cyclopropyl] -carbamic acid. A mixture of the product of Example 84, step of part (b) (520 mg), 37% formaldehyde aq (0.47 ml), acetic acid (0.1 ml) and sodium triacetoxyborohydride (2.26 g) in 1,2-dichloroethane ( 10 ml), was stirred for 3.5 hours. A solution of sodium bicarbonate was added and the mixture was extracted with dichloromethane. The organic phases were dried, evaporated and purified (Si02, petroleum / ether, 1: 1 as eluent) to obtain the subtitle compound (431 mg).

NMR dH CDCl 3) 7.13 (1H, t), 6.56 (1H, dd), 6.49-6.46 (2H, m), 4.80 (1H, s), 3.92 (6H, s), 2.79-2.76 (H, m), 2.02-1.96 (1H, m), 1.46 (9H, s), 1.21-1.09 (2H,). b) (IR-trans) -2- (3-dimethylamino) -cyclopropanamine. A product solution from step (a) (417 mg) in trifluoroacetic acid (3 ml) was stirred for 3 hours. The solvent was removed in vacuo, the residue was basified with a sodium bicarbonate solution and extracted with ethyl acetate. The organic phases were dried, evaporated and purified (SiO2, dichloromethane / ethanol / ammonia, 150: 8: 1 as eluent) to obtain the subtitle compound (198 mg). NMR dH (CDCl 3) 7.12 (1H, t), 6.55 (1H, dd), 6.46-6.44 (H, m), 6.35 (1H, dd), 2.93 (6H, s), 2".60-2.52 (H) , m), 1.86-1.80 (ÍH,), 1.72 (2H, s), 1.04-0.94 (2H, m) c) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] ] -6- [7- [[2- (3-dimethylaminophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [, 5-d] -pyrimidin-3- il] -cyclopentan-l, 3-dioxol-4-ol was prepared according to the method of Example 24, step of subsection (f) using the product of step of subsection (b). MS (APCI) 526 (M + H +, 100%). d) [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-dimethylaminophenyl) -cyclopropyl] -amino] -5- (propylthio) - 3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. It was prepared according to the method of Example 1, step of item (b) using the product of the step of part (c). P.f. 187-188 ° C. MS (APCI) 486 (M + H +, 100%) NMR dH (de-DMSO) 9.29-9.25 (HH, m), 7.07 (HH, dd), 6.55-6.52 (2H, m), 6.64 (1H, d), 5.10 (1H, d), 5.02-5.00 (ÍH, m), 4.96-4.92 (lH, m), 4.90 (1H, d), 4.68-4.62 (ÍH, m), 3.94-3.91 (1H, m), 3.79-3.75 (lHm,) , 3.25-2.92 (2H, m), 2.87 (6H, s), 2.62-2.53 (lH, m), 2.10-2.03 (1H, m), 1.96-1.88 (ÍH, m), 1.53-1.25 (4H, ), 0.82 (3H, t). EXAMPLE 93 • [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (3-fluoro-4-methoxyphenyl) -cyclopropyl] -amino] - 5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cislopentane-1,2,3-triol. a) [3aR- [3aa, 4a, 6a- (IR *, 2S *), 6aa]] -6- [7- [[2- (3-fluoro-4-methoxyphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H- 1,2,3-triazolo- [4,5-dJ-pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopentan-l, 3-dioxol-4-ol . The subtitle compound was prepared according to the method of Example 1, step of part (a) using the products of Example 24, step of part (d) and Example 76, step of part (d). MS (APCI) 531 (M + H +, 100%). b) [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-luoro-4-methoxyphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. It was prepared in accordance with the method of Example 1, step of item (b) using the product of the step of part (a). P.f. 156-157 ° C. MS (APCI) 491 (M + H +, 100%) dH NMR (d6_DMSO) 9.32 (ΔI, d), 7.10-6.94 (3H,), 5.11 (1H, d), 5.03 (1H, d), 4.93 (1H , d), 4.90 (1H, d), 4.69-4.63 (HH, m), 3.96-3.90 (lH, m), 3.81 (3H, s), "3.79-3.75 (HH, m), 3.14-3.08 ( 1H, m), 3.01-2.82 (2H, m), 2.63-2.54 (HH, m), 2.10-2.03 (1H, m), 1.96-1.87 (HH, m), 1.57-1.45 (3H, m), 1.34-1.27 (ÍH, m), 0.83 (3H, t) EXAMPLE 94 [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [7- [[2- ( 3, 5-dimethylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [[4,5-d] -pyrimidin-3-yl] -cyclopentane-1, 2 , 3-triol a) 3- (3,5-dimethylphenyl) -prop-2-enoic acid Prepared according to the method of Example 64, step of part (a) using 3,5-dimethylbenzaldehyde MS (APCI) ) 175 (M-H +, 100%). b) [3aS- [l- (E), 3aa, 6a, 7aβ]] - l- [3- (3,5-dimethylphenyl) -l-oxo-2-propenyl] -hexahydro-8,8-dimethyl- 3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, subsection step (f) using the product of step (a). MS (APCI) 374 (M + H +, 100%). c) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7aβ]] -1- [[2- (3,5-dimethylphenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8- dimethyl-3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, subsection step (g) using the product of step (b). MS (APCI) 388 (M-H +, 100%). d) Acid (IR-trans) -2- (3,5-dimethylphenyl-cyclopropanecarboxylic acid) The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of step (b) MS (APCI) 189 (M-H +, 100%) e) [R- (R *, R *)] -2, 3-dihydroxybutane-dioate (IR-trans) -2- (3,5-dimethylphenyl) ) -cyclopropanamine. (1: 1) The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (c). NMR dH (de-DMSO) 6.80 (HH, s), 6.70 (2H, s), 3.90 (2H, s), 2.66-2.6K1H, m), 2.06-1.99 (HH, m), 1.20-1.13 (HH) , m), 1.11-1.04 (ÍH, m). f) [lS- [la, 2β, 3β-4a- (lS *, 2R *)]] - 4- [7 - [[2- (3,5-dimethylphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. The title compound was prepared according to the method of Example 24, step of part (f) using the products of step (e) and Example 24, step of part (d). MS (APCI) 471 (M + H +, 100%) NMR dH (de-DMSO) 9.31 (H, d), 6.81 (3 H, s), 5.12-5.11 (H, m), 5.04-5.00 (lH, m), 4.94-4.91 (H, m), 4.67- 4.63 (ÍH, m), 3.95-3.92 (ÍH, m), 3.78-3.76 (ÍH, m), 3.21-3.1 (ÍH, m), 2.99-2.84 (2H, m), 2.60-2.57 (1H, m ), 2.24 (6H, s), 2.05-2.03 (ÍH, m), 1.92-1.9K1H, m), 1.56-1.45 (2H, m), 1.32-1.27 (2H, m), 0.83 (3H, t) . EXAMPLE 95 [ÍS- [la, 2β, 3β, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-chloro-4-methoxyphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) 3- (3-Chloro-4-methoxyphenyl) -prop-2-enoic acid. It was prepared according to the method of Example 64, step of part (a) using 3-chloro-4-methoxybenzaldehyde. NMR dH, (de-DMSO) 7.83 (H, d), 7.68-7.64 (H, m), 7.55-7.49 (1 H, m), 7.19-7.17 (1 H, m), 6.50-6.46 (H, d) 3.90 (3H, s). b) [3aS- [l- (i7) -3aa, 6a, 7aß]] -1- [3- (3-sloro-4-methoxyphenyl) -1-oxo-2-propeni1] -hexahydro-8, 8- dimethyl-3H-3a, 6-methano-2,1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (f) using the product of step-of part (a). MS (APCI) 408 (M-H +, 100%). c) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7aβ]] -1- [[2- (3-chloro-4-methoxyphenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8-dimethyl-3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (g) using the product of the step of part (b). MS (APCI) 424 (M + H +, 100%). d) Acid (IR-trans) -2- (3-chloro-4-methoxyphenyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of the step of part (c). NMR dH (CDC13) 7.13 (HH, d), 7.02-6.99 (HH, m), 6.85 (1H, d), 3. 88 (3H, s). e) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3-sloro-4-methoxyphenyl) -cyclopropanamine. (1: 1) The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (d). NMR dH (de-DMSO) 7.20-7.19 (1H, m), 7.09-7.05 (2H, s), 2.66-2.61 (1H, m), 2.10-2.04 (H, m), 1.19-1.05 (2H, m ). f) [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (3-chloro-4-methoxy-enyl) -cyclopropyl] -amino] - 5- (propylthio) -3H- 1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. The title compound was prepared according to the method of Example 24, step of part (f) using the products of step (e) and Example 24, step of part (d). MS (APCI) 505 (M + H +, 100%) dH NMR (de-DMSO) 9.33 (H, d), 7.32-7.31 (H, m), 7.14-7.12 (1H, m), 7.07-7.05 (lH ,), 5.17-5.15 (HH, m), 5.05-5.04 (1H, m), 4.94-4.93 (2H, m), 4.66-4.64 (HH, m), 3.94-3.93 (1H, m), 3.83 ( 3H, s), 3.80 (3H, s), 3.29-3.27 (HH, m), 3.12-2.78 (2H, m), 2.63-2.53 (HH, m), 2.09-2.04 (HH, m), 1.95- 1.881H, m), 1.56-1.46 (2H, m), 1.36-1.29 (ÍH, m), 0.84-0.81 (3H, t). EXAMPLE 96 [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3-chloro-4-methoxyphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [[2- (3-chloro-4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-l, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cislopenta-l, 3-dioxol-4-methanol . It was prepared in accordance with the method of Example 1, step of part (a) using the product of Example 95, step of part (e). MS (APCI) 561/563 (M + H +), 561 (100%). b) [IR- [la, 2a, 3β- (IR *, 2S *), 5β]] -3- [7- [[2- (3-chloro-4-methoxyphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 1, step of item (b) using the product of the step of part (a). MS (APCI) 521/523 (M + H +), 521 (100%) dH NMR (de-DMSO) 9.31 (ÍH, d), 7.33-7.05 (3H, m), 5.00 (1H, q), 4.44- 4.41 (ÍH, M9, 3.90-3.86 (ÍH, m), 3.83 (3H, S), 3.54-3.43 (2H, m), 3.11-3.07 (ÍH, m), 3.03-2.84 (2H, m) 2.31- 2.21 (1H, m), 2.07-2.00 (2H, m), 1.90-1.80 (HH,), 1.58-1.48 (3H, m), 1.33-1.24 (HH, m), 0.84 (3H, t). 97 [R- [la- (lS *, 2R *), 2β, 3β, 4a]] - N- [3- [2,3-dihydroxy-4- (hydroxymethyl) -cyclopenti] -5- (propylthio) - 3H-1,2,3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -methanesulfonamide a) [3aS- [3aa, 4a- (lR *, 2S *), 6a, 6aa] -N- [3- [2- [3- [tetrahydro-6- (hydroxymethyl) -2, 2-dimethyl-4H-cyclopenta-1, 3-dioxol-4-yl] - 5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-7-ylamino] -cyclopropyl] -phenyl] -methanesulfonamide. The subtitle compound was prepared according to the method of Example 1, step of part (a) using the product of Example 84, step of part (d). MS (APCI) 590 (M + H +, 100%). b) [lR- [la- (lS *, 2R *), 2β, 3β, 4a]] - N- [3 - [[2- [3, [2,3-dihydroxy-4- (hydroxymethyl) -cyclopentyl) ] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -methanesulfonamide. The subtitle compound was prepared according to the method of Example 1, step of item (b) using the product of the step of part (a). MS (APCI) 550 (M + H +, 100%) dH NMR (d6-DMSO) 9.62 (1H, s), 9.32 (1H, d), 7.25 (1H, t), 7. 05-6.91 (3H, m), 5.01-4.95 (2H, m), 4.74-4.70 (2H, m), 4.43-4.40 (1H, m), 3.87 (1H, q), 3.49-3.43 (2H, m ), 3.22-3.19 (HH, m), 1.55-1.48 (3H, m), 1.29-1.26 (HH, m), 0.83 (3H, t). EXAMPLE 98 [R- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3,5-dimethoxyphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 1, step of item (a) using the product of Example 64, step of item (e), followed by the method of Example 1, step of item (b). MS (APCI) (M + H +), 517 (100%) dH NMR (de-DMSO) 9.31 (ÍH, d), 6.35-6.30 (3H, s), 4.98-4.96 (2H, m), 4.72-4.70 (2H, m), 3.05-2.80 (2H, m), 2.30-2.20 (1H, s), 2.10-2.03 (2H, m), 1.92-1.81 (ÍH, m); 1.60-1.40 (2H, m) , 1.40-1.30 (2H, m), 0.84 (3H, t).

EXAMPLE 99 [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] - 4- [7 - [[2- (3-fluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. a) [3aS- [l- (E), 3aa, 6a, 7aß]] -1- [3- (3-fluorophenyl) -l-oxo-2-propenyl] -hexahydro-8,8-dimethyl-3H- 3a, 6-methane-2, 1-bensisothiazole-2, 2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (f) using 3- (3-fluorophenyl) -2-propenoic acid. MS (APCI) (M + H +), 364 (100%). b) [3aS- [1- (SS *, 2S *), 3aa, 6a, 7aβ]] -1- [[2- (3-fluorophenyl) -cyclopropyl] -carbonyl] -hexahydro-8,8-dimethyl- 3H-3a, 6-methane-2, 1-benzisothiazole-2, 2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of subsection (g) using the product of the step of part (a). MS (APCI) 378 (M + H +, 100%). c) Acid (IR-trans) -2- (3-fluorophenyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h) using the product of the step of part (b). NMR dH (CDC13) 1.36-1.43 (1H,), 1.65-1.71 (ÍH,), 1.88-1.94 (1H, m), 2.56-2.63 (lH, m), 6.79 (1H, d, J = 9.9 Hz) , 6.88-6.94 (2H, m), 7.21-7.29 (ÍH, m). d) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3-fluorophenyl) -cyclopropanamine, (1: 1). The subtitle compound was prepared according to the method of Example 20, step of part (b) using the product of the step of part (c). NMR dH (de-DMSO) 1.12-1.28 (2H, m), 2.12-2.18 (HH, m), 2.69-2.74 (1H, m), 3.95 (2H, s), 6.92-7.02 (3H, m), 7.27-7.34 (ÍH, m). e) [ÍS- [la, 2ß, 3ß-4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-fluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2,3-triol. The title compound was prepared according to the method of Example 24,. step of subsection (f) using the products of the passage of subsection (d) and of Example 24, step of subsection (d). MS (APCI) 461 (M + H +, 100%) NMR dH (de-DMSO) 9.37 (1H, d, J = 4.2 Hz), 7.36-7.28 (HH, m), 7.06-6.96 (3H, m), 5.10-4.91 (4H, m), 4.69-4.63 ( ÍH, m), 3.97-3.91 (1H, m), 3.79 (1H, s) 3.25-3.19 (ÍH, m), 2.78 (2H, m), 2.65-2.55 (lH, m), 2.18-2.11 (ÍH) , m), 1.96-1.87 (ÍH, m), 1.61-1.35 (4H, m), 0.81 (3H, t, J = 7.2 Hz).

EXAMPLE 100 [lR- [la- (lS *, 2R *), 2β, 3β, 4a]] - N - [[3- (2,3-dihydroxy-4-hydroxymethylcyclopentyl) -5- (propylthio) -3H- 1, 2, 3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -acetamide. It was prepared according to the method of Example 1, step of item (a) using the products of Example 87, step of item (b), followed by the method of Example 1, step of item (b). MS (APCI) 528 (M + H +, 100%) dH NMR (de-DMSO) 9.86 (1H, s), 9.32 (1H, d), 7.41-7.36 (2H,), 7.22-7.16 (lH,), 6.87-6.85 (1H, m), 5.01-4.95 (2H, m), 4.71-4.45 (2H,), 4.43-4.39 (ÍH, m), '3.88-3.85 (ÍH, m), 3.51-3.45 (2H ,), 3.21-3.18 (ÍH,), 2.97-2.83 (2H, m), 2.27-2.05 (3H, m), 2.05 (3H, t), 1.89-1.79 (ÍH, m), 1.55-1.50 (3H , m), 1.48-1.26 (1H, m), 0.83 (3H, t). EXAMPLE 101 [IR- [la, 2a, 3β- (IR *, 2S *), 5β]] -3- [7- [[2- (3,5-dichlorophenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (IR *, 2S *) -6aa] -6- [7- [(2- (3,5-dichlorophenyl) -cyclopropyl) -amino] -5- (propylthio) ) -3H- 1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -te-rahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-methanol.

It was prepared according to the method of Example 1, step of part (a) using the product of Example 83, step of part (d). MS (APCI) 565 (M + H +, 100%). b) [R- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3,5-dichlorophenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 1, step of item (b) using the product of the step of part (a). Purification (HPLC, Symmetry® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, isocratic elution with 50% MeCN in a period of 30 minutes) yielded the title compound (98 mg). NMR dH (de-DMSO) 9.39 (1H, d), 7.40 (H, s), 7.31 (2H, d), 7. 23UH, S), 5.04-4.97 (2H, m), 4.74-4.70 (2H, m), 4.39 (1H,), 3.89-3.85 (lH, m), 3.51-3. 5 (2H, m), 3.19-3.10 (HH, m), 2.93-2.80 (2H, m), 2.30-2.20 (HH, m), 2.10-2.06 (2H, m), 1.89-1.79 (1H, m ), 1.67-1.49 (HH, m), 1, 58 (HH, m), 0.84 (3H, t). EXAMPLE 102 Modifications to the 7-position of [ÍS- (la, 2a, 3ß, 5ß)] -3- (2-hydroxymethyl) -5- [5- (propylthio) -3H-1, 2, 3-triazolo- [ 4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) Acid [3aR- (3aa, 4a, 6a, 6aa)] -6- [7-amino-5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin- 3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-carboxylic acid. A solution of the product of Example 6, step of part (b) (1.40 g) and ammonia in 1,4-dioxane (0.5 M, 60 ml) was stirred at 50 ° C for 3 hours. The reaction mixture was evaporated to dryness, the residue was triturated with water and the subtitle compound was isolated by filtration (1.20 g). MS (APCI) 395 (M + H +, 100%). b) [3aR- (3aa, 4a, 6a, 6aa)] -6- [7-amino-5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] - methyl ester. pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-acetic acid. Isobutyl chloroformate (0.33 ml) was added to an ice-cooled solution of the product from the step of part (a) (0.50 g) and N-methylmorpholine (0.26 ml) in tetrahydrofuran (10 ml). The solution was stirred at room temperature for 60 minutes and then added to a solution of diazomethane (1.0 g) in ether (100 ml). The reaction mixture was stirred for 60 minutes and then concentrated. The crude diazoketone (0.50 g) was taken up in methanol (20 ml) and silver oxide (I) was added. (250 mg) per portion at 60 ° C. The mixture was heated for 3 hours, diluted with chloroform (100 ml) and then vigorously stirred with 0.88 aqueous ammonia (50 ml) and water (50 ml) for 20 minutes. The mixture was extracted with chloroform and the extracts were washed with water and then dried and concentrated. The purification (SÍO2, ether / isohexane, 2: 1 as eluent) yielded the subtitle compound (0.50 g). MS (APCI) 423 (M + H +, 1.00%). C) [3aR- (3aa, 4a, 6a, 6aa)] - [7-bromo-5- (propylthio) -3H, 1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl ] -tetrahydro-2,2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-ethanol. DIBAL-H® (1.5 M solution in toluene, 5 ml) was added to an ice-cooled solution of the product from step (b) (0.20 g) in toluene (10 ml) and the solution was stirred at this temperature for 30 minutes before adding water (2 ml). The product was extracted with ether, the solution was filtered through a pad of celite, dried and concentrated (175 mg). The resulting foam (175 mg) was collected with bromoform (5 ml) / isoamyl nitrite (1 ml) and then heated at 85 ° C for 40 minutes. The solution was concentrated and purified (SiO2, ether / isohexane, 2: 1 as eluent) to obtain the subtitle compound (0.15 g). MS (APCI) 400 (M + H + -57, 100%). d) Modifications to position 7 of the [ÍS- (la, 2a, 3ß, 5ß)] - 3- (2-hydroxyethyl) -5- [5- (propylthio) -3H-l, 2,3-triazolo- [ 4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. The product from step (c) (2.5 x 10 mol) in 1,4-dioxane (90 μl) and N, N-diisopropylethylamine (1.0 x 10 ~ 5 mol) in 1,4-dioxane (100 μl), were added to each of the amine salts listed below (5.0 x 10-6 mol). The reaction mixtures were heated at 60 ° C for 4 hours before adding a phthalate buffer (pH 4, 400 μl) and the reaction mixtures were extracted with ethyl acetate (4 x 200 μl). The extracts were concentrated and the residues were collected with 80% acetic acid (150 μl) and then heated to 80 ° C for 30 minutes. The reaction reaction mixtures were concentrated and then subjected to azeotropic distillation with ethanol (2 x 200 μl) to obtain the title compounds. The following amines were used (preparations previously described in the experimental part): [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-txans) -N-3- [(2-aminociclopropyl) - phenyl] -methanesulfonamide, (1: 1).

[R- (R *, R *)] -2, 3-dihydroxybutane-dioate of (IR-rans) -2- (4-phenoxy-nyenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (2-phenoxyphenyl) -cyclopropanamine, (1: 1).

[R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (3-flenoxyphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (4-bromophenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- [(1,1'-biphenyl) -2-yl] -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- [. (1,1'-biphenyl) -3-yl] -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (3, 5-dichlorophenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (3,4-dichlorophenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (lR-trans) -2- (3-chloro-4-methoxyphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutane-dioate of (IR-rans) -2- (3, 4-dimethoxyphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (1S-trans) -N-4- [(2-aminociclopropyl) -phenyl] -acetamide, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (3-chloro-4-methylphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (1R-trans) -2- (4-chloro-3-methylphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutane-dioate of (IR-trans) -2- (4-fluoro-3-methylphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3-nitrophenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (4-methoxy-3-methylphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (3-methoxy-4-methylphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (4-N, N-dimethylphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutane-dioate of (IR-rans) -2- (3, 4-difluorophenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3, 5-difluorophenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3-chlorophenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutane-dioate of (IR-trans) -2- (4-chlorophenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-rans) -2- (4-methoxyphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutane-dioate of (IR-trans) -2- (2-methoxyphenyl) -cyclopropanamine, (1: 1). [R- (R +, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (3-methoxyphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (IR-trans) -2- (3, 5-dimethylphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (4-fluorophenyl) -cyclopropanamine, (1: 1).

[R- (R *, R *)] -2, 3-dihydroxybutane-dioate of (IR-trans) -2- (3-fluorophenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2,3-dihydroxybutanedioate of (lR-trans) -2- (2-methylphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutane-dioate of (IR-trans) -2- (3-methylphenyl) -cyclopropanamine, (1: 1). [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (4-methylphenyl) -cyclopropanamine, (1: 1). The following products were obtained: a) [lR- [la, - (lS *, 2R *), 2β, 3β, 4a]] -N- [3- [2,3-dihydroxy-4- (2-hydroxyethyl)] -cyclopentyl] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -methanesulfonamide. MS (APCI) 564 (M + H +, 100%). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -4- (2-hydroxyethyl) -5- [7- [[2- (4-phenoxyphenyl) -cyclopropyl] - amino] -5- (propylthio) -3H-1, 2,3-triazolo- [, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. MS (APCI) 563 (M + H +, 100%). c) [lS- [la, 2a, 3β, 5β- (lS *, 2R *))] -3- (2-hydroxyethyl) -5- [-7- [[2- (3-enoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-dio. MS (APCI) 563 (M + H +, 100%). d) [IR- [la, 2a, 3β- (IR *, 2S *), 5β]] -3- [7- [[2- (4-bromophenyl) -syclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol. MS (APCI) 551, 549 (M + H +, 100%). e) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- [(1,1'-biphenyl) -2-yl] -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol . MS (APCI) 547 (M + H +, 100%) f) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- [(1, 1 '-biphenyl) -3-yl] -cyclopropyl] -amino] -5- (propylthio) -3H-1,2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol. MS (APCI) 547 (M + H +, 100%) g) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3.5 - dichlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cislopentane -1, 2-diol. MS (APCI) 539, 541, 543 (M + H +, 100%) h) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3,4-dichlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2- hydroxyethyl) -cyclopentane-1,2-diol.

MS (APCI) 539, 541, 543 (M + H, 100%) i) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3-Chloro-4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [, 5-d] -pyrimidin-3-yl] -5- (2 hydroxyethyl) -cyclopentane-1,2-diol. MS (APCI) 537, 535 (M + H +, 100%) j) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] - 3- [7 - [[2- (3 , 4-di-ethoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) ) -cyclopentane-1,2-diol. MS (APCI) 531 (M + H +, 100%) k) [lR- [la- (lS *, 2R *), 2β, 3β, 4β]] -N- [3- [2- [[3- [ 2,3-dihydroxy-4- (2-hydroxyethyl) -syclopentyl] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -acetamide. MS (APCI) 528 (M + H +, 100%) 1) [IR- [la, 2a, 3β- (IR *, 2S *), 5β]] -3- [7- [[2- (3-Chlorine 4-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) - cislopentane-l, 2-diol. MS (APCI) 521, 519 (M + H +, 100%) m) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (4 Chloro-4-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2- hydroxyethyl) -cyclopentane-1,2-diol. MS (APCI) 521, 519 (M + H +, 100%) n) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (4 -fluoro-3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2- hydroxyethyl) -cyclopentane-1,2-diol. MS (APCI) 519 (M + H +, 100%) o) [SS- [la, 2a, 3β, 5β- (1S *, 2R *)]] -3- (2-Hydroxyethyl) -5- [7- [[2- (3-nitrophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane- 1 , 2-diol. MS (APCI) 516 (M + H +, 100%) p) [ΔS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (2-hydroxyethyl) -5- [7- [[2- (4-methoxy-3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] - cyclopentane-l, 2-diol. MS (APCI) 515 (M + H +, 100%) q) [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (2-hydroxyethyl) -5- [7- [[2- (3-methoxy-4-methylphenyl) -syclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] - cyclopentane-l, 2-diol. MS (APCI) 515 (M + H +, 100%) r) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (4-N , N-dimethylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-l, 2-diol. MS (APCI) 514 (M + H +, 100%) s) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3,4 - difluorophenyl) -syclopropyl) -amino3 -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane- 1, 2-diol. MS (APCI) 507 (M + H +, 100%) t) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3.5 - difluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane -l, 2-diol. MS (APCI) 507 (M + H +, 100%) u) [lR- [la, 2a, 3ß- (lR *, 2S *), 5ß]] -3- [7- [[2- (3-Chloro-enyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2.3 -triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol. MS (APCI) 507, 505 (M + H +, 100%) v) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethyl) -5- [ 7- [[2- (4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane - 1,2-diol. MS (APCI) 507, 505 (M + H +, 100%) w) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethyl) -5- [ 7- [[2- (2-methoxy-enyl) -cissopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] - cyclopentano-1,2-diol. MS (APCI) 501 (M + H +, 100%) x) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethyl) -5- [7- [[2- (4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1 , 2-diol. MS (APCI) 501 (M + H +, 100%) y) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethyl) -5- [7- [[2- (3-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3-yl, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane- 1 , 2-diol. MS (APCI) 501 (M + H +, 100%) z) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3.5 - dimethylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane -l, 2-diol MS (APCI) 499 (M + H +, 100%) aa) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7-112- (4-fluoro-enyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) ) -cyclopentane-1,2-diol. MS (APCI) 489 (M + H +, 100%) bb) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3-fluorophenyl)] ) - cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- [2-hydroxyethyl] -cyclopentane- 1 , 2-diol. MS (APCI) 489 (M + H +, 100%) ce) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethyl) -5- [7- [[2- (2-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane- 1 , 2-diol. MS (APCI) 485 (M + H +, 100%) dd) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethyl) -5- [7- [[2- (3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyridin-3-yl] -cyclopentane - 1,2-diol. MS (APCI) 485 (M + H +, 100%) ee) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethyl) -5- [7- [[2- (4-methyl-enyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane- 1,2-diol. MS (APCI) 485 (M + H +, 100%) ff) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethyl) -5- [7- (cyclopropylamino) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. MS (APCI) 461 (M + H +, 100%) EXAMPLE 103 [ΔS- [la, 2a, 3β, 5β- (1S *, 2R *)]] -3- (2-hydroxy-2-methylpropoxymethyl) -5 - [7- [(2-phenylscyclopropyl) -amino) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1, 2 -diol. a) Ethyl ester of the acid [3aR- [3aa, 4a, 6a- (1R *, 2S *), 6aa]] -2- [6- [7- [(2-enylcyclopropyl) -amino] -5 (propylthio) - 3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methoxy] -acetic. A solution of [3aR- [3aa, 4a, 6a- (ÍS *, 2R *), 6aa]] - 6- [7-chloro-5- (propylthio) -3H-1, 2, 3-triazolo- [4 , 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4i? -cyclopenta-l, 3-dioxol-4-methanol (0.7 g) rhodium acetate (0.39 g) in dichloromethane (20ml ) was treated with a solution of ethyl diazoacetate (0.21 ml) in dichloromethane (10 ml) over a period of 3 hours. The reaction mixture was stirred at room temperature for 60 minutes, concentrated and purified (SiO2, isohexane / ethyl acetate, 3: 1 as eluent). The resulting intermediate was taken up in THF (10 ml), [R- (R *, R *)] -2, 3-dihydroxybutanedioate (lR-t-rans) -2-phenylcyclopropanamine (1: 1) (0.2) was added. g) and N, N-diisopropylethylamine (0.2 ml) and the solution was stirred for 18 hours and then concentrated. Purification (SIO2, ether / isohexane, 2: 1 as eluent) yielded the subtitle compound (0.23 g). MS (APCI) 583 (M + H +), 545 (100%). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxy-2-methylpropoxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared according to the method of Example 10, using the product of the step of part (a). Purification (HPLC, Syrametry® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, isocratic elution with 30% MeCN in a period of 30 minutes, afforded the title compound (115 mg) .dHR (de-DMSO) ) 9.32 (ÍH, d), 7.31-7.15 (5H, m), 5.00-4.98 (2H, m) 478 (ÍH, d), 4.46-4.44 (ÍH, m), 4.29 (ÍH, s), 3.89- 3.86 (ÍH, m), 3.51-3.48 (2H, m), 3.18-3.17 (3H, m), 2.96-2.84 (2H, m), 2.27-2.26 (ÍH,), 2.21-2.13 (ÍH, m) , 2.13-2.11 (HH, m), 1.88-1.86 (1H, m), 1.50-1.48 (3H, m), 1.32-1.31 (HH, m), 1.09 (6H, s), 0.81 (3H, t) EXAMPLE 104 [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3-Chloro-4-methylphenyl) -cyclopropyl] -amino] - 5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol a) Acid 3- (3-chloro-4-methylphenyl) -2-propenoic acid.

The subtitle compound was prepared according to the method of Example 64, step of the subsection (a) using (3-chloro-4-methyl) -benzaldehyde (prepared according to the method of S.O. Nwauk et al., Tetrahedron Lett., 1982, 23, 3131). MS (APCI) 191 (M + H +, 100%). b) [3aS- [l- (E), 3aa, 6a, 7aß]] -l- [3- (3-chloro-4-methylphenyl) -1- oxo-2-propeni1) -hexahydro-8, 8- dimethyl-3H-3a, 6-methano-2,1-benzisothiazole-2,2-dioxide. The subtitle compound was prepared according to the method of Example 19, step of part (f), using the product of the step of part (a). MS (APCI) 394/392 (M-H +) 392 (100%). c) [3aS- [l- (lS *, 2S *), 3aa, 6a, 7aβ]] -1- [[2- (3-chloro-4-methylphenyl) -cyclopropyl] -carbonyl] -hexahydro-8, 8- dimethyl-3H-3a, 6-methane-2, 1-benzisothiazole-2,2-dioxide The subtitle compound was prepared according to the method of Example 19, step of part (g), using the product of step of subsection (b). P.f. 154-156 ° C d) Acid (IR-rans) -2- (3-chloro-4-methylphenyl) -cyclopropanecarboxylic acid. The subtitle compound was prepared according to the method of Example 19, step of part (h), using the product of step (c). MS (APCI) 209 (M-H +, 100%). e) [R- (R *, R *)] -2, 3-dihydroxybutanedioate of (IR-trans) -2- (3-chloro-4-methylphenyl) -cyclopropanamine, (1: 1). The subtitle compound was prepared according to the method of Example 20, step of part (b), using the product of the step of part (d). MS (APCI) 182 (M + H +, 100%). f) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [[2- (3-chloro-4-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-l, 3-dioxol-4-methanol . The subtitle compound was prepared according to the method of Example 1, step of part (a), using the product of step "in part (e) .MS (APCI) 547, 545 (M + H +), 545 (100 %) g) [IR- [la, 2a, 3ß- (IR *, 2S *), 5ß]] -3- [7- [[2- [3-chloro-4-methylphenyl) -cyclopropyl] -amino ] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. The subtitle was prepared according to the method of Example 57, step of item (b), using the product of step (f), MS (APCI) 507, 505 (M + H +), 505 (100%).

NMR dH (de-DMSO) 9.32 (ΔI, d), 7.29-7.21 (2H, m), 7.08-7.01 (ΔI, m), 5.04-4.95 (2H, m), 4.74-4.71 (2H, m), 4.46-4.39 (ÍH, m), 3.90-3.86 (1H, m), 3.55-3.43 (2H, m), 3.17-3.09 (ÍH, m), 3.00-2.80 (2H,), 2.29 (3H, 5) , 2.26-2.20 (HH, m), 2.12-2.05 (2H, m), 1.89-1.79 (HH, m), 1.57-1.45 (3H, m), 1.39-1.32 (HH, m), 0.84 (3H, t). EXAMPLE 105 [lR- [la- (lS *, 2R *), 2β, 3β, 4a]] -4- [2- [[3- (2,3,4-trihydroxycyclopentyl) -5- (propylthio) -3H -1, 2, 3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenylsulonamide a) (I-trans) -4- (2-aminociclopropyl) -hydrochloride - phenylsulfonamide The title compound was prepared from (IR-trans) -phenylcyclopropanamine in accordance with the method described in US Pat. No. 3,487,154. P.f. 211-212 ° C. NMR dH (de-DMSO) 8.71 (3H, 5), 7.72 (2H, d), 7.35 (2H, d), 7.33 (2H, 5), 2.94-2.82 (HH, m), 2.47-2.42 (HH, m), 1.55-1.47 (HH, m), 1.28 (HH, q). b) [3aS- [3aa, 4a, 6a- (IR *, 2S *), 6aa] -1-4- [2- [[3- (2, 2-dimethyl-6-hydroxytetrahydro-4H-cyclopenta-1 , 3-dioxol-4-yl) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenylsulonamide.

It was prepared according to the method of Example 24, step of part (f) using the product of the step of part (a) and the product of Example 24, step of part (d). MS (APCI) 562 (M + H +, 100%) c) [lR- [la- (lS *, 2R *), 2β, 3β, 4a]] -4- [2- [[3- [2,3 , 4-trihydroxycyclopentyl) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenylisuiponamide. It was prepared in accordance with the method of Example 1, step of subsection (b) using the product of the step of subsection (b). P.f. 200-210 ° C. MS (APCI) 522 (M + H +, 100%). NMR dH (de-DMSO) 9.40 (OH, "d), 7.78 (2H, d), 7.52 (2H, d), 5.76 (2H, 5), 5.18-4.88 (4H, m), 4.71-4.60 (HH, m), 3.98-3.87 (HH, m), 3.81-3.75 (HH, m), 3.29 -3.22 (HH, m), 2.97-2.79 (2H, m), 2.65-2.51 (1H, m), 2.25-2.18 (HH, m), 1.96-1.85 (HH, m), 1.75-1.40 (3H , m), 0.81 (3H, t). EXAMPLE 106 [R- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [5- (butylthio) -7- [(2-phenylopropyl) -amino] -3H-1, 2 , 3-triazolo- [4,5-dJ-pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. a) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylopropyl) -amino] -5- (propylsulfonyl) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared according to the method of Example 4, step of part (a) using the product of Example 1, step of part (b). MS (APCI) 489 (M + H +, 100%) b) [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [5- (butylthio) -7- [( 2-phenylopropyl) -amino] -3H-1, 2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol. It was prepared in accordance with the method of Example 4, step of item (b) using the product of step (a) and butanediol. MS (APCI) 471 (M + H +, 100%) dH NMR (de-DMSO) 9.32 (ΔI, d), 7.33-7.15 (5H, m), 5.01-4.96 (2H, m), 4.73-4.69 (2H , m), 4.45-4.42 (HH, m), 3.87 (HH, q), 3.49-3.44 (2H, m), 3.22-3.19 (HH, m), 3.00-2.85 (2H, m), 2.30-2.20 (ÍH,), 2.17-2.08 (2H, m), 1.90-1.80 (ÍH, m), 1.53-1.44 (3H, m). 1.33-1.20 (3H, m), 0.81 (3H, t). EXAMPLE 107 [ÍS- [la, 2a, 3ß, 5ß- (1S *, 2R *)]] -3-. { hydroxymethyl) -5- [5- (pentthio) -7- [(2-phenylopropyl) -amino] -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane -l, 2-diol. It was prepared according to the method of Example 4, step of item (b) using the product of Example 107, step of part (a) and pentanothiol. MS (APCI) 485 (M + H +, 100%) dH NMR (de-DMSO) 9.33 (1H, d), 7.31-7.16 (5H, m), 5.03-4.97 (2H, m), 4.72-4.70 (2H , m), 4.45-4.40 (ÍH, m), 3. 88-3.86 (ÍH, m), 3.49-3.45 (2H, m), 3.21-3.19 (ÍH, m), 3. 00-2.94 (ÍH, m), 2.89-2.82 (ÍH, m), 2.33-2.22 (ÍH, m), 2. 14-2.09 (2H, m), 1.87-1.79 (HH, m), 2.94 (HH, m), 2.89-2.82 (HH, m), 2.33-2.22 (HH, m), 2.14-2.09 (2H, m ), 1.87-1.79 (ÍH, m), 1.53-1.31 (5H, m), 1.21-1.19 (3H,), 0.81 (3H, t). EXAMPLE 108 [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylopropyl) -amino] -5- (prop- 2-inylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [ÍS- [la, 2a, 3β, 5β- (1S *, 2R *)]] -3- (hydroxymethyl) -5- [5- (mercapto) -7- [(2-phenylopropyl) -amino] -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. A solution of the product of Example 107, step (a) (0.4 g) in DMSO (10 ml) was treated with hydrous sodium hydrosulfide (0.4 g) and the mixture was stirred at room temperature for 2 hours. The mixture was poured into aqueous brine (150 ml) containing acetic acid (2 ml) and extracted with ethyl acetate (3 x 100 ml). The organic extracts were combined and the combined was dried and concentrated to obtain the subtitle compound (0.3 g). MS (APCI) 415 (M + H +, 100%) b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [( 2- phenylopropyl) -amino] -5- (prop-2-inylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -syclopentane-1,2-diol . A solution of the product from the step of part (a) (168 mg) in DMF (5 ml) was treated with N, N-diisopropylethylamine (58 mg), followed by propargyl bromide (58 mg). The mixture was heated at 60 ° C for 1 hour and then emptied into aqueous brine (100 ml) and extracted with ethyl acetate (100 ml). The organic phase was washed with more aqueous brine (3 x 100 ml), dried and concentrated and the residue was purified (SiO2, chloroform / methanol, 95: 5 as eluent) to obtain the title compound (40 mg). MS (APCI) 453 (M + H +, 100%). NMR dH (de-DMSO) 9.44 (HH, d), 7.31-7.16 (5H, m), 5.00-4.95 (2H, m), 4.71-4.70 (2H, m), 4.44 (HH, q), 3.94- 3.71 (3H, m), 3.54-3.44 (2H, m), 3.23-3.18 (ÍH), m), 3.05- 3.01 (HH, m), 2.30-2.27 (HH, m), 2.20-2.09 (2H, m), 1.93- 1.85 (HH, m), 1.52-1.47 (HH, m), 1.37 -1.30 (lH, m). EXAMPLE 109 [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (3,5-dimethylphenyl) -cyclopropyl] - amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -tetrahydro ^^ - dimethyl-e - ^ - [[2- (3,5-dimethylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -4H-cyclopenta-1,3-dioxol-4-methanol. It was prepared according to the method of Example 1, step of part (a) using the product of Example 94, step of part (e). MS (APCI) 525 (M + H +, 100%). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (3,5-dimethylphenyl) -cyclopropyl] - amino-5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. It was prepared according to the method of Example 57, step of item (b) using the product of the step of part (a). MS (APCI) 485 (M + H +, 100%). NMR dH (de-DMSO) 9.29 (1H, d), 6.85-6.73 (3H, m), . 06-4.94 (2H,), 4.75-4.68 (2H, m) .4.48-4.39 (ÍH, m), 3. 91-3.85 (ÍH, m), 3.56-3.41 (2H, m), 3.19-3.11 (ÍH, m), 3. 05-2.82 (2H, m), 2.32-2.16 (7H, m), 2.13-2.00 (2H.m), 1.92-1.78 (ÍH, m), 1.61-1.41 (3H, m), 1.37-1.22 (ÍH) , m), 0.90-0.80 (3H, t). EXAMPLE 110 [SS- [la, 2a, 3β, 5β- (1S *, 2R *)]] -3- (2-hydroxyethyl) -5- [5- (methylthio) -7- ((2-phenylcyclopropyl) - amino] -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -6- [7- [(2-phenylcyclopropyl) -amino] -5- (propylsulfonyl) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin- 3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-l, 3-dioxole-4-ethanol. DIBAL-H® (1.5 M solution in toluene, 20 ml) was added to an ice-cooled solution of the product of Example 11, step (a) (2.00 g) in toluene (30 ml) and the solution was stirred at room temperature. this temperature for 30 minutes before adding ethyl acetate (2 ml). The solution was washed with water and concentrated. The residue (1.8 g) was collected with ethanol and cooled to 4 ° C before adding 3-chloroperoxybenzoic acid (50-55%, 2.5 g) and the reaction mixture was allowed to stir at room temperature for 18 hours. The solution was washed with an aqueous solution of sodium metabisulfite (3 x 10 ml) and then dried and concentrated. Purification (SIO2, ether / isohexane, 80:20 as eluent) yielded the title compound of the subtitle (1.8 g).

MS (APCI) 543 (M + H +, 100%) b) [lS- (la, 2a, 3β, 5β- (lS *, 2R *)] -3- (2-hydroxyethyl) -5- [5- ( methylthio) -7- ((2-phenylcyclopropyl) -amino] -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. by the method of Example 4, step of item (b) using the product of step (a) and commercially available sodium methanethiolate, then deprotected using the method of Example 1, step of item (b). purification (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate / acetonitrile, isocratic elution with 30% MeCN in a period of 30 minutes) yielded the title compound (110 mg) .dH NMR (de-DMSO) 7.31-7.15 (5H, m), 5.01-4.99 (1H, m) 4.40-4.35 (1H, m), 3.76-3.72 (ÍH, m), 3.47-3.40 (2H, m), 3.18-3.13 (ÍH, m), 2.37-2.30 (4H,? t?), 2.16-2.10 (ÍH, m), 2.05-2.00 (ÍH, m), 1.75-1.65 (2H, m), 1.56-1.49 (2H, m), 1.35-1.32 (1H,). EXAMPLE 111 [lR- (la, 2a, 3β- (lR *, 2S *), 5β]] -3- [5- (butylthio) -7- [(2-phenyl) cyclopropyl) -amino] -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl-cyclopentane-1,2-diol. Prepared by the method of Example 4, step of item (b) using the product of Example 100, step of part (a) and butanethiol, then deprotected using the method of Example, step of part (d). Purification (HPLC, Novapak C18 column, 0.1% aqueous ammonium acetate / acetonitrile, isocratic elution with 45% MeCN in a period of 30 minutes) yielded the title compound (210 mg). NMR dH (de-DMSO) 9.33 (H, d), 7.31-7.15 (5H, m), 5.01-4.94 (2H, m), 4.77 (H, d), 4.49-4.39 (H, m), 3.80- 3.75 (ÍH, m), 3.50-3.48 (2H, m), 3.19-3.10 (ÍH, m), 3.00-2.85 (2H, m), 2.38-2.29 (ÍH, m), 2.18-2.13 (ÍH, m ), 2.05-2.00 (ÍH, m), 1.79-1.64 (2H, m), 1.51-1.38 (4H, m), 1.35-1.21 (3H, t). EXAMPLE 112 [IR- (la, 2a, 3β- (IR *, 2S *), 5β]] -3- [7- ([2- (4-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- (4, 5-d) -pyrimidin-3-yl] -5- ((2-hydroxy) -ethoxy] -cyclopentane-1,2-diol a) 1, 2- [[(1 S-cis) -4-azido-2-cyclopen-1-yl] -oxy] -acetic acid 1-dimethyl ester added drip (lS-cis) -4-azido-2- Cyclopenten-1-ol (3.4 g) (prepared in the manner described by DR Deardorff et al., J. Org Chem, 1989, 54, 2759) in tetrahydrofuran (60 ml) to a suspension of sodium hydride (1.1 g) of a 60% suspension in oil) in tetrahydrofuran (60 ml) at 0 ° C. At the end of the addition, the mixture was allowed to reach room temperature and this mixture was added dropwise to a solution of tert-butyl bromoacetate ( 10.1 ml) in tetrahydrofuran (60 ml) at 0 ° C. Water (200 ml) was added and the product was extracted with ethyl acetate (200 ml) and then dried and concentrated., ethyl acetate / isohexane, 10:90 as eluent) yielded the subtitle compound (3.6 g). NMR dH (de-DMSO) 6.21-6.18 (HH, m), 6.02-5.99 (HH, m), 4.49-4.44 (HH, m), 4.33-4.22 (HH, m), 4.03 (2H, s), 2.72-2.64 (ÍH, m), 1.63-1.55 (ÍH, m), 1.43 (9H, s). b) 1- [1- [(lS-cis) -4- [6-chloro-5-nitro-2- (propylthio) -pyrimidin-4-yl] -amino] -2- cyclopenten -1-yl] -oxi] -acetic. To a solution of the product from step (a) (3.5 g) in tetrahydrofuran (250 ml) and water (25 ml), triphenylphosphine (4.3 g) was added and the reaction mixture was stirred at room temperature for 3 days . The solvent was evaporated and traces of water were removed by evaporation in toluene. A solution of the resulting amine (3.0 g) in tetrahydrofuran (100 ml) was added dropwise over a period of one hour to a solution of 4,6-dichloro-5-nitro-2- (propylthio) -pyrimidine (prepared in the manner described in International Publication WO 9703084) (3.7 g). The reaction mixture was stirred for one hour, the solvents were evaporated and the product redissolved in ethyl acetate (500 ml) and then washed with water (200 ml). The organic phases were separated, dried and evaporated. Purification (SIO2, ethyl acetate / isohexane, 5:95 as eluent) yielded the subtitle compound (2.5 g). MS (APCI) 445/447 (M + H), 445 (100%). c) 2- [[[(lS-cis) -4- [5-amino-6-chloro-2- (propylthio) -pyrxmidin-4-yl] -amino] -2- cyclopenten 1,1-dimethylethyl ester -1-yl] -oxi] -acetic. It was prepared in accordance with the method of Example 12, step of subsection (b) using the product of the step of subsection (b). MS (APCI) 415/417 (M + H), 415 (100%). d) 2- [(lS-cis) -4- [7-chloro-5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin 1,1-dimethylethyl ester] -3-yl] -2-cyclopenten-l-yl] -oxi-3-acetic acid. It was prepared according to the method of Example 6, step of item (b) using the product of the step of part (c). MS (APCI) 426/428 (M + H), 426 (100%). e) 2- [(lS-cis) -4- [7-amino-5- (propyl-x-3) -3H- [1,2,3] -triazolo- [4,5-d] 1,1-dimethylethyl ester] -pyrimidin-3-yl] -2-cyclopenten-1-yl] -oxi] -acetic acid. It was prepared according to the method of Example 1, step of part (a) using the product of step (b) and ammonia solution "880". MS (APCI) 407 (M + H +, 100%). f) [3aR- (3aa, 4a, 6a, 6aa)] -2- [[6- [7-amino-5- (propylthio) -3H- 1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] -oxy] -acetic acid. It was prepared according to the method of Example 15, step of item (c) using the product of step "of item (e) MS (APCI) 481 (M + H +, 100%) g) [3aR- (3aa , 4a, 6a, 6aa)] -2- [[6- [7-bromo-5- (propylthio) -3H- 1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] -oxi] -ethanol DIBAL-H® (1.5 M solution in toluene, 4 ml) was added to a solution cooled in ice of the product from the step of part (f) (0.30 g) in toluene (9 ml) The solution was stirred at this temperature for 30 minutes before adding ethyl acetate (2 ml) and water (5 ml). The reaction mixture was filtered through a pad of Kieselguhr, washed with brine, dried and evaporated The product was redissolved in bromoform (5 ml) and isoamyl nitrite (2 ml) was added. at 80 ° C for 30 minutes, the mixture was cooled and the solvent was evaporated, purification (SIO2, ethyl acetate / isohexane, 3: 7 as eluted). te) produced the subtitle compound (0.11 g). MS (APCI) 474/476 (M + H), 474 (100%). h) [IR- [la, 2a, 3ß- (IR *, 2S *), 5-]] -3- [7- [[2- (4-slorophenyl) -syclopropyl] -amino] -5- (propylthio) ) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- [(2-hydroxy) -ethoxy] -cyclopentane-1,2-diol. The title compound was prepared according to the method of Example 1, step of item (b) using the product of the step of part (g). NMR dH (d6-DMSO) 9.35 (HH, 5), 7.33 (HH, d), 7.22 (HH, d), 5.15 (2H, m), 4.95 (HH, q), 4.61 (1H, m), 4.57- 4.54 (HH, m), 3.96-3.91 (HH, m), 3.77-3 74 ( ÍH, m), 3.56- 3.44 (4H, m), 3.15-3.19 (ÍH,), 2.96-2.79 (2H, m), 2.67- 2.59 (ÍH, m), 2.15-2.10 (ÍH, m), 1.58 -1.53 (HH, m), 1.51-1.44 (2H, m), 1.39-1.32 (HH, m), 0.80 (3H, t). MS (APCI) 521/523 (M + H +), 521 (100%). EXAMPLE 113 [YES- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- [(3 , 3,3-trifluoropropyl) -thio] -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. a) [3aR- [3aa, 4a, 6a- (lR *, 2S *), 6aa] -tetrahydro-2,2-dimethyl-6- [7- [(2-phenylcyclopropyl) -amino] -5- [( 3,3,3-trifluoropropyl) -thio] -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -4H-cyclopenta-1,3-dioxol-4-methanol . The subtitle compound was prepared according to the method of Example 6, step of part (b), using [3aR- [3aa, 4a, 6a, 6aa] -6- [[5-amino-6-chloro-2] - [(3,3,3-trifluoropropyl) -thio] -4-pyrimidinyl] -amino] -tetrahydro-2,2-dimethyl-4i? -cyclopenta-l, 3-dioxol-4-methanol (prepared in the manner described in International Publication WO 9703084), followed by the method of Example 1, step of part (a). b) [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] - 3- (hydroxymethyl) -5- [7 - [(2-phenylcyclopropyl) -amino] -5- [(3 , 3,3-trifluoropropyl) -thio] -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol. The title compound was prepared according to the method of Example 1, step of item (b) using the product of the step of part (a). MS (APCI) 511 (M + H +, 100%). NMR dH (de-DMSO) 9.43 (1H, d), 7.32-7.27 (2H, m), 7. 21-7.16 (3H, m), 5.01-4.95 (2H, m), 4.72-4.70 (2H, m), 4.44-4.41 (ÍH, m), 3.88-3.84 (ÍH,), 3.50-3.44 (2H, m), 3. 25-3.11 (3H, m), 2.75-2.70 (ÍH, m), 2.28-2.19 (2H, m), 2. 15-2.05 (ÍH, m), 1.85-1.78 (ÍH, m), 1.49-1.46 (ÍH, m), 1.36-1.10 (2H, m). EXAMPLE 114 [ÍS- [la, 2β, 3β, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-chloro-4-ethylphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol. It was prepared according to the method of Example 24, step of item (f) using the products of Example 24, step of item (d) and Example 104, step of item (e). MS (APCI) 493/491 (M + H +), 491 (100%). NMR dH (d6-DMSO) 9.85 (HH, d), 7.28 (2H, d), 7.26 (HH, d), 7.06 (HH, dd), 5.11 (HH, d), 5.02 (HH.D), 4.96 (ÍH, q), 4.92 (ÍH, d), 4.69-4.62 (ÍH, m), 3.96-3.89 (ÍH,), 3.82-3.75 (ÍH, m), 3.19-2.79 (3H, m), 2.64- 2.52 (ÍH, m), 2.29 (3H, 5), 2.25-2.05 (ÍH, m), 195-1.86 (ÍH, m), 1. 73-1.31 (4H, m), 0.80 (3H, t). Pharmacological Data The preparation for the assay of the agonist / antagonist activity of the P2r receptor in washed human platelets, for the compounds of the present invention, was carried out in the following manner. Human venous blood (100 ml) was distributed equally in 3 tubes, each containing 3.2% trisodium citrate (4 ml) as anticoagulant. The tubes were centrifuged for 15 minutes at 240 G to obtain a platelet-rich plasma (PRP), to which 300 ng / ml of prostacyclin was added to stabilize the platelets during the washing procedure. An RBC-free PRP was obtained by centrifugation for 10 minutes at 125 G, followed by an additional centrifugation for 15 minutes at 640 G. The supernatant was discarded and the platelet pellet was resuspensed in a modified calcium-free Tyrode solution (10 ml ) (CFT), whose composition is as follows: 137 mM NaCl, 11.9 mM NaHCO3, 0.4 mM NaH2P04, 2.7 mM KCl, 1.1 mM MgCl2, 5.6 mM dextrose, was gassed with 95% O2 / C02 5% and maintained at 37 ° C. After the addition of another 300 ng / ml of PGI2, the mixed suspension was centrifuged once more for 15 minutes at 640 G. The supernatant was discarded and the platelets were initially resuspended in 10 ml of CFT and more CFT was added until adjusted the final platelet count at 2 x 10 / ml. This final suspension was stored in a 60 ml syringe at 3 ° C, having excluded the air. To allow the recovery of PGI2 inhibition from normal function, platelets were used in aggregation studies not earlier than 2 hours after the final resuspension. In all studies, 3 ml aliquots of the platelet suspension were added to tubes containing a CaCl 2 solution (60 μl of a 50 mM solution with a final concentration of 1 mM). Human fibrinogen (Sigma, F 4883) and 8-sulphophenylteophylline (8-SPT, which was used to block any Pi agonist activity of the compounds), were added to obtain final concentrations of 0.2 mg (ml (60 μl of a solution of 10 mg / ml coagulable protein in saline) and 300 nM (10 μl of a 15 mM solution in 6% glucose), respectively, Platelets or buffer, as appropriate, were added in a volume of 150 μl to individual wells in a 96-well plate All measurements were made in triplicate in platelets from each donor The agonist / antagonist potency was evaluated as follows The aggregation responses in 96-well plates were measured using the change of absorbance given by the plate reader at 660 nm A Bio-Tec Ceres 900C or a Dynatech MRX was used as plate readers The absorbance of each well of the plate was read at 660 n to establish a baseline number. HE added saline or the appropriate test solution to each well, in a volume of 10 μl to obtain a final concentration of 0, 0.01, 0.1, 1, 10 or 100 mM. Then, the plate was stirred for 5 minutes on an orbital shaker set at 10 and the absorbance at 660 nm was read. The aggregation at this point was indicative of agonist activity of the test compound. Subsequently, saline or ADP (30 mM) was added.; 10 μl of a 450 mM solution) to each well and the plate was stirred for another 5 minutes before reading the absorbance again at 660 nm. The antagonist potency was estimated as the% inhibition of the ADP response with respect to the control, to "obtain an IC50." The exemplified compounds have pIC values greater than 5.0.It is noted that in relation to this date, the best method known to the applicant to carry out the said invention, is that which is clear from the present description of the invention.

Claims

CLAIMS Having described the invention as an antecedent, the content of the following claims is claimed as property:

1. A compound of the Formula (I) characterized in that: R is an alkyl radical of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or a phenyl group, each group being optionally substituted with one or more substituents that are selected from the group consisting of halogen radicals, OR, NR R, SR 11 or alkyl of 1 to 6 carbon atoms (this optionally substituted with one or more halogen atoms; 2 R is an alkyl radical of 1 to 8 carbon atoms optionally substituted with one or more substituents which are selected from the group consists of halogen radicals, OR, NR R, SR, cycloalkyl of 3 to 8 carbon atoms, aryl (optionally substituted with one or more alkyl groups and / or halogen atoms) or alkyl of 1 to 6 carbon atoms; * "is a cycloalkyl group of 3 to 8 carbon atoms optionally substituted with one or more substituents selected from the group consisting of halogen radicals, OR, NR R, SR, alkyl of 1 to 6 carbon atoms or phenyl, these two latter groups being optionally substituted with one or more substituents which are selected from the group consisting of halogen radicals, N02, C (0) R8, OR8, SR11, NR12R13, a fused saturated ring of 5 or 6 members containing one or two atoms of oxygen, phenyl or alkyl of 1 to 6 carbon atoms, these last two groups being optionally substituted with radicals OR, NR R or one or more halogen atoms; 3 4 one of R and R is a hydroxy radical and the other is hydrogen, hydroxy or NR R; R is a group (CR5R6) mOR7, where m is 0 or 1, R5 and R are independently a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms or phenyl, these last two groups being optionally substituted with a radical halogen and R7 is hydrogen, alkyl of 1 to 6 carbon atoms or (CR R) nR, wherein R and R are as those previously defined, n is 1 to 3 and R 14 is COOH, OR15, NR16R17 or CONR16R17; or R is an alkyl radical of 1 to 4 carbon atoms or alkenyl of 2 to 4 carbon atoms, each of which is substituted with one or more groups which are selected from the group consisting of radicals = S, or OR21 and optionally substituted with one or more groups selected from the group consisting of halogen radicals, alkyl of 1 to 4 carbon atoms, phenyl, SR21, N02 or NR22R23 (wherein R21, R22 and R23 are independently an hydrogen, an alkyl radical of 1 to 4 carbon atoms or phenyl; R is OR 4 or NR R, where R is hydrogen, alkyl of 1 to 4 atoms carbon or phenyl and R2 and R26 are independently hydrogen, alkyl of 1 to 4 carbon atoms, aryl, acyl of 1 to 6 carbon atoms, arylsulfonyl or arylcarbonyl); QR is a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms optionally substituted with a hydrogen Q, or R is a phenyl radical optionally substituted with one or more substituents that are selected from the group consisting of halogen radicals, N02, C (O) R6, OR6, SR9, R10RU; R 9, R 10 and R 11 are independently a hydrogen atom or an alkyl radical of 1 to 6 carbon atoms; R 12 and R 13 are independently a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms, acyl, alkyl, sulfonyl optionally substituted by halogen, or phenylsulfonyl optionally substituted by an alkyl radical of 1 to 4 carbon atoms; and R, R and R are independently a hydrogen atom or an alkyl radical of 1 to 6 carbon atoms; or a pharmaceutically acceptable salt or solvate thereof.

2. A compound of Formula (I) characterized in that it has the following stereochemistry:

3. A compound according to any of claims 1 6 2, characterized in that R 1 is an alkyl radical of 1 to 4 carbon atoms or phenyl substituted with trifluoromethyl.

4. A compound according to any one of claims 1 to 3, characterized in that R is a butyl or cyclopropyl radical optionally substituted with phenyl, the phenyl group itself being optionally substituted with one or more halogen groups, alkyl of 3 to 8 carbon atoms , phenoxy or phenyl. 5. A compound according to any of claims 1 to 4, characterized in that R 3 and R 4 they are hydroxy groups. 6. A compound according to any of claims 1 to 5, characterized in that R and R are hydrogen. 7. A compound according to any of claims 1 to 6, characterized in that R is a group OH, CH2OH, CHCH2OH, OCH2CH2OH, CHOCH2C (CH3) 2OH and

OCH2C (CH3) 2OH. 8. A compound according to claim 1, characterized in that it is: [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [( 2- phenylcyclopropyl) amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [SS- ( la, 2a, 3ß, 5ß)] -5- [7- [(cyclopropyl) amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3- il] -3- (hydroxymethyl) -cyclopentane-1,2-diol, [IS- (la, 2a, 3ß, 5ß)] -5- [7- (butylamino) -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -3- (hydroxymethyl) -cyclopentane-1,2-diol, [lS- (la, 2a, 3ß, 5ß)] -5 - [7- (Butylamino) -5- [[4- (trifluoromethyl) -phenyl] -thio] -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -3 - (hydroxymethyl) -cyclopentane-1,2-diol, 2- [[[IR- [la, 2ß, 3ß, 4a)] -4- [7- (butylamino) -5- (propylthio) -3H- 1 , 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -2,3-dihydroxycyclopentyl] -methoxy] -acetic, l- [[lS- [la, 2ß, 3ß, 4a- ( lS *, 2R *)]] -2-hydroxy-4- [7- [(2- f enylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -2, 3-dihydroxycyclopentyl] -ethanone, l- [[ is- [la, 2ß, 3ß, 4a]] -4- [7- (butylamino) -5- (propylthio) -3H- 1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3- il] -2, 3- dihydroxycyclopentyl] -2-hydroxyethanone, l- [[lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -2, 3-dihydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentyl] -ethanone, 1- [[ ÍS- [la, 2ß, 3ß, 4a] -4- [7- (butylamino) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl ] -2, 3- dihydroxycyclopentyl] -ethanone, [ÍS- [la, 2β, 3β, 5β- (ÍS *, 2R *)]] -3- (1-hydroxy-1-methylethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [ lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) - 3H-1, 2, 3- triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1 , 2-diol, [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, 2- ([[[S] - [la, 3ß, a- (lS *, 2R *)]] -3-hydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentyl] -oxy] -acetic acid, 2- [[[lS- [la, 2ß, 4a- (1S *, 2R *)]] -2-hydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyc-opentyl] -oxy] -acetic , 2- [[[lS- (la, 2ß, 3ß, 4a)] -4- [7- (butylamino) -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5] d] -pyrimidin-3-yl] -2,3-dihydroxycyclopentyl] -oxy] -acetic, 2- [[[S- (la, 2ß, 3ß, 4a)] -4- [7- (butylamino) -5 - (propylthio) -3H- 1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -2, 3-dihydroxycyclopentyl] -oxy] -acetamide, [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [[5- (methylthio) -7- [(2-phenylcyclopropyl) -amino] -3H-1, 2, 3-triazo lo- [, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [5- [(Methylethyl) -thio] -7- [(2-phenylcyclopropyl) amino] -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1 , 2, 3-triol, [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [7- [[2- (4-fluorophenyl) -cyclopropyl] -amino] - 5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lS- [la, 2ß, 3ß, a- (lS *, 2R * )]] -4- [7- [[2- (4-methoxyphenyl) -cyclopropyl] -aminol-5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidine- 3-yl] -cyclopentane-1,2,3-triol, [S S- [la, 2β, 3β, 4a- (SS *, 2R *)]] -4- [7- [[2- (4-methylphenyl)] ) - cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [ ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (4-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, - [[[lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -2, 3-dihydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5 d] -pyrimidin-3-yl] -cyclopentyl] oxy] -acetamide, [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (3 -methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol , [! S- [la, 2ß , 3ß, 4a (lS *, 2R *)]] -4- [7- [[2- (3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo - [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol,

HS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (3-chlorophenyl) -cyclopropyl] -aminol-5- (propylthio) -3H-1 , 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lS- [la, 2ß, 3ß, 4a- (lS *, 2R * )]] -4- [7- [[2- (3-nitrophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidine -3-yl] -cyclopentane-1,2,3-triol, [lS- [(Ia, 2β, 3β, 4a- (1S *, 2R *)]] -4- [7- [[2- (4 phenoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol , [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [7- [[2- (3-phenoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) - 3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lS- [la, 2ß, 3ß, 4a- (lS * , 2R *)] -4- [7- [[2- (3-aminophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [IS- (la, 2a, 3ß, 5ß)] -3- [7- (butylamino) -5- (propylthio) -3H- 1 , 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (3 hydroxypropoxy) -cyclopentane-1,2-diol, [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-hydroxyethoxy) -5- [7- [(2 - phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-methoxyphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol,

[R- [la, 2a, 3β- (lS *, 2R *), 5b]] -5- [7- [[(2- (4-chlorophenyl) -cyclopropyl)] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -3- (hydroxymethyl) -cyclopentane-1,2-diol, [IR- [la, 2a, 3ß- (ÍS *, 2R *), 5β]] -3- [7- [[2- (3-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [ 4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)]] - 3- (methoxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl ] -cyclopentane-l, 2-diol, [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [5- (methylthio) -7- [(2-phenylcyclopropyl) -amino] - 3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5 [(1-methylethyl)] -thio] -3H-1, 2, 3- triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [1S- [la, 2a, 3ß, 5ß- ( lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (prop-2-enylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [ÍS- [la, 2a, 3β, 5β- (ls *, 2R *)]] -3- (hydroxymethyl) -5- [5- (4-methylphenylthio) -7- [(2-phenylcyclopropyl) -amino] -3H-1, 2, 3- triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [ 4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3β, (R *), 5β- (ÍS *, 2R *)]] -3 - (1-hydroxyethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2,3-triazolo- [4,5-d] -pyrimidin-3- il] -cyclopentane-1, 2-diol, [lS- [la, 2a, 3β, (S *), 5β- (lS *, 2R *)]] -3- (1-hydroxyethyl) -5- [7 - [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol,

[IR- [la, 2a, 3β- (IR *, 2S *), 5β]] -3- [5- (ethylthio) -7- [[2- phenylcyclopropyl] -amino] -3H-1, 2, 3 -triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol,

[R- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- [(1,1'-biphenyl) -4-yl] -cyclopropyl] -amino ] -5 (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [IR- ( la, 2a, 3ß, 5ß)] -3- [7- (butylamino) -5- (cyclopentylthio) -3H-1,2,3-triazolo- [4, 5d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [(2-phenylcyclopropyl)] ) -amino] -5- [4- (trifluoromethyl) -phenylthio] -3H-l, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] - • cyclopentane-1,2-diol, [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *) ]] -3- (hydroxymethyl) -5- [7- [[2- (4-phenoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4, 5] -d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lR- [la, 2a, 3β- (lS *, 2R *), 5β]] -3- [7- [[2- (2-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane -l, 2-diol, [1S- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (2-hydroxyethoxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] ] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol,

[R- [la, 2a, 3β, 4a- (lR *, 2S *)]] -3-hydroxy-2-methoxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentanomethanol, [R- [la, 2a, 3β, 4a- (lR *, 2S *)]] - 2-hydroxy-3-methoxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3 -yl] -cyclopentanemethanol, [lS- [la, 2a, 3β- (E), 5β- (1S *, 2R *)]] -3- (3-hydroxy-prop-1-enyl) -5- [7- [(2-phenylcyclopropyl ) -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (3-hydroxypropyl) -5- [7- [(2-phenylcyclopropyl) amino] -5- (propylthio) -3H-1, 2, 3- triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, l - [[lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)] ] -2, 3-dihydroxy-4- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2, 3-triazolo- [4, 5-d] -pyrimidin-3 -yl] -cyclopentyl] -2- methoxyethane, [ÍS- (la, 2a, 3ß, 5ß)] -3- (hydroxymethyl) -5- [7- [[(trans) -2- (3, 4-methylenedioxyphenyl ) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [ [la, 2a, 3β, 5β- (ÍS *, 2R *)] 1-3- (hydroxymethyl) -5- [7- [[2- (3-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) ) -3H- 1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3 β, 5β- (1S *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-hydroxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1 , 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)] ] -3- (hydroxymethyl) -5- [7- [[2- (3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5] d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7 - [[2- (3-phenoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane- 1,2-diol, [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (4-fluorophenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1, 2, 3-triazolo- [4,5- d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (3-nitrophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H -1, 2, 3- triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lR- [la, 2a, 3ß, 5ß- (lR *, 2S * )] ] -3- [7- [[2- (3-aminophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3 -yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- ( 3, 5-dimethoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1, 2, 3-triol, [lS- [la, 2a, 3β, 5β- (lS * 2R *)]] -3- [(2-hydroxy-2, 2-dimethyl) -ethoxy] -5- [7- [( 2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -1, 2-cyclopentanediol, [lS- [la , 2a, 3ß, 5ß- (lS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- [4- (1-melethyloxy) -phenyl] -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)]] -3- (3-hydroxypropoxy) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [ 4,5-d] -pyrimidin-3-yl] -1, 2-cyclopentanediol, [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2 - (3. 4 -difluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol , [lR- [la, 2a, 3β- (lS *, 2R *), 5β]] -3- [7- [[2- (3,4-difluorophenyl) -cyclopropyl] -amino] -5 (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [7- [[2- (3, 5-difluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo - [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lS- [la, 2ß, 3ß, 4a- [lS *, 2R *)]] - 4- [7- [[2- [[1, 1 '-biphenyl] -3-yl] -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] ] -pyrimidin-3-yl] -cyclopentane-l, 2, 3-triol, [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- [1, 1'-biphenyl] -3-il ] - cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2 -diol, N-Ethyl- [[[lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -2, 3-dihydroxy-4- [7- [(2-phenylcyclopropyl) -amino] ] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentyl] oxy] -acetamide, [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [7- [[2- (3-methoxy-4-methylphenyl) cyclopropyl] -amino] -5- (propylthio) -3H-1,2, 3- triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [IR- [la, 2a, 3ß- (IR *, 2S *), 5ß]] -3 - [7- [[2- (4-N, N-dimethylaminophenyl) cyclopropyl] -amino] -5- (propylthio) -3H- 1,2,3-triazolo- [4,5-d] -pyrimidin-3 -yl] -5-hydroxymethyl-cyclopentane-1,2-diol, [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3- fluoro-4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) - cyclopentane- l, 2-diol, [ÍS- [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (hydroxymethyl) -5- [7- [[2- (4-methoxy-3- methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [IR - [la, 2a, 3ß- (IR *, 2S *), 5β]] -3- [7- [[2- (3, 4-dichlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H -1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -3- (hydroxymethyl) -cyclopentane-1,2-diol, S- [la, 2a, 3ß, 5ß- ( ÍS *, 2R *)] -3- [(2-amino) -ethoxy] -5- [7- (2-phenylcyclopropyl) -amino] -5-propylthio-3H- [1, 2, 3] -triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [IR- [la, 2a, 3ß- (IR *, 2S *), 5ß)] -3- [7- [[2- (3, 4-dimethylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5 - (hydroxymethyl) -cyclopentane-l-2-diol, [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [7- [[2- (3,4-dimethylphenyl)] - cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2, 3-t riol, [IR- (la, 2a, 3ß, 5ß)] -3- [7- (cyclopropylamino) -5- [[4- (trifluoromethyl) -phenyl] -thio] -3H-1, 2, 3-triazolo - [4, 5-d] - pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [1S- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)] ] -4- [7- [[2- (3, 5-dichlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidine -3-yl] -cyclopentane-1, 2, 3-triol, [lR- [la- (lS *, 2R *), 2ß, 3ß, 4a]] -N- [3- [2- [[3- (2, 3, 4-trihydroxy-cyclopentyl) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl ester ] - methanesulfonamide, [lS- [la, 2ß, 3ß, 4ß- (lS *, 2R *)]] -4- [7- [[2- (3, 4-dimethoxyphenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lS- [la, 2ß, 3ß, 4a (lS *, 2R *)]] -4- [7- [[2- (4-methoxy-3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3- triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lR- [la- (lS *, 2R *), 2ß, 3ß, 4a]] -N - [3- [2- [[3- (2, 3, 4-trihydroxy-cyclopentyl) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] - - pyrimidin-7-yl] -amino] -cyclopropyl] - phenyl] -acetamide, [SS- [la, 2β, 3β, 4a- (SS *, 2R *)]] -4- [7- [[(2- (3, 4-dichlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [7- [[2- (4-chloro-3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2 , 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2, 3-triol, [IS- [la, 2ß, 3ß, 4a- [trans)]] -4- [7- [[2- (phenylmethyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo [4, 5-d] pyrimidin-3-yl] -cyclopentane-1, 2,3- triol, [lR- [la, 2a, 3ß- (lR *, 2S *), 5ß]] -3- [7- [[2- (4-Chloro-3-methylphenyl) -cyclopropyl] - amino] -5- (propylthio) -3H-1,2,3-triazolo [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (3-dimethylaminophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane- 1, 2, 3-triol, [lS- [la, 2β, 3β, 4a- (lS *, 2R *)]] -4- [7- [[2- (3-fluoro-4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [ , 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (3, 5-dimethylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *) ]] -4- [7- [[2- (3-chloro-4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4,5-d] ] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lR- [la, 2a, 3ß- (lR *, 2S *), 5ß]] -3- [7- [[2- (3-Chloro-4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- ( hydroxymethyl) -cyclopentane-1,2-diol,

[LR- [la- (lS *, 2R *), 2β, 3β, 4a]] -N- [3- [[2- [3- [2, 3-dihydroxy-4- (hydroxyethyl) -cyclopentyl] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -methanesulfonamide, [R- [la, 2a , 3ß- (lR *, 2S *), 5β]] -3- [7- [[2- (3,5-dimethoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [lS- [la, 2ß, 3ß, 4a- (lS *, 2R *)]] -4- [7- [[2- (3-fluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] - pyrimidin-3-yl] -cyclopentane-1,2,3-triol, [lR- [la (lS *, 2R *), 2ß, 3ß, 4a]] -N- [[3- [2- [3- (2,3-dihydroxy-4-hydroxymethylcyclopentyl) -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl ester ] -acetamide, [IR- [la, 2β, 3β- (IR *, 2S *), 5β]] -3- [7- [[2- (3,5-dichlorophenyl) -cyclopropyl] -amino] -5 - (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [lR- [la- (1S *, 2R *), 2ß, 3β, 4a]] -N- [3- [2- [[3- [2,3-dihydroxy-4- (2-hydroxyethyl) -cyclopentyl] ] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -methanesulfonamide, [lS- [la, 2β, 3β, 5β- (1S *, 2R *)]] - 3 - (2-hydroxyethyl) -5- [7- [[2- (4-phenoxyphenyl) -cyclopropyl] -amino} -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3ß, 5β- (1S *, 2R *)]] - 3 - (2-hydroxyethyl) -5- [7- [[2- (3-phenoxyphenyl) -cyclopropyl] -amino} -5- (propylthio) -3H- 1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lR- [la, 2a, 3ß- (LR *, 2S *), 5 ~]] -3- [7- [[2- (4-bromophenyl) -cyclopropyl] -amino} -5 (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [IR- [la, 2a, 3β- (IR *, 2S *), 5β]] -3- [7- [[2- [(1,1'-biphenyl) -2-yl] -cyclopropylamino] -5- (propylthio) ) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [R- [la, 2a , 3ß- (lR *, 2S *), 5β]] -3- [7 - [[2- [(1,1'-biphenyl) -3-yl] -cylo-clopropylamino] -5- (propylthio) - 3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [lR- [la, 2a, 3ß (lR *, 2S *), 5β]] -3- [7- [[2- (3, 5-dichlorophenyl) -cyclopropylamino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4 , 5- d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopenta-1, 2-diol, [lR- [la, 2a, 3ß (lR *, 2S *), 5ß]] - 3- [7- [[2- (3, 4-Dichlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3 -yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [lR- [la, 2a, 3ß- (lR *, 2S *), 5ß]] -3- [7- [[2 - (3-Chloro-4-methoxyphenyl) -cyclopropyl] -am ino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [R- [lo, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (3, 4-dimethoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [lR- [la (lS * , 2R *), 2ß, 3ß, 4a]] -N- [3- [2- [[3- [2,3-Dihydroxy-4- (2-hydroxyethyl) -cyclopentyl] -5- (propylthio) -3H -1,2, 3-. triazolo- [4, 5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenyl] -acetamide, [IR- [la, 2a, 3ß (IR *, 2S *), 5ß]] -3 - [7- [[2- (3-Chloro-4-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin- 3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[ 2- (4-Chloro-4-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-t-azolo- [4,5-d] -pyrimidin-3-yl] - 5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (4- Fluoro-3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) ) - cyclopentane-1,2-diol, [1? - [la, 2a, 3β, 5β- (ÍS *, 2R *)]] -3- (2-Hydroxyethyl) -5- [7- [[2- (3-nitrophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol , [ÍS- [la, 2a, 3ß, 5ß- (ÍS *, 2R *)]] -3- (2-Hydroxyethyl) -5- [7- [[2- (4-methoxy-3-methylphenyl) - cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la , 2a, 3β, 5β (lS *, 2R *)]] -3- (2-Hydroxyethyl) -5- [7- [[2- (3-methoxy-4-methylphenyl) -cyclopropyl] -amino} -5- (propylthio) -3H-.1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol,

[IR- [la, 2a, 3β- (IR *, 2S *), 5β]] -3- [7- [[2- (4-N, N-Dimethylphenyl) -cyclopropyl] -amino] -5- ( propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [IR- [la, 2a, 3β- (IR *, 2S *), 5β]] -3- [7- [[2- (3, 4-Difluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2 , 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [IR- [la, 2a, 3ß- (IR *, 2S *), 5β]] -3- [7- [[2- (3, 5-Difluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [lR- [la, 2a, 3ß- (lR *, 2S *), 5ß]] - 3- [7- [[2- (3-Chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] ] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (2-Hydroxyethyl) -5- [7- [[2- (4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3ß, 5β- (1S *, 2R *)]] -3- (2-Hydroxyethyl) -5- [7- [[2- (2-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [IS- [la, 2a, 3ß, 5ß- (1S *, 2R *) ]] -3- (2-Hydroxyethyl) -5- [7- [[2- (4-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4 , 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)]] -3- (2-Hydroxyethyl) -5- [7- [[2- (3-methoxyphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H- 1, 2, 3-triazolo- [4,5-d] -pyrimidin-3- il] -cyclopentane-1,2-diol, [lR- [la, 2a, 3ß- (lR *, 2S *), 5ß]] -3- [7- [[2- (3, 5-Dimethylphenyl) - cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2 -diol, [IR- [the, 2a, 3β- (IR *, 2S *), 5β]] -3- [7- [[2- (4-Fluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3 -triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [lR- [la, 2a, 3ß- (lR *, 2S * ), 5β]] -3- [7- [[2- (3-Fluorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl) -cyclopentane-1,2-diol, [SS- [la, 2a, 3β, 5β- (SS *, 2R *)]] -3- (2 -Hydroxyethyl) -5- [7- [[2- (2-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4,5-d] -pyrimidine -3-yl] -cyclopentane-1,2-diol, [ΔS- [la, 2a, 3β, 5β [lS *, 2R *)]] -3- (2-Hydroxyethyl) -5- [7- [[ 2- (3-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2 -diol, [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)]] -3- (2-Hydroxyethyl) -5- [7- [[2- (4-methylphenyl) -cyclopropyl]] -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [SS- [la, 2a , 3β, 5β- (1α *, 2R *)]] -3- (2-hydroxyethyl) -5- [7- (cyclopropylamino) -5- (propylthio) -3H-1, 2, 3-triazolo- [4 , 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol [lS- [la, 2a, 3ß, 5ß- (lS *, 2R *)]] -3- (2-Hydroxy-2 - methylpropoxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (propylthio) -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] - Cyclopentane-1, 2-diol, [lR- [la, 2a, 3β (lR *, 2S *), 5β]] -3- [7- [[2- (3-Chloro-4-methylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol, [ IR- [la (ÍS *, 2R *), 2ß, 3β, 4a]] -4- [2- [[3- (2, 3, 4-Trihydroxycyclopentyl) -5- (propylthio) -3H-1, 2 , 3-triazolo- [4,5-d] -pyrimidin-7-yl] -amino] -cyclopropyl] -phenylsulfonamide, [IR- [la, 2a, 3ß- (IR *, 2S *), 5ß]] - 3- [5- (Butylthio) -7- [(2-phenylcyclopropyl) -amino] -3H-1,2,3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- (hydroxymethyl) ) -cyclopentane-1, 2-diol, [1S- [la, 2a, 3ß, 5ß- (ÍS *, 2R *)]] -3- (Hydroxymethyl) -5- [5- (pentthio) -7- [(2-phenylcyclopropyl) -amino] -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1 , 2-diol, [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (Hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- (prop-2-inylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [SS- [la, 2a, 3ß, 5ß- (SS *, 2R *)] ] -3- (Hydroxymethyl) -5- [7- [[2- (3, 5-dimethylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2-diol, [ÍS- [la, 2a, 3ß, 5ß- (ÍS *, 2R *)]] -3- (2-Hydroxyethyl) - 5- [5- (Methylthio) -7- [(2-phenylcyclopropyl) -amino] -3H-1, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -cyclopentane-1, 2-diol, [lR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [5- (Butylthio) -7- [(2-phenylcyclopropyl) -amino] -3H-1 , 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] -5- (2-hydroxyethyl-cyclopentane-1,2-diol,

[LR- [la, 2a, 3β- (lR *, 2S *), 5β]] -3- [7- [[2- (4-chlorophenyl) -cyclopropyl] -amino] -5- (propylthio) -3H -1, 2, 3-triazolo- [4,5-d] -pyrimidin-3-yl] -5- [(2-hydroxy) -ethoxy] -cyclopentane-1,2-diol, [lS- [la, 2a, 3β, 5β- (lS *, 2R *)]] -3- (Hydroxymethyl) -5- [7- [(2-phenylcyclopropyl) -amino] -5- [(3,3,3-trifluoropropyl) - thio] -3H-l, 2, 3-triazolo- [4, 5-d] -pyrimidin-3-yl] - cyclopentane-1,2-diol, [ÍS- [la, 2ß, 3ß, 4a- (ÍS *, 2R *)]] -4- [7- [[2- (3-Chloro-4-ethylphenyl) -cyclopropyl] -amino] -5- (propylthio) -3H-1, 2, 3-triazolo- [ 4, 5-d] -pyrimidin-3-yl] -cyclopentane-1,2,3-triol, or the pharmaceutically acceptable salts or solvates thereof. 9. A pharmaceutical composition characterized in that it comprises a compound according to any of claims 1 to 8, in combination with a pharmaceutically acceptable diluent, adjuvant or vehicle. 10. A compound according to any of claims 1 to 8, characterized in that it is used in therapy. 11. A compound according to any of claims 1 to 8, characterized in that it is used in the treatment or prevention of myocardial infarction, thrombotic attack, transient ischemic attacks, peripheral vascular disease and angia. 12. A compound according to any of claims 1 to 8, characterized in that it is used in the treatment or prevention of angina. 13. A method of trapping a platelet aggregation disorder, characterized in that it comprises administering to a patient suffering from such disorder, a therapeutically effective amount of a compound according to any one of claims 1 to

14. A process for the preparation of a compound of the Formula (I), characterized in that it comprises: (a) reacting a compound of the Formula (II) wherein R, R 1, R 3 and R 4 are as defined in Formula (I) or are protected derivatives thereof, and L is a leaving group, with a compound of the Formula (III): R2NH2 (III) 2 wherein R is as defined in Formula (I) or is a protected derivative thereof, or (b) reacting a compound of the Formula (IV): wherein R 1 and R 2 are as defined in Formula (I) or are protected derivatives thereof and P and P are protective groups or hydrogen, with a suitable reagent to introduce a substituent R group, or, for compounds in where m is 0: (c) hydroxylating a compound of the Formula (V): wherein R 1, R 2 and R 7 are as defined in Formula (I) or are protected derivatives thereof and, optionally, after the steps of part (a), (b) or (c) and in any order: • transform one or more functional groups into other functional groups • remove any protecting group to form a pharmaceutically acceptable salt or solvate.